Table of Contents

As filed with the Securities and Exchange Commission on May 20, 2024.

Registration No. 333-   

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form F-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

 

FIDELIS INSURANCE HOLDINGS LIMITED

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Bermuda   6331   Not Applicable

(State or other jurisdiction

of incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

  (I.R.S. Employer Identification Number)

Fidelis Insurance Holdings Limited

Wellesley House South 90 Pitts Bay Road

Pembroke

Bermuda HM08

+1 (441) 279-2590

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

 

 

Puglisi & Associates

850 Library Avenue, Suite 204

Newark, Delaware 19711

Attention: Mr. Donald J. Puglisi

(Address, Including Zip Code, of Registrant’s agent for service)

 

 

Copies to:

 

Joseph D. Ferraro

Jennifer Tait

Willkie Farr & Gallagher (UK) LLP

Citypoint, 1 Ropemaker Street

London EC2Y 9AW

United Kingdom

Telephone: +44 20 3580 4700

 

Gary D. Boss

Benjamin J. Cohen

Kirsten Gaeta

Latham & Watkins LLP

1271 Avenue of the Americas

New York, New York 10020

Telephone: (212) 906-1200

 

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box ☐

If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

 

Emerging growth company  

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to Section 8(a), may determine.

 

 

 


Table of Contents

SUBJECT TO COMPLETION, DATED May 20, 2024

 

LOGO

FIDELIS INSURANCE HOLDINGS LIMITED

9,000,000 Common Shares

 

 

The selling shareholders named under the caption “Principal and Selling Shareholders” below (the “Selling Shareholders”) are offering 9,000,000 common shares, par value $0.01 per share, of Fidelis Insurance Holdings Limited (the “Common Shares”). We will not receive any proceeds from the sale of the Common Shares sold by the Selling Shareholders in this offering.

Our Common Shares are listed on the New York Stock Exchange (the “NYSE”) under the symbol “FIHL.” The last reported sale price of our Common Shares on the NYSE on May 17, 2024 was $18.53 per Common Share.

Investing in our Common Shares involves risks. See “Risk Factors” beginning on page 27. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

 

     Per Common
Share
     Total  

Public offering price

   $           $       

Underwriting discounts and commissions (1)

   $           $       

Proceeds, before expenses, to the Selling Shareholders

   $           $       
  

 

 

    

 

 

 

 

(1)

We have agreed to reimburse the underwriters for certain expenses in connection with this offering. Please see “Underwriting” for a description of compensation payable to the underwriters.

The underwriters also may purchase up to 1,350,000 additional Common Shares from the Selling Shareholders at the public offering price less the underwriting discounts and commissions, within 30 days from the date of this prospectus.

The underwriters expect to deliver the Common Shares to purchasers on or about   , 2024.

 

 

 

Barclays   J.P. Morgan   Goldman Sachs & Co. LLC

 

  Evercore ISI   Citigroup  

 

BMO Capital Markets  

Keefe, Bruyette & Woods

        A Stifel Company

  UBS Investment Bank

 

 

Citizens JMP

  Dowling & Partners Securities, LLC

 

 

Prospectus dated   , 2024


Table of Contents

TABLE OF CONTENTS

 

     Page  

About This Prospectus

     1  

Summary

     5  

Summary Financial and Operating Data

     23  

Risk Factors

     27  

Use of Proceeds

     31  

Dividend Policy

     32  

Cautionary Note Regarding Forward-Looking Statements

     33  

Business

     36  

Management and Corporate Governance

     55  

Principal and Selling Shareholders

     64  

Material Contracts and Related Party Transaction

     66  

Comparison of Shareholder Rights

     67  

Shares Eligible for Future Sale

     75  

Certain Tax Considerations

     78  

Underwriting

     82  

Legal Matters

     92  

Experts

     93  

Where Prospective Investors Can Find Additional Information

     94  

 

i


Table of Contents

ABOUT THIS PROSPECTUS

We and the Selling Shareholders have not authorized anyone to provide any information different from that contained in this prospectus or in any free writing prospectuses prepared by us or on our behalf or to which we have referred prospective investors. We and the Selling Shareholders take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give prospective investors. This prospectus is an offer to sell only the Common Shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is accurate only at the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or any sale of our Common Shares.

We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to the registration statement of which this prospectus is a part were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be a representation, warranty or covenant made to prospective investors or for the benefit of prospective investors. Moreover, such representations, warranties or covenants were accurate only at the date they were made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

Certain Defined Terms

Certain abbreviations and definitions of certain insurance, reinsurance, financial and other terms used in this prospectus are defined in our Annual Report on Form 20-F for the year ended December 31, 2023, as filed with the SEC on March 15, 2024 incorporated by reference in this prospectus (the “2023 Annual Report”).

Exchange Control

The permission of the Bermuda Monetary Authority (the “BMA”) is required, under the provisions of the Exchange Control Act 1972 of Bermuda and related regulations, for all issuances and transfers of shares (which includes the Common Shares) of Bermuda companies to and/or from a non-resident of Bermuda for exchange control purposes, other than in cases where the BMA has granted a general permission. The BMA, in its notice to the public dated June 1, 2005, has granted a general permission for the issue and subsequent transfer of any securities of a Bermuda company from and/or to a non-resident of Bermuda for exchange control purposes for so long as any “Equity Securities” of the company (which would include the Common Shares) are listed on an “Appointed Stock Exchange” (which would include the NYSE). In granting the general permission, the BMA accepts no responsibility for our financial soundness or the correctness of any of the statements made or opinions expressed in this prospectus.

Service of Process and Enforcement of Civil Liabilities

We are a Bermuda exempted company. As a result, the rights of holders of our Common Shares will be governed by Bermuda law and our memorandum of association and the Amended and Restated Bye-Laws. The rights of shareholders under Bermuda law may differ from the rights of shareholders of companies incorporated in other jurisdictions. See “Comparison of Shareholder Rights.” Some of our directors and officers are not residents of the United States, and a substantial portion of our assets are located outside the United States. As a result, it may be difficult for investors to effect service of process on those persons in the United States or to enforce in the United States judgments obtained in U.S. courts against us or those persons based on the civil liability provisions of the U.S. securities laws. It is doubtful whether courts in Bermuda will enforce judgments obtained in other jurisdictions, including the United States, against us or our directors or officers under the securities laws of those jurisdictions or entertain actions in Bermuda against us or our directors or officers under the securities laws of other jurisdictions.

 

1


Table of Contents

Investors Outside the United States

Neither we nor any of the Selling Shareholders have done anything that would permit the possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our Common Shares and the distribution of this prospectus outside of the United States.

REGISTERED TRADEMARKS AND TRADEMARK APPLICATIONS

We own or have rights to use trademarks, service marks or trade names that we use in connection with the operation of our business. Other trademarks, service marks and trade names appearing in this prospectus are the property of their respective owners. Solely for convenience, the trademarks, service marks, trade names and copyrights referred to in this prospectus are listed without the ©, ® and symbols, but we will assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks, trade names and copyrights.

MARKET AND INDUSTRY DATA AND FORECASTS

Certain market, peer and industry data and forecasts included in this prospectus were obtained from independent market research, industry publications and surveys, governmental agencies and publicly available information, including information from our peer group. Industry surveys, publications and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but that the accuracy and completeness of such information is not guaranteed. We have not independently verified any of the data from third-party sources, nor have we ascertained the underlying assumptions relied upon therein. Similarly, independent market research and industry forecasts, which we believe to be reliable based upon our management’s knowledge of the industry, have not been independently verified. Our peer group includes Beazley (“BEZ”), Lancashire (“LRE”), Conduit (“CRE”), Hamilton (“HG”), Everest (“EG”), Axis (“AXS”), Berkley (“WRB”) and Markel (“MKL”). The calculations of our peers’ GPW excludes BEZ for 2023, CRE from 2018 to 2020 and 2023, LRE for 2023 and HG for 2018. The average NPE of our peers for 2018 to 2023 excludes BEZ and LRE for 2023, CRE from 2018 to 2020 and 2023 and HG for 2018. Our peers’ average loss ratios and combined ratios for 2021 and 2022 are calculated from a peer group including BEZ, LRE, CRE, HG, EG, AXS, WRB and MKL. Our peer average loss ratios and combined ratios for 2023 and the three months ended March 31, 2024, are calculated from a peer group consisting of HG, EG, AXS, WRB and MKL. BEZ, LRE and CRE are excluded from the calculations of our peer average loss ratios and combined ratios for 2023 and the three months ended March 31, 2024 as combined ratios are no longer reported on a like for like basis as compared to previous years following the adoption of IFRS 17. CRE, BEZ and LRE are excluded in 2023 from the calculations of our peers’ average combined ratios for 2018 to 2023, as their combined ratios are no longer reported on a like for like basis as compared to previous years following the adoption of IFRS 17. CRE is also excluded from 2018 to 2020 and HG for 2018. For fiscal years prior to 2022, HG financial information is calculated using a fiscal year ending on November 30.

While we are not aware of any material misstatements regarding the market, peer or industry data presented herein, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading “Risk Factors” and Item 3. Key Information—D. Risk Factors of the 2023 Annual Report.

BASIS OF PRESENTATION

Presentation of Financial Information

References to “Fidelis Insurance Group” refer to Fidelis Insurance Holdings Limited (“FIHL”) and its consolidated subsidiaries. Unless otherwise indicated, or the context otherwise requires, references herein to

 

2


Table of Contents

“Fidelis,” “Group,” “we,” “our,” “us,” and other similar references refer to Fidelis Insurance Group. The term “TFP HoldCo” refers to Shelf Holdco II Limited. References to “The Fidelis Partnership” (formerly known as “Fidelis MGU”) or “TFP” refer to TFP HoldCo and its consolidated subsidiaries. Unless otherwise stated or the context otherwise requires, all information in this prospectus reflects the completion of this offering. References to “segment(s)” and “pillar(s)” shall have the same meaning as used herein and shall be used interchangeably to refer to each of the three pillars or segments of our business, Specialty, Bespoke and Reinsurance.

The financial information included herein has been derived from the financial statements and accounting records of Fidelis Insurance Group and has been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). Amounts in this prospectus and the financial statements included in this prospectus are presented in U.S. dollars rounded to the nearest million, unless otherwise noted. Certain amounts presented in tables are subject to rounding adjustments and, as a result, the totals in such tables may not sum.

The financial information included herein contains the following measures, which we use to assess the financial performance of our business:

Premiums Written

 

   

Gross premiums written (“GPW”) means total premiums received; and

 

   

Net premiums written (“NPW”) means GPW less reinsurance premiums ceded.

Premiums written are recorded on inception of the policy. Premiums written include estimates based on information received from insureds, brokers and cedants, and any subsequent differences arising on such estimates are recorded as premiums written in the period in which they are determined.

Earned and Unearned Premiums

Premiums written are earned on a basis consistent with risks covered over the period the coverage is provided. NPW, when earned, are referred to herein as net premiums earned (“NPE”).

The portion of the premiums written applicable to the unexpired terms of the underlying contracts and policies are recorded as unearned premium (“UPR”).

Non-U.S. GAAP Financial Measures

Our financial statements included in this prospectus have been prepared in accordance with U.S. GAAP. We have included certain non-U.S. GAAP financial measures in this prospectus, as further described below, that may not be directly comparable to other similarly titled measures used by other companies and therefore may not be comparable among companies. For purposes of Regulation G and Section 10(e) of Regulation S-K, a non-U.S. GAAP financial measure is a numerical measure of a company’s historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable measure calculated and presented in accordance with U.S. GAAP in the statements of operations, balance sheets, or statement of cash flows of the company; or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable measure so calculated and presented. Pursuant to the requirements of Regulation G and Section 10(e) of Regulation S-K, we have provided reconciliations of non-U.S. GAAP financial measures to the most directly comparable U.S. GAAP financial measures. These non-U.S. GAAP measures are provided because our management uses these financial measures in monitoring and evaluating our ongoing results and trends.

This prospectus contains “non-U.S. GAAP financial measures,” including accident year loss ratio excluding catastrophes, large losses and prior year reserve movements (also known as the “attritional loss ratio” (in total and for each operating segment)), operating net income, operating earnings per diluted Common Share

 

3


Table of Contents

(“Operating EPS”), and operating return on average common equity (“Operating ROAE”), which are financial measures that are not required by, or presented in accordance with U.S. GAAP.

We believe that, in addition to our results determined in accordance with U.S. GAAP (that include performance measures such as ratio of losses and loss adjustment expenses to NPE (“loss ratio”), underwriting ratio, TFP commissions ratio (formerly, Fidelis MGU commissions ratio), policy acquisition expenses ratio, general and administrative expenses ratio, combined ratio, net investment return, total investment return, net investment return percentage, total investment return percentage and return on average common equity (“ROAE”)), certain non-U.S. GAAP measures, including accident year loss ratio excluding catastrophes, large losses and prior year reserve movements (also known as the “attritional loss ratio” (in total and for each operating segment)), operating net income, Operating EPS, and Operating ROAE are useful in evaluating our business and the underlying trends that are affecting our performance. Such non-U.S. GAAP measures are primary indicators that our management uses internally to conduct and measure its business and evaluate the performance of its consolidated operations. Our management believes these non-U.S. GAAP financial measures are useful as they provide meaningful analysis of the performance of the business. These non-U.S. GAAP financial measures are used in addition to and in conjunction with results presented in accordance with U.S. GAAP. These non-U.S. GAAP financial measures reflect an additional way of viewing aspects of our operations that, when viewed with our U.S. GAAP results and, where applicable, the accompanying reconciliations to corresponding U.S. GAAP financial measures, provide a more complete understanding of factors and trends affecting our business. A material limitation associated with these non-U.S. GAAP measures compared to the U.S. GAAP measures is that they may not be comparable to other companies with similarly titled items that present related measures differently. The non-U.S. GAAP measures should be considered as a supplement to, and not as a substitute for or superior to, the corresponding measures calculated in accordance with U.S. GAAP.

See “Summary—Summary Financial and Operating Data—Reconciliation of Operating EPS” together with Item 5. Operating and Financial Review and Prospects—A. Operating Results—Performance Measures and Non-GAAP Financial Measures of the 2023 Annual Report and Management’s Discussion and Analysis of Financial Condition and Results of Operations—Performance Measures and Non-GAAP Financial Measures of Exhibit 99.2 of our Current Report on 6-K related to our quarterly financial results for the three months ended March 31, 2024, as filed with the SEC on May 9, 2024, incorporated by reference in this prospectus (the “Q1 2024 Quarterly Report”) for an explanation and reconciliation of these non-U.S. GAAP financial measures to the most directly comparable financial measures stated in accordance with U.S. GAAP.

 

4


Table of Contents

SUMMARY

This summary highlights information contained elsewhere in this prospectus and includes forward-looking statements. Because this is only a summary, it does not contain all of the information that you should consider before investing in our Common Shares and it is qualified in its entirety by, and should be read in conjunction with, the more detailed information appearing elsewhere in this prospectus. You should read the entire prospectus carefully, including “Risk Factors,” “Cautionary Note Regarding Forward-Looking Statements,” any applicable free writing prospectus and the documents incorporated by reference herein and therein, including the 2023 Annual Report and the Q1 2024 Quarterly Report. You should read all such documents carefully, especially the risk factors and cautionary notes regarding forward-looking statements contained therein and our financial statements and the related notes incorporated by reference in this prospecuts or therein, before deciding to purchase our Common Shares. Unless otherwise indicated, or the context otherwise requires, references herein to “Fidelis,” “Group,” “we,” “our,” “us,” and other similar references refer to Fidelis Insurance Group.

Certain abbreviations and definitions of certain insurance, reinsurance, financial and other terms used but not defined in this prospectus shall have the same meaning as in the 2023 Annual Report.

Our History; Then to Now

Fidelis Insurance Group is a global specialty insurer, leveraging strategic partnerships to offer innovative and tailored insurance solutions. We have a highly diversified portfolio focused on three segments: Specialty, Bespoke, and Reinsurance, which we believe allows us to take advantage of the opportunities presented by evolving (re)insurance markets, proactively shift our business mix, and produce superior underwriting returns across market cycles. Headquartered in Bermuda, with subsidiaries located in Ireland and the UK, Fidelis Insurance Group operating companies have a financial strength rating of A from AM Best, A- from S&P and A3 from Moody’s, as of May 17, 2024.

FIHL was formed under the principles of a focused, process-driven and disciplined underwriting and risk selection, strong client and broker relationships and nimble capital deployment. Fidelis completed its initial funding and began underwriting business in June 2015 under the direction of an innovative and experienced management team.

Since then, FIHL has assembled a diversified global book of (re)insurance business and achieved scale with GPW of $3.6 billion and NPE of $1.8 billion for the year ended December 31, 2023. Between 2018 and 2023, our GPW and NPE have grown at compounded annual rates of 38.9% and 44.5%, respectively, and we have delivered an average loss ratio of 45.1% and an average combined ratio of 85.8% over the same period.

The Separation Transactions

On January 3, 2023, the Separation Transactions were completed and two distinct holding companies and businesses were created: FIHL and TFP HoldCo. FIHL, the parent holding company for Fidelis Insurance Group, owns the insurance operating subsidiaries of Fidelis, comprised of Fidelis Insurance Bermuda Limited (“FIBL”), Fidelis Underwriting Limited (“FUL”) and Fidelis Insurance Ireland DAC (“FIID”). Fidelis Insurance Group also has its own service company, FIHL (UK) Services Limited, with a branch in Ireland (“FIHL (UK) Services”).

TFP HoldCo is the parent holding company for the managing general underwriting platform (“TFP”) that carries on origination and underwriting activities on behalf of Fidelis Insurance Group. TFP HoldCo’s principal operating subsidiaries are Pine Walk Capital Limited (“Pine Walk Capital”), Pine Walk Europe SRL (“Pine Walk Europe”) and Shelf Opco Bermuda Limited (“TFP Bermuda”). The underwriting activities of each of the licensed insurance carriers of Fidelis Insurance Group (FIBL, FUL and FIID) are outsourced to the corresponding operating subsidiaries of TFP on a jurisdictional basis (TFP Bermuda, Pine Walk Capital and Pine Walk Europe,

 

5


Table of Contents

respectively). Each of the operating subsidiaries of TFP has delegated underwriting authority to source and bind contracts for and on behalf of each of FIBL, FUL and FIID, respectively. See Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions of the 2023 Annual Report.

On December 20, 2022, FIHL and TFP HoldCo entered into a rolling 10-year framework agreement (the “Framework Agreement”) that governs the ongoing relationship between the two groups of companies (see “—Our Corporate Structure” for additional details).

Following the consummation of the Separation Transactions, FIHL can access the underwriting expertise of TFP while enabling TFP to attract and retain highly sophisticated underwriting talent by allowing them to focus their time and expertise on underwriting activities. We believe that the Separation Transactions and the Framework Agreement have structural benefits for both groups of companies, including increased flexibility to quickly respond to evolving insurance and reinsurance market conditions and to help sustain our strong underwriting results through access to top talent. Our objective following the completion of the Separation Transactions remains to further solidify Fidelis Insurance Group’s position as a leading specialty, bespoke and reinsurance underwriter.

Our Company

Fidelis Insurance Group is a global specialty insurer focused on three segments: Specialty, Bespoke and Reinsurance. The Specialty and Bespoke segments together accounted for 82.8% of total GPW in 2023.

Fidelis Insurance Group is led by Mr. Daniel Burrows who has more than 35 years of experience in the insurance industry and is supported by a highly experienced management team that manages the operations of Fidelis Insurance Group based on our founding principles.

We have an exclusive right of first access to TFP’s underwriting business via the Framework Agreement where FIHL collaborates closely with TFP to match what we believe are superior priced risks with efficient sources of capital to produce attractive returns for shareholders. Through this operating model, we believe we are well positioned to be nimble, thoughtful, and efficient decision-makers, and we believe that we are able to respond quickly to an ever-changing world and a constantly evolving marketplace. Furthermore, FIHL’s strong capital position provides flexibility to underwrite attractive opportunities and make strategic capital allocation decisions.

We focus on nimble underwriting designed to capitalize on current market trends and dislocations as well as emerging risk solutions. The team of underwriters at TFP continues to maintain the processes and technology that have been key to Fidelis Insurance Group’s historical success at ensuring its underwriting efforts capture recent market developments. We believe this close coordination reduces the likelihood of siloed underwriting and gives us a competitive advantage in our underwriting, risk assessment and ability to offer as many products as possible to clients. A crucial and distinguishing part of those processes is the daily Underwriting and Marketing Conference Call (the “UMCC”). Members of Fidelis Insurance Group attend and participate in the UMCC on a daily basis, together with TFP practice leads and key members of TFP senior management (including risk modeling, actuarial, legal, compliance, contract wordings and claims representatives) to provide live market insights and multiple perspectives to allow underwriters to quickly assess emerging opportunities, achieve strong underwriting and cross-sell across our product range. See “—Our Competitive Strengths” below for further detail.

Our scale and access to the highly selective underwriting capabilities of TFP via our strategic relationship allows us to capitalize on current insurance market trends and continue focusing on delivering growth coupled with strong underwriting results.

 

6


Table of Contents

Since we began underwriting business in 2015, Fidelis Insurance Group has grown in scale in specialty and bespoke insurance and property reinsurance markets while delivering robust results. Our GPW grew from $0.7 billion for the year ended December 31, 2018 to $3.6 billion for the year ended December 31, 2023, a compound annual growth rate of 38.9%, compared to our peers’ average compounded annual growth rate for GPW of 22.1% for the same period. During that same period, we delivered an average combined ratio of 85.8%, compared to our peers’ average combined ratio of 100.2%. Our average loss ratio was 45.1% during that same period.

Our NPE grew from $0.3 billion for the year ended December 31, 2018 to $1.8 billion for the year ended December 31, 2023, a compound annual growth rate of 44.5%, compared to our peers’ average of 31.9%. Our GPW and NPE continued to grow to $1,514.3 million and $488.0 million, respectively, for the three months ended March 31, 2024, compared to $1,245.3 million and $386.0 million, respectively, for the three months ended March 31, 2023.

Our loss and combined ratio for the three months ended March 31, 2024 were 37.4% and 85.8%, respectively, compared to our peers’ average loss and combined ratios of 60.0% and 91.0%, respectively. Our loss ratio was 60.1%, 55.3% and 38.1% in 2021, 2022 and 2023, respectively, compared to our peers’ average loss ratios of 64.7%, 62.7% and 61.8%, respectively. Over the same period, our combined ratio was 93.0%, 91.9% and 82.1%, compared to our peers’ average combined ratios of 100.1%, 96.1% and 93.8%. Our peer group includes Beazley (“BEZ”), Lancashire (“LRE”), Conduit (“CRE”), Hamilton (“HG”), Everest (“EG”), Axis (“AXS”), Berkley (“WRB”) and Markel (“MKL”). For information on how peer group data is included or excluded see “Market and Industry Data and Forecasts.”

Fidelis Insurance Group is subject to varying degrees of regulation and supervision in the jurisdictions in which it operates. In particular, the businesses of our three insurance operating subsidiaries, FIBL, FUL and FIID, are authorized by, and subject to insurance laws and regulations that are administered and enforced by, a number of different governmental and non-governmental self-regulatory authorities and associations in each of their respective jurisdictions and internationally. For a summary of the regulatory environment of our insurance operating subsidiaries, primarily in their respective jurisdictions of Bermuda, U.K. and Ireland, see Item 4. Information on the Company—B. Business Overview—Regulatory Matters of the 2023 Annual Report.

As of the date of this prospectus, Fidelis Insurance Group was assigned an “A” (Excellent) financial strength rating by A.M. Best Company (“A.M. Best”), the third-highest of 13 rating levels, with a stable outlook on all entities. A.M. Best’s ratings range from “A+” to “D.” Each A.M. Best rating category from “A+” to “C” may be designated either an additional plus (+) or a minus (-) sign as a rating notch that reflects a gradation of financial strength within the rating category. Additionally, A.M. Best assigned a “BBB” long-term issuer credit rating to FIHL (with stable outlook), which indicates a good ability to meet ongoing senior financial obligations and a financial strength rating of “A” (Excellent) and the long-term issuer credit rating of “A” (Excellent) to each of FIBL, FUL and FIID (with stable outlook).

As of the date of this prospectus, Fidelis Insurance Group was assigned an “A-” financial strength rating by S&P Global Ratings (“S&P”), with a stable outlook, which indicates strong capacity to meet financial commitments but somewhat more susceptibility to the adverse effects of changes in circumstances and economic conditions than those in higher-rated categories. S&P’s ratings range from “AAA” to “D.” Each S&P rating category from “AA” to “CCC” may be modified by the addition of a plus (+) or minus (-) sign to show relative standing within the rating categories. Additionally, S&P has assigned a “BBB” long-term issuer rating to FIHL, which indicates adequate capacity to meet financial commitments but greater susceptibility to adverse economic conditions.

As of the date of this prospectus, Moody’s Investor Service (“Moody’s”) assigned a “Baa2” long-term issuer rating to FIHL and “A3” insurance financial strength ratings to FIBL, FUL and FIID. The outlook for

 

7


Table of Contents

FIHL is stable. Moody’s generic rating classifications range from “Aaa” to “C.” Each Moody’s generic rating classification from “Aa” to “Caa” may be modified to append numerical modifiers 1, 2, or 3 to show relative position within the rating categories. See Item 4. Information on the Company—B. Business Overview—Insurer Financial Strength Rating of the 2023 Annual Report for further discussion of ratings assigned to Fidelis Insurance Group’s insurance operating subsidiaries.

Strategic Relationship with TFP

We believe the insurance industry is evolving rapidly and is primed for further value chain disaggregation which will allow specialist underwriters to benefit from access to clients and risks and to provide access to alternate forms of capital.

Following the consummation of the Separation Transactions, TFP HoldCo became a minority investor in FIHL (holding 9.9% of the Common Shares) and entered into the Framework Agreement with FIHL to build a long-term agency relationship that provides strong economic and strategic alignment between the two groups of companies. Pursuant to the Framework Agreement, TFP manages underwriting, origination, certain outwards reinsurance placements, actuarial and claims services with close review and oversight from Fidelis Insurance Group to ensure adherence with the agreed upon annual plans, which set out our underwriting parameters and risk tolerances in respect of our three segment underwriting strategy on a gross / net basis for each annual period. For more details on our outsourcing arrangements with TFP, see Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions—Framework Agreement of the 2023 Annual Report.

Pursuant to our outsourcing arrangements with TFP, we leverage their sophisticated underwriting technology and talent and will benefit from our shared history in underwriting principles, strategic visions, and managerial approaches. Our arrangement is governed by arm’s-length terms for origination and management consistent with industry commission levels, including market overrider commissions, and with a focus on aligning incentives for strong underwriting performance. Ceding commissions payable to TFP are charged for underwriting, claims and actuarial pricing services. Such ceding commissions are calculated based on NPW to ensure alignment on reinsurance purchasing. To avoid fee duplication, ceding commissions payable for open market business sourced by TFP are set at 11.5% and ceding commissions payable for business sourced by TFP via third-party managing general underwriters to whom underwriting authority has been sub-delegated by TFP are set at 3.0%. Business that continues to be sourced by subsidiary cells of Pine Walk Capital will continue to follow the fees and commissions set under those agreements (approximately 10%). Long-term objectives are further aligned by FIHL paying an ongoing portfolio management fee of 3.0% (the “Portfolio Management Fee”) to TFP and a 20.0% profit commission on Operating RoE (“Binder Operating RoE”) above a hurdle rate of 5.0% calculated on an aggregate basis for Fidelis Insurance Group. Binder Operating RoE is defined in the Framework Agreement as FIHL’s consolidated net underwriting margin (disregarding any business not underwritten by TFP following the date of the Framework Agreement and the effect of any FIHL Procured Outwards Reinsurance, as defined in the Framework Agreement) plus all overriders retained by Fidelis Insurance Group (disregarding the effect of any FIHL Procured Outwards Reinsurance), minus an Administrative Expenses Allowance (defined in the Framework Agreement as a sum equating to 2.3% of net premiums written), minus the proportion of FIHL’s costs of financing its debt and preference securities included in FIHL’s total capital that is deemed to be allocated to TFP, minus the total accumulated ceding commission that is payable by Fidelis Insurance Group to TFP, minus the Portfolio Management Fee relating to business underwritten by TFP, divided by the proportion of FIHL’s opening common shareholders’ equity adjusted for dividend and equity raises (as set out in year-end consolidated audited financial statements) that is deemed to be allocated to TFP. The calculation of such profit commission includes a deficit carry-forward mechanism for a maximum of three years in which the Binder Operating RoE is below zero. For a more detailed discussion of the fees and commissions payable by Fidelis Insurance Group in connection with its outsourced relationship with TFP, see Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions—Framework Agreement—Fees and Commissions of the 2023 Annual Report.

 

8


Table of Contents

Our Commitment to Environmental, Social and Governance Matters

Fidelis Insurance Group is committed to working together with TFP to implement standards for environmental, social and governance (“ESG”) matters. We carried out a joint study on approximately $8.2 billion of premiums and 28,500 policies spanning between 2012 and 2021, which demonstrated that higher third-party ESG ratings were generally correlated with lower loss ratios. As such, we aim to embed ESG factors in our underwriting processes where appropriate, including through TFP’s existing underwriting restrictions. These underwriting restrictions include not directly insuring thermal coal (including dedicated infrastructure projects such as ports and railways), tar sand extraction, Arctic oil and gas exploration and drilling and fracking operations. Further, we do not provide cover to companies whose revenues from the above-mentioned activities account for more than 20% of their total revenues. TFP also uses policy language with the aim to minimize exposure to forced labor and modern slavery, in particular in the marine cargo line of business. Additionally, together with TFP, we are currently committed to transitioning our insurance portfolios to net-zero greenhouse gas emissions by 2050. To work towards this, to the extent possible, TFP are developing tools to measure the insurance-associated emissions of their insurance portfolios.

Furthermore, FIHL’s fixed income investment portfolio (which represents 98.6% of invested assets as of December 31, 2023) is managed in a manner that is consistent with Fidelis Insurance Group’s sustainability principles and ESG objectives. At December 31, 2023, 3.3% of Fidelis Insurance Group’s fixed income portfolio was invested in green, social and sustainable (“GSS”) bonds. The GSS Indices utilize the Bloomberg Global Aggregate Index, the Bloomberg Sustainable Finance Group’s GSS bond indicators and fields that show alignment with the International Capital Market Association Green Bond, Social Bond and Sustainability Bond Principles and Guidelines. Furthermore, the investment portfolio includes restrictions against holding securities of issuers that have a ‘poor’ MSCI Inc. (“MSCI”) ESG rating (with a rating below ‘B’ or issuers that currently have a ‘red’ MSCI controversy flag). Securities of these issuers may only be held if Fidelis determines it is appropriate to do so after considering whether the investment manager has a positive forward-looking ESG view of the issuer. Fidelis Insurance Group has also adopted negative screens to work to limit exposure to certain industries and activities in its fixed income investment portfolio. These include screens against holding securities of any issuers involved in thermal coal, oil and gas (though an issuer may derive up to 20% of its annual revenues from oil and gas) or arms (certain types of arms are completely excluded, others such as firearm sales are permitted to comprise up to 10% of annual revenues), and restrictions against those that fail animal welfare and for-profit prisons screens. As a result of such negative screens, Fidelis was able to limit the fixed income portfolio’s direct exposure to the securities of companies deriving revenues from fossil fuels to seven companies, which at December 31, 2023 comprised 0.7% of Fidelis Insurance Group’s fixed income portfolio. Furthermore, currently Fidelis Insurance Group has no direct exposure in its investment portfolio to energy companies and its exposure to corporate securities identified as “utilities” comprised 1.1% of the fixed income portfolio at December 31, 2023.

Additionally, we have taken action in each year since 2018 to more than offset our operational carbon emissions and we are committed to continuing to do so going forward. We partner with relevant industry specialists to calculate our carbon emissions.

Diversity, equity and inclusion are integral to Fidelis Insurance Group. We pursue a diversity, equity and inclusion strategy that includes accountability, representation, advancement, culture, outreach and fostering a sense of belonging for all our employees. We employ targeted recruiting strategies to identify a wide range of qualified candidates and partner with external agencies to advertise vacancies with the goal of increasing the hiring of women and ethnically diverse employees. Where available, we monitor certain diversity, equity and inclusion statistics (gender, ethnicity, age, marital status, religion, caring responsibilities and disability, each as provided by candidates on a voluntary basis) both at the outreach/interview stage and for our employee

 

9


Table of Contents

population so that we can see progress with respect to the composition of our qualified candidate pools. Comparative data on diverse candidate sourcing available to us demonstrates a diversity mix of approximately 48% female identifying applicants, and approximately 70% of applicants identifying as people of a diverse ethnicity. During the period from March 2023 to February 2024, approximately 82% of open roles for which the Company recruited achieved a short list including diverse candidates.

Our Business; Overview

Our business comprises three segments: “Specialty,” “Bespoke” and “Reinsurance.” We believe our strategy and capabilities allow us to take advantage of the opportunities presented by evolving (re)insurance markets and to proactively shift our business mix across market cycles to generate strong returns. We have built a diverse portfolio of over 100 products within our 11 lines of business across our three segments, serving numerous industries, types of exposure, and geographies.

The Specialty segment comprises a portfolio of Aviation and Aerospace, Energy, Marine, Property, Property D&F business and Other Specialty risks.

The Bespoke segment is highly specialized in nature providing customized risk solutions for clients which includes Credit & Political Risk and Other Bespoke risk transfer opportunities.

The Reinsurance segment includes Property Reinsurance, Retrocession and Whole Account reinsurance.

Specialty

For the year ended December 31, 2023, the Specialty segment accounted for 62.6% of our GPW and 65.7% of our NPE with an underwriting ratio of 72.5% and a loss ratio of 48.5%. In 2023, the Specialty segment generated $331.1 million in underwriting income. GPW in the Specialty segment grew from $44.1 million for the year ended December 31, 2018 to $2.2 billion for the year ended December 31, 2023, a compound annual growth rate of 119.4%. During the period from 2018 to 2023, our average underwriting ratio was 68.1%. For the three months ended March 31, 2024 our Specialty GPW grew to $1,034.0 million compared to $834.1 million for the three months ended March 31, 2023. Our Specialty segment from 2018 to 2023 accounted for 6.4%, 12.1%, 36.6%, 40.0%, 53.6%, and 62.6%, respectively, of our GPW. Property D&F accounted for 25%, Marine 19%, Aviation and Aerospace 10%, Energy 4%, Property 3% and Other Specialty 2% of our GPW for the twelve months ended March 31, 2024.

The Specialty segment comprises a portfolio of tailored risks across specialty business lines. “Hard” market conditions following years of compound rate increases across multiple business lines within the Specialty segment have provided opportunities for targeted growth and the ability to leverage leadership and scale. This, combined with long established relationships, has enabled Fidelis Insurance Group to build across specialty classes. Given the current market environment we have increasingly used our Specialty segment to deploy capital targeted to natural catastrophe exposure through the Property D&F line of business rather than through our Reinsurance segment. This allows a more selective approach to managing aggregate exposure. We further capitalized on market dislocations and associated rate increases in key classes such as Marine and Aviation and Aerospace to increase the amount of business written. Our Aviation and Aerospace, Property D&F and Marine businesses are among the leading franchise positions in the London market. The Specialty segment benefits from a program of reinsurance protections which are tailored across product lines. The program incorporates facultative covers as well as proportional and non-proportional treaties including aggregate, occurrence, per risk and parametric products such as cat bonds and industry loss warranties, which reduce the impact of frequency and severity claims, and protect capital.

 

10


Table of Contents

Our Specialty segment provides us with access to more capital-efficient business and facilitates diversification of our exposures. In the Specialty segment, our underwriters work closely with TFP’s experts to develop collaborative relationships with brokers and clients and offer them the full suite of our existing products as well as working with them to innovate new product ideas. We have consistently demonstrated a sophisticated ability to adapt to constantly evolving market dynamics by developing specialized and tailored pricing and aggregation models while maintaining a disciplined underwriting approach. We typically seek out capacity-driven layers with attractive pricing, often focusing on dislocated markets, and look to ensure successful and sustainable growth in this segment through developing and maintaining an excellent broker network. This relationship-driven, flexible approach enables underwriters to identify additional underwriting opportunities from existing clients for providing cover on other related lines of business.

Bespoke

For the year ended December 31, 2023, the Bespoke segment accounted for 20.2% of our GPW and 20.5% of our NPE with an underwriting ratio of 61.9% and a loss ratio of 24.5%. In 2023, the Bespoke segment generated $143.2 million in underwriting income. GPW in the Bespoke segment grew from $320.5 million for the year ended December 31, 2018 to $720.4 million for the year ended December 31, 2023, a compound annual growth rate of 17.6%, despite our GPW in 2020 remaining at the same level as in 2019 due to a cautious approach to underwriting in light of political and economic uncertainties arising from the COVID-19 pandemic. During the period from 2018 to 2023, our average underwriting ratio was 59.8%. For the three months ended March 31, 2024, our Bespoke GPW was $153.5 million, compared to $150.8 million for the three months ended March 31, 2023. Credit & Political Risks accounted for 12% and Other Bespoke risk 7% of our GPW for the twelve months ended March 31, 2024.

The Bespoke segment business focuses primarily on highly tailored, innovative and specialized products, where the buying motivation is often driven by regulatory capital relief, capital efficiency or transaction facilitation versus more traditional drivers of insurance needs. The portfolio includes policies covering Credit & Political Risk and Other Bespoke risk transfer opportunities, including political violence and terrorism, limited cyber reinsurance, tax liabilities, title, transactional liabilities and other bespoke solutions to fit our clients’ needs. Given the increased global conflict and national economies shifting further to intellectual property driven value, we believe that the Bespoke segment continues to see significant opportunity for beneficial pricing, terms and conditions and growth. The relationships we have formed with clients and brokers, the underwriting expertise required, and nature of the underlying risks create a higher barrier to entry and help us maintain our position as a leader in the industry. Typically, these lines do not follow the established (re)insurance cycle and are largely influenced by prevailing economic conditions at a given time. As such, these products require highly specialized pricing and other models tailored to the risk profile. For example, for certain significant risk transfer transactions, pricing is largely driven by counterparty credit quality which has low correlation with the current (re)insurance cycle and high correlation with the overall economy and macro events. As a result, Bespoke policies follow a different and diversified loss pattern relative to our Specialty and Reinsurance segments.

The Bespoke portfolio has several economic features that we believe are financially attractive. The contracts often have multi-year tenors, and the products are generally expected to have low and stable attritional loss ratios over the exposure period. The combination of longer tenor and lower expected loss experience creates the potential to capture additional embedded value as premiums are earned over the exposure period under U.S. GAAP. Additionally, the contracts are highly capital-efficient as these risks tend to have little or no correlation to peak natural catastrophe perils driving a higher return on equity than other lines. Furthermore, the contracts typically have customized provisions rather than standard market contractual provisions, creating opportunities to optimize pricing and establish proprietary, recurring relationships with clients. The custom and direct nature of the business have allowed us to lead on substantially all of our contracts creating tailored terms, conditions and pricing.

 

11


Table of Contents

The Bespoke segment benefits from a program of reinsurance protections which are tailored across product lines. The program incorporates facultative covers as well as proportional and non-proportional treaties including aggregate, occurrence and per risk products, which reduce the impact of frequency and severity claims, and protect capital.

Reinsurance

For the year ended December 31, 2023, the Reinsurance segment accounted for 17.2% of our GPW and 13.8% of our NPE with an underwriting ratio of 36.5% and a loss ratio of 9.3%. In 2023, the Reinsurance segment generated $161.0 million in underwriting income. GPW in the Reinsurance segment grew from $328.0 million for the year ended December 31, 2018 to $617.3 million for the year ended December 31, 2023, a compound annual growth rate of 13.5%. During the period from 2018 to 2023, our average underwriting ratio was 76.9%. For the three months ended March 31, 2024 our Reinsurance GPW was $326.8 million compared to $260.4 million for the three months ended March 31, 2023. Our Reinsurance segment from 2018 to 2023 accounted for 47.3%, 45.7%, 41.7%, 38.7%, 20.1% and 17.2%, respectively of our GPW. Property Reinsurance accounted for 17% and other reinsurance 1% of our GPW for the twelve months ended March 31, 2024.

Our Reinsurance segment consists of an actively managed, primarily residential property catastrophe reinsurance book, with closely controlled aggregates using FireAnt, TFP’s proprietary aggregation and analytics system, to monitor exposures in real time. The Reinsurance segment also includes property retrocession and a limited amount of composite and multi-class asset reinsurance. In the context of excess of loss reinsurance products, we focus on underwriting attachment points largely exposed only to true catastrophe events. The portfolio is global in nature with a strong North American concentration and smaller exposures in Japan, Europe, Australasia and elsewhere throughout the world. The Reinsurance segment benefits from a program of retrocession protections which are tailored across product lines. The program incorporates proportional and non-proportional treaties including aggregate, occurrence and parametric products such as cat bonds and industry loss warranties, which reduce the impact of frequency and severity claims, and protect capital. We believe our strategy of pursuing closely controlled aggregates and focusing on residential portfolios in the Reinsurance segment helps keep volatility lower than a portfolio with a greater focus on commercial occupancies.

We benefit from TFP’s sophisticated analytics capabilities and live aggregation tools, excellent relationships with a blend of regional and nationwide carriers (both in the United States and internationally), and strong retail and wholesale broker relations in the distribution of our products. Since 2021, we have developed a view of risk informed by thorough analysis and discussions with weather and forecasting experts. We have concluded that the effects of climate change on perils such as hurricanes, convective storms, floods and wildfires are not currently represented adequately in current vendor models. As such, we have superimposed our own expectations of frequency and severity on third-party vendor models, to form a base for exposure and aggregation tracking.

We have taken proactive steps to reduce volatility and reshape our Reinsurance portfolio to focus only on clients with stronger financial and loss adjustment capabilities and the resources to adjust and manage high volumes of claims in-house. As a consequence, the property reinsurance portfolio was reduced in 2022 and remained at reduced levels throughout 2023. We are increasingly deploying reinsurance capital across large-scale, well-resourced national accounts away from smaller regional underwriters, who we believe are less able to adjust and manage large catastrophe events. We have reduced our exposure to the middle layers of treaty accounts which are more exposed to increased frequency and severity of losses as a result of climate change and secondary perils associated with floods and wildfires without commensurate increases in rates. We expect the impact of these changes to improve the quality of our natural catastrophe-exposed portfolios and reduce volatility. As ever, we will continue to leverage a nimble underwriting approach to adapt to constantly evolving market dynamics to source business when favorable market conditions are present. If there is an increase in property catastrophe rates, as well as favorable terms and conditions, we would intend to capitalize on those trends and dislocations.

 

12


Table of Contents

Insurance Market Conditions

We believe we have significant market opportunities given our ability to innovate and adapt to evolving market conditions. Global economic and industrial development, population increases, greater product awareness and distribution, as well as inflation continue to drive increased need for insurance and reinsurance. The current insurance and reinsurance market environment has experienced a prolonged period of rate increases, structural enhancements and continued improvement of terms and conditions. In 2022, following a period of higher loss ratios due to the frequency and severity of catastrophes, many of our competitors reevaluated and reduced their catastrophe reinsurance business, leading to a decrease in available capacity and a hardening of rates, which persisted into 2023 across both property reinsurance and D&F lines. Specialty markets such as aviation, marine and cyber have seen significant rate hardening in recent years driven by underperformance and market and geopolitical uncertainty. We believe that this combination of factors is driving a sustainable and favorable market environment, with a focus on risk management, disciplined risk selection, improved terms and profitable business, which presents significant market opportunities for us. Property D&F pricing is at the mature phase of the cycle, with rating at the highest levels in the past two decades. Marine cargo prices are elevated and pricing in aviation lines remain hard. We believe the favorable rate environment should persist for the near future across the lines of business on which FIHL focuses.

We believe that the following prevailing factors will contribute to sustained pricing levels across multiple lines:

 

   

Climate Change. The frequency and severity of catastrophes is rising as seen by the increases in catastrophe losses globally in more recent years, requiring rate increases to keep pace. The period between 2017 and 2023, for example, saw 67% more weather events in the United States that cost in excess of $1 billion and 59% higher losses caused by these severe events as compared to the period between 2011 and 2016. We believe that the impact of a warming climate and increased atmospheric moisture and changing weather patterns will result in increased frequency and severity of elemental catastrophe losses (elemental risks related to the elements i.e., weather related hail and storms etc.). 2023 was the warmest year on record and, despite no individual loss exceeding $7 billion, produced catastrophe losses of over $100 billion. The frequent incidence of annual industry-wide natural catastrophe losses in excess of $100 billion in the aggregate during the period from 2017 to 2023 has led us to reshape our portfolio and reduce our exposure to certain perils, thereby reducing the volatility traditionally associated with the property reinsurance classes. Many of our competitors have reevaluated their levels of premiums written against catastrophe reinsurance (see “Business—Competition”). Decreased participation created a lack of supply of reinsurance capacity causing upward pressure on price in the 2022 and 2023 renewal periods. The adjustment to terms, conditions and attachment points meant that due to the lack of significant catastrophe losses in 2023, most reinsurers were able to achieve improved terms. This market adjustment has led to more orderly and measured renewal conditions for 2024. However, given the continued frequency and severity of events, and the significant loss levels prior to 2023, we expect a level of discipline to remain, allowing TFP to underwrite select attractive policies on our behalf and position us to deliver strong risk-adjusted returns.

 

   

Casualty. We believe reserves across the industry remain deficient for accident years from 2013 to 2019 given the levels of claims inflation and nuclear verdicts, with several casualty underwriters seeing prior year adverse developments. Additional concerns have arisen with respect to adequacy of reserves for more recent accident years 2021 to 2023. Further adverse developments and actual loss payouts may deplete competitors’ capital and impair their ability to underwrite. Given Fidelis Insurance Group has made the strategic decision not to write the traditional casualty classes such as general liability, financial lines, directors and officers, and errors and omissions, it is not affected by these potential capital constraining issues, which we believe provides us with a competitive advantage due to our continued position of strength.

 

   

Cost Inflation. Numerous countries including the United States are experiencing inflation in wages, materials and parts. Real inflation for expert loss adjusters and building materials, exacerbated following a catastrophe, is causing an increase in loss costs for many insurers and complicating future estimates. This effect is increasing losses for multiple areas of the Excess & Surplus, Property & Casualty and reinsurance

 

13


Table of Contents
 

markets leading to rate increases and decreased appetite. Fidelis Insurance Group incorporates a specific cost inflation factor in its risk modeling to mitigate the effects of inflation. In addition, social inflation driven by changes in societal views on litigation aimed at insurers is a recent and developing risk highlighted by industry leaders and leading to larger claims. See Item 5. Operating and Financial Review and Prospects—D. Trend Information of the 2023 Annual Report.

 

   

Geopolitical Tensions and Conflicts. The escalation of geopolitical tensions, including conflict in the Middle East and the ongoing Ukraine Conflict, has created uncertainty and potential losses for both global direct insurers and reinsurers. Some lines of business, exacerbated by war and armed conflict, are likely to see reduced supply and/or accelerated rate changes. Fidelis Insurance Group continues to monitor such geopolitical tensions and conflicts to determine the ultimate impact from lines of business which may be exposed.

We believe that these market conditions have led to compelling dislocated underwriting opportunities.

Strengths

We believe that our competitive advantages are based on the following key strengths:

 

   

High quality, mature and well positioned specialty insurance portfolio. We believe our scale achieved since inception and our access to TFP’s sophisticated underwriting analytics and technology platform provides us a competitive advantage. Since we started underwriting in 2015, we have grown our insurance book significantly through organic business expansion including through increased client penetration, new product development, long-term relationships and new reinsurance partnerships. Between 2018 and 2023, we had strong growth with a compound annual growth rate of 38.9% for GPW and compound annual growth rate of 44.5% for NPE. Our GPW continued to grow in the three months ended March 31, 2024 to $1.5 billion compared with $1.2 billion in the three months ended March 31, 2023.

 

   

Strong premium growth in attractive lines capitalizing on market conditions. Our business comprises three segments: Specialty, Bespoke, and Reinsurance. We believe our strategy and capabilities allow us to take advantage of the opportunities presented by evolving (re)insurance markets and to proactively shift our business mix across market cycles to generate strong returns. We have built a diverse portfolio of over 100 products across our three segments serving numerous industries, types of exposure, and geographies. Within our 11 core lines of business we try to take lead positions where possible, and together with TFP, our ability to price and aggregate bespoke risks, adapt to evolving market dynamics in the specialty market, and continually optimize in reinsurance markets uniquely positions us to continue to grow a profitable portfolio. The breadth of our portfolio offering in conjunction with our strategic relationship with TFP also allows us to adjust line sizes and retention rates based on prevailing market conditions and achieve optimal economics for the overall portfolio. The three-segment strategy is central to our growth as it allows us to deliver attractive risk-adjusted returns to shareholders in the long term by managing through (re)insurance cycles and deploying to the most favorable market conditions across the three segments.

We focus on building first mover advantages across our markets. Our product portfolio evolves in response to client demand for tailored products and our market-driven, real-time assessment of risk.

 

   

We have a nimble approach and focus on bottom line. We take pride in making reasoned decisions to actively enter and grow or reduce and exit specific lines of business as opportunity arises or diminishes. We believe our nimble approach and firm focus on bottom-line profitability (i.e., net income, as opposed to top-line growth) of each line of business is key to our strategy and success. Through our oversight of underwriting operations and participation at the UMCC, we are able to identify areas of underperformance quickly and work with our underwriting partners to remediate.

Our strategy is to increase line sizes where appropriate, take the lead in requiring rate changes and establish ourselves as the “go to” market for solutions through our in-force portfolio and new classes of specialty and bespoke products. Depending on market conditions, we exercise discretion in coordination with TFP, where

 

14


Table of Contents

applicable, to increase retention by reducing outwards quota shares to take further advantage of the continued hardening of rates. Similarly, we may also coordinate with TFP to increase line sizes as conditions warrant. We intend to grow specialty classes by writing meaningful line sizes to further push rate increases, achieve differential pricing through leadership and access new classes where there is significant market dislocation. We expect to grow our specialty and bespoke products through a combination of organic growth of our already well-established footprint, systematic cross-selling to clients and innovative new products while maintaining quality underwriting information, high-quality risk selection and multi-line aggregation tools and technology.

 

   

Proven track record of delivering compelling combined ratios, supported by “First choice” access to one of the best underwriting teams in the industry. Fidelis Insurance Group has a proven track record of delivering profitable underwriting results, as evidenced through FIHL’s combined ratio. Between 2018 and 2023, Fidelis Insurance Group achieved strong underwriting performance with an average loss ratio of 45.1% and an average combined ratio of 85.8%. In the year ended December 31, 2023 our loss ratio was 38.1% and combined ratio was 82.1%, respectively.

The performance of our business portfolio written by TFP is primarily driven by the capabilities of the TFP management team, led by Richard Brindle, who is the Chairman and CEO of TFP. Mr. Brindle brings 40 years of experience in the insurance industry and is known for his track record of outperformance across Lloyd’s syndicates and Lancashire under his leadership. We secured a long term agency relationship with TFP under the Framework Agreement, with right of first access to its underwriting business, and strong economic and strategic alignment between the two businesses.

 

   

Robust capital position. We have a strong balance sheet and are committed to preserving our financial strength. At December 31, 2023, our total assets were $10.0 billion and our cash and cash equivalents, restricted cash and cash equivalents, and investments totaled $4.3 billion, primarily highly rated, liquid fixed maturity assets. Our $3.0 billion total capitalization as of December 31, 2023 (which comprises shareholders’ equity plus preference securities and long term debt) provides us with the flexibility to engage in attractive underwriting opportunities and scale quickly when market conditions warrant increased business.

 

   

Highly experienced management team. Our management team consists of industry veterans with many years of relevant experience in insurance, providing FIHL with the necessary functional support, supplemented by the services stipulated under the Framework Agreement and Inter-Group Services Agreement. We are led by Mr. Daniel Burrows, who, prior to joining Fidelis Insurance Group in 2015, was the co-CEO of Aon Benfield’s Global Re Specialty (“GRS”) division. Prior to assuming the CEO role at FIHL, Mr. Burrows had been leading Fidelis Insurance Group’s Bermuda operations and was most recently the Executive Chairman of FIBL and Group Managing Director. The other members of the management team are a mix of experienced individuals who have had held key roles at Fidelis Insurance Group and have long histories of working with TFP, along with other experienced professionals from other industry peers.

 

   

Embedded ESG initiatives that are core to our business. Fidelis Insurance Group is committed to working together with TFP to implement standards for ESG matters. TFP incorporates an ESG assessment into its underwriting on our behalf and is continually refining its process for reviewing individual insurance risks. TFP in the U.K. market has promoted the use of a forced labor clause prohibiting the use of any form of forced labor in marine cargo business and is cooperating with the U.K. Independent Anti-Slavery commissioner and Anti-Slavery International, a non-profit organization to develop a commitment to which insurers and brokers can sign up.

Fidelis Insurance Group and TFP are both members of ClimateWise. The ClimateWise Principles require members to disclose their assessment of the risks and opportunities of climate change and are aligned with the Task Force on Climate-related Financial Disclosure framework. Further, TFP was a founding member of The Poseidon Principles on Marine Insurance, which pledges a net zero marine hull insurance portfolio by 2050. We actively support the transition to a net zero global economy by making renewable energy one of our classes of underwriting through TFP, including the construction of offshore wind turbine farms.

 

15


Table of Contents

We maintain underwriting and investment restrictions that align with our ESG principles as well as those principles that are consistent with leading to long-term value, such as excluding a number of sectors that we believe pose risks of harm to people, animals and the environment. Furthermore, FIHL’s investment portfolio is managed in a manner that is consistent with Fidelis Insurance Group’s sustainability principles and its ESG objectives. The fixed maturity portfolio has a minimum requirement for investments that meet ESG thresholds, prohibits investing in issuers with poor ESG ratings, and restricts exposure to certain industries and behaviors.

Further, our Enterprise Resource Group (the “ERG”) works to enhance employee engagement by providing opportunities that match their workplace values. We believe that this voluntary, employee-driven initiative encourages community, support, and advocacy, involving diversity, equity, inclusion, employee

engagement, environmental concerns, and philanthropy. In 2024, the ERG is prioritizing charitable causes aligned with our company values and community impact, which we hope to result in impactful grants, more cultural exchanges, and enhanced educational resources on diversity.

Our Strategy

We are set up to be nimble, thoughtful, and efficient decision-makers and we believe that we are able to respond quickly to an ever-changing world and a constantly evolving marketplace. We believe these attributes allow us to target opportunities that we expect to offer a compelling balance of risk and reward that creates long-term value through the cycle by delivering consistent returns to shareholders. We intend to scale our business to reflect market conditions and pursue prudent capital management and profitable underwriting on a loss ratio and combined ratio basis in pursuance of our financial targets.

Our strategy involves the following:

 

   

Profitable underwriting. We will continue to focus on underwriting profitably through (re)insurance cycles. As our insurance portfolio matures and scales, we believe we will also have an opportunity to increase our underwriting leverage. We seek to direct capital to attractively priced opportunities based on market conditions to address client needs.

We seek to manage volatility over the cycle in our underwriting result by writing a balanced and diversified portfolio of predominantly specialty business, maintaining strict underwriting and pricing discipline and strategic reinsurance protection. Our strategy has frequently generated better risk-adjusted returns than many of our competitors who focus on specific niches exclusively or have large exposure to natural catastrophe reinsurance. We have taken measures to actively manage and in many cases reshape our natural catastrophe exposure in light of greater severity and frequency of catastrophe events and concerns around global climate change.

We leverage our relationship with TFP to continue disciplined underwriting with the use of TFP’s integrated technology solutions, including monitoring real-time market conditions to best capture unique opportunities. TFP’s daily processes, which we actively participate in, will enable it, on our behalf, to maintain a live, dynamic picture of the current underwriting environment that drives daily underwriting decisions, including the daily UMCCs. We believe that our risk selection as a result of these processes should allow us to deploy significant line sizes that in turn allow us to be a “rate maker” rather than a “rate taker.”

 

   

Expand our presence in the specialty insurance market. The Specialty segment has benefited from a hard pricing environment over recent years which has generated profitable growth. To take advantage of mature hard market conditions, following year-on-year compound rate increases across specialty lines we will seek to grow our top-line income and maintain leading market positions that facilitate differential pricing terms and conditions through a disciplined and nimble approach to underwriting in conjunction with our underwriting partners who are carefully selected based on their underwriting performance. We expect to

 

16


Table of Contents
 

continue to leverage our access to TFP’s long-standing and trusted relationships with brokers and clients, built over the years by key executives, some of whom have almost 40 years of experience in insurance, both specialty and bespoke markets. The continued access to such long-standing and trusted relationships coupled with TFP’s extensive expertise will provide significant opportunity to quote, underwrite and bind attractive niche specialty insurance policies in an efficient manner. By leveraging the UMCC, where all lines of business are considered in real time, we expect to be able to pivot quickly to the most attractive opportunities. By focusing on markets in which we have expertise and in which we can provide innovative new products, we believe we have a strong ability to capture profitable business.

A recent example of such innovation is the cooperation between Fidelis Insurance Group and TFP to launch Itasca MGA, an aviation-focused managing general agent (“MGA”) of Pine Walk, a wholly owned subsidiary of TFP. Itasca MGA specializes in underwriting, structuring and managing risks associated with secured commercial aviation financing. We believe with the experience and expertise of the Itasca MGA team and their partnerships with established market participants that they are positioned to become one of the key solution providers for global airlines and the broader aviation market.

Furthermore, in March 2024, Fidelis Insurance Group jointly announced with TFP the launch of Syndicate 3123. Fidelis Insurance Group’s participation in Syndicate 3123 includes a 9.9% contribution of Syndicate 3123’s total capital requirement for the second half of 2024, and a variable quota share of the book of business underwritten by Syndicate 3123. TFP is also contributing 9.9% of Syndicate 3123’s capacity, further demonstrating alignment of interest between the parties, with individual members at Lloyd’s and other investors providing the remainder of the capital requirements.

 

   

Manage and develop strategic partnerships. We aim to optimize underwriting results via comprehensive management and oversight of our strategic underwriting partners. Our business model enables us to focus on building relationships with first in class underwriting teams while also achieving operational excellence through collaboration, enhanced efficiencies and effective oversight processes.

We have an exclusive right of first access to TFP’s underwriting business during the term of the Framework Agreement. Based on Fidelis’ historical experience, we expect this long-term partnership to deliver strong returns to our shareholders, primarily driven by our underwriting results. We aim to be good stewards of capital by effectively balancing capital deployment across market opportunities with capital distributions to our shareholders.

Subject to the exclusivity obligations set out in the Framework Agreement (see Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions—Framework Agreement—Exclusivity, Rights of First Offer and Rights of First Refusal of the 2023 Annual Report), we continue to explore additional avenues for the deployment of capital into new underwriting opportunities by targeting strategic partners across lines of business which support our growth strategy, in order to achieve diversification and meet return criteria.

 

   

Uphold a strong balance sheet. We believe as interest rates remain elevated, we will continue to have opportunities to earn a higher yield while maintaining an appropriately conservative investment portfolio to support our business. We maintain robust procedures for setting our reserves for losses and loss adjustment expenses and actively managing risk in our portfolio. From January 1, 2018 to December 31, 2023, we had net favorable prior year reserve development of $192.6 million from our reserves for losses and loss adjustment expenses. We believe a robust balance sheet best positions us to be a provider of choice for policyholders and take advantage of large or sudden market pricing dislocations.

 

   

Active capital management. We invest and manage our capital proactively with a goal of maximizing value for our shareholders by growing book value, generating consistent returns and optimizing capital management. We maintain a strong, highly rated balance sheet with total capital of $3.0 billion as of December 31, 2023. We have had net favorable prior year reserve development every year since inception, demonstrating our consistent and prudent approach to reserving. In addition, our focus is on short-tail lines with carefully managed catastrophe exposure and no longer tail casualty business. This approach, and our minimal exposure to social

 

17


Table of Contents
 

inflation risk, reinforces our confidence that we can avoid meaningful reserve volatility moving forward. Further, we continue to strategically use reinsurance, including our 20% whole account quota share with Travelers that recently renewed for a second year, as a flexible and aligned source of capital.

Looking ahead, our primary focus remains capitalizing on the attractive growth opportunities to deliver profitable returns while also continuing to explore ways to optimize our capital structure and create value for shareholders. Our strategic capital management priorities include: allocating capital back into the business and deploying capital into attractive underwriting opportunities; reassessing our outwards reinsurance purchasing program; and returning capital to shareholders through a combination of our recently announced share repurchase program of up to $50.0 million of our outstanding Common Shares (the “Share Repurchase Program”) and our dividend policy (see “Dividend Policy”) .

In relation to the Share Repurchase Program, we reported in Exhibit 99.2 of the Q1 2024 Quarterly Report that during the three months ended March 31, 2024, we repurchased 357,602 Common Shares for $5.0 million. Subsequently, from April 1, 2024, to May 17, 2024, we repurchased an additional 1,026,968 Common Shares for $18.9 million.

 

   

Foster a strong employee culture: Operate a supportive and respectful performance led culture of openness, honesty, challenge and inclusiveness. Key to our strategy is the development of a culture that reflects the shared values, behaviors and standards that contribute to a workplace environment which encourages and supports performance and ethical behaviors. Our employee values are as follows:

 

   

Autonomy: Fidelis Insurance Group cultivates a culture of empowerment, accountability and self-direction within our organization. We foster an environment where individuals have the freedom to exercise their judgement, set ambitious goals, and work towards achieving them in ways that they deem most effective.

 

   

Connected: We foster an inclusive and community orientated culture which recognizes that strength lies in unity and a shared sense of purpose among all stakeholders. We recognize that our purpose is to create tangible benefit for customers, shareholders and society at large, reflecting a commitment to ethical and socially responsible business practices.

 

   

Expert: Our Group values expertise, encourages intellectual curiosity and fosters a dynamic environment where individuals can push boundaries to explore new possibilities. We cultivate a culture of creative thinking, experimentation with new ideas, and a willingness to embrace change to drive progress and innovation within our organization.

Summary Risk Factors

Investing in the Common Shares involves risks. Prospective investors should carefully consider the risks described in “Risk Factors,” below and in Item 3. Key Information—D. Risk Factors of the 2023 Annual Report, as well as other information contained in this prospectus before making an investment decision. Any of the factors set forth under “Risk Factors” and in Item 3. Key Information—D. Risk Factors of the 2023 Annual Report could materially adversely affect our business, financial condition, results of operations or cash flows and could impact any forward-looking statements. Prospective investors should note that such risks are not the only ones we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect us in the future. Among these important risks are the following:

 

   

the inherent uncertainties of modeling and reserving processes on which we rely and failure of any risk management and loss limitation methods we employ;

 

   

the impact of epidemics, pandemics or any other public health crises, including the COVID-19 pandemic;

 

   

the impact of current global economic, inflationary and geopolitical environment, the Ukraine Conflict and the conflict in the Middle East, as well as changing climate conditions;

 

18


Table of Contents
   

the level of success of our acquisition and investment strategies;

 

   

the high level of competition and consolidation in our industry;

 

   

a downgrade or withdrawal of, or other negative action relating to, the financial strength rating(s) by insurance rating agencies;

 

   

loss of business reputation or negative publicity, including as a result of litigation or coverage disputes;

 

   

our ability to retain and recruit key personnel;

 

   

industry and market conditions, volatility and developments, which could impact our investment portfolio;

 

   

our ability to adjust to developments in the legal, economic, tax or regulatory environment;

 

   

the volatile, unpredictable and highly cyclical nature of the industry in which we operate;

 

   

technology breaches or failures, including those resulting from malicious cyber-attacks;

 

   

data protection failures;

 

   

our exposure to low frequency, high severity events;

 

   

the impact of any deterioration or termination of our relationship with TFP; and

 

   

our reliance on third parties for certain critical business operations.

 

19


Table of Contents

Our Corporate Structure

The following chart presents a simplified summary overview of the corporate structure for Fidelis Insurance Group, which, other than the percentage ownership changes noted at note (1) below, will remain unchanged following the consummation of this offering.

 

LOGO

 

(1)

See “Principal and Selling Shareholders” for detail of the percentage ownership of FIHL prior to this offering, as well as the percentage ownership of FIHL following the consummation of this offering by each of TFP HoldCo, the Founders, certain other institutional investors and directors and senior managers as a group.

(2)

FUL is a limited liability company incorporated in England and Wales, authorized by the Prudential Regulation Authority (the “PRA”), and supervised by the Financial Conduct Authority (the “FCA”) and the PRA as an insurer.

(3)

FIBL is a limited liability company incorporated in Bermuda, authorized and supervised by the BMA as an insurer.

(4)

FIHL (UK) Services is a limited liability company incorporated in England and Wales and is the service company of Fidelis Insurance Group. FIHL (UK) Services also has a branch in Ireland.

(5)

FEHL is a limited liability company incorporated in England and Wales.

(6)

FIID is a designated activity company incorporated in Ireland, authorized and supervised by the Central Bank of Ireland (the “CBI”) as an insurer.

 

20


Table of Contents

Director Nomination Rights

Under the terms of the Amended and Restated Common Shareholders Agreement, TFP HoldCo and certain of the existing major investors in FIHL are entitled to nominate representative directors to the Board, so long as they each beneficially own a specified minimum percentage of our Common Shares. Under the terms of the Amended and Restated Common Shareholders Agreement, the right to nominate one individual (a “Nominee”) to serve as a director on the Board is afforded to each of the Crestview Funds (as defined below, see “Principal and Selling Shareholders”), CVC Falcon Holdings Limited (“CVC”) and Pine Brook Feal Intermediate, L.P. (“Pine Brook”) (each a “Founder” and together, the “Founders”) and to TFP HoldCo, so long as they each beneficially own a specified minimum percentage of our Common Shares. Under the terms of the Amended and Restated Common Shareholders Agreement, if a Nominee is not appointed or elected to the Board because of such person’s death, disability, disqualification, withdrawal as a Nominee, failure to be elected or for another reason is unavailable or unable to serve on the Board, the applicable nominating Founder or TFP HoldCo shall be entitled to designate promptly another Nominee, the director position for which the original Nominee was nominated shall not be filled pending such designation and FIHL shall use commercially reasonable efforts and consistent with the NYSE corporate governance standards to cause the Board to promptly fill the vacancy with such successor Nominee.

 

21


Table of Contents

The Offering

 

Common Shares offered by the Selling Shareholders

9,000,000 Common Shares

 

Common Shares outstanding after this offering

116,898,062 Common Shares
 

 

Underwriters’ option to purchase additional Common Shares from the Selling Shareholders

The Selling Shareholders have granted the underwriters an option to purchase up to an additional 1,350,000 Common Shares at the public offering price less underwriting discounts and commissions, for 30 days after the date of this prospectus.

 

Use of proceeds

The Selling Shareholders will receive all of the net proceeds from the sale of the Common Shares offered pursuant to this prospectus. We are not selling any Common Shares under this prospectus and will not receive any of the proceeds from the sale of our Common Shares in this offering, including from any exercise by the underwriters of their option to purchase additional Common Shares.

 

Dividend Policy

Any decision to declare and pay dividends in the future will be made at the sole discretion of our Board and will depend on various factors. See “Dividend Policy.”

 

NYSE Symbol

FIHL

 

Risk Factors

See “Risk Factors” beginning on page 25 of this prospectus and the risk factors included in Item 3. Key Information—D. Risk Factors of the 2023 Annual Report, as well as other information included in this prospectus, for a discussion of factors you should carefully consider before deciding to invest in our Common Shares.

Except as otherwise indicated, the number of Common Shares outstanding after this offering:

 

   

excludes 3,252,154 Common Shares reserved for issuance under our long-term 2023 share incentive plan (the “Long-Term Incentive Plan”) as of May 17, 2024;

 

   

excludes 1,660,965 Common Shares underlying restricted share unit awards granted under the Long-Term Incentive Plan as of May 17, 2024; and

 

   

assumes the underwriters’ option to purchase additional Common Shares from the Selling Shareholders will not be exercised.

 

22


Table of Contents

SUMMARY FINANCIAL AND OPERATING DATA

The tables below present summary financial and operating data at, and for, the periods indicated. The following information is only a summary and should be read in conjunction with Item 5. Operating and Financial Review and Prospects and Item 18. Financial Statements of the 2023 Annual Report and Exhibit 99.2 of the Q1 2024 Quarterly Report.

The summary balance sheet data at December 31, 2023 and 2022 and the summary statement of operations data for the years ended December 31, 2023, 2022 and 2021 have been derived from our audited consolidated financial statements and the related notes thereto, incorporated by reference from the 2023 Annual Report. The summary balance sheet data at March 31, 2024 and the summary statement of operations data for the three months ended March 31, 2024 and 2023 have been derived from our unaudited consolidated financial statements and related notes thereto, incorporated by reference from Exhibit 99.2 of the Q1 2024 Quarterly Report. In our opinion, the unaudited consolidated financial statements have been prepared on a basis consistent with the audited consolidated financial statements and contain all adjustments, consisting only of normal and recurring adjustments, necessary for a fair statement of such financial statements. We have included, in our opinion, all adjustments necessary to state fairly our results of operations for those periods.

These historical results are not necessarily indicative of the results that may be expected for any future period.

SUMMARY STATEMENT OF OPERATIONS DATA

 

     Three Months Ended
March 31,
    Year ended December 31,  
     2024     2023     2023     2022     2021  
     ($ in millions)  

Revenues

          

Gross premiums written

   $ 1,514.3     $ 1,245.3     $ 3,579.0     $ 3,018.1     $ 2,800.8  

Reinsurance premiums ceded

     (736.2     (585.6     (1,442.4     (1,159.7     (1,194.2
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net premiums written

     778.1       659.7       2,136.6       1,858.4       1,606.6  

Change in net unearned premiums

     (290.1     (273.7     (304.0     (357.9     (446.9
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net premiums earned

     488.0       386.0       1,832.6       1,500.5       1,159.7  

Net realized and unrealized investment gains/(losses)

     (9.0     2.8       4.9       (33.7     13.5  

Net investment income

     41.0       20.4       119.5       40.7       20.6  

Other income

     —        3.5       0.1       1.9       1.0  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues before net gain on distribution of TFP

     520.0       412.7       1,957.1       1,509.4       1,194.8  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Net gain on distribution of The Fidelis Partnership

     —        1,639.1       1,639.1       —        —   
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total revenues

     520.0       2,051.8       3,596.2       1,509.4       1,194.8  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Expenses

          

Losses and loss adjustment expenses

     182.3       159.6       698.8       830.2       696.8  

Policy acquisition expenses

     212.9       129.2       723.8       384.4       250.1  

General and administrative expenses

     23.6       16.6       82.7       165.5       130.7  

Corporate and other expenses

     —        1.5       4.1       20.5       2.7  

Net foreign exchange (gains)/losses

     (2.5     1.5       4.1       (6.8     0.4  

Financing costs

     8.6       8.6       35.5       35.5       35.4  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total expenses

     424.9       317.0       1,549.0       1,429.3       1,116.1  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

23


Table of Contents
     Three Months Ended
March 31,
    Year ended December 31,  
     2024     2023     2023      2022     2021  
     ($ in millions)  

Income before income taxes

     95.1       1,734.8       2,047.2        80.1       78.7  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Income tax (expense)/benefit

     (13.9     (2.2     85.3        (17.8     (0.4
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Net income

     81.2       1,732.6       2,132.5        62.3       78.3  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Net income attributable to non-controlling interests

     —        —        —         (9.7     (10.0
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

Net income available to common shareholders

   $ 81.2     $ 1,732.6     $ 2,132.5      $ 52.6     $ 68.3  
  

 

 

   

 

 

   

 

 

    

 

 

   

 

 

 

SUMMARY BALANCE SHEET DATA

 

     At March 31,      At December 31,  
     2024      2023      2022  
     ($ in millions)  

Total investments

   $ 3,350.4      $ 3,341.4      $ 2,425.0  
  

 

 

    

 

 

    

 

 

 

Cash and cash equivalents and restricted cash and cash equivalents

     892.2        964.1        1,407.9  
  

 

 

    

 

 

    

 

 

 

Reinsurance balances

        

Reinsurance balance recoverable on paid losses

     193.0        182.7        159.4  

Reinsurance balance recoverable on reserves for losses and loss adjustment expenses

     1,135.2        1,108.6        976.1  

Deferred reinsurance premium

     1,469.2        1,061.4        823.7  

Premiums and other receivables

     2,836.6        2,209.3        1,862.7  

Other assets

     1,390.1        1,160.6        657.7  
  

 

 

    

 

 

    

 

 

 

Total assets

     11,266.7        10,028.1        8,312.5  
  

 

 

    

 

 

    

 

 

 

Liabilities, and shareholders’ equity

        

Liabilities

        

Reserves for losses and loss adjustment expenses

     2,541.1        2,448.9        2,045.2  

Unearned premiums

     3,846.2        3,149.5        2,618.6  

Reinsurance balances payable

     1,414.4        1,071.5        1,057.0  

Long term debt

     448.4        448.2        447.5  

Preference securities

     58.4        58.4        58.4  

Other liabilities

     441.1        401.8        98.7  
  

 

 

    

 

 

    

 

 

 

Total liabilities

     8,749.6        7,578.3        6,325.4  
  

 

 

    

 

 

    

 

 

 

Commitments and contingencies

        

Shareholders’ equity

        

Total shareholders’ equity including non-controlling interests

     2,517.1        2,449.8        1,987.1  
  

 

 

    

 

 

    

 

 

 

Total liabilities and shareholders’ equity

     11,266.7        10,028.1        8,312.5  
  

 

 

    

 

 

    

 

 

 

 

24


Table of Contents

OTHER DATA

 

       Three Months Ended
March 31,
       Year ended December 31,  
       2024        2023        2023        2022        2021  
       ($ in millions, except for per share amounts)  

Loss ratio(1)

       37.4        41.3        38.1        55.3        60.1

Policy acquisition expenses (third party) ratio(2)

       27.9        27.2        27.2        25.6        21.6

Underwriting ratio(3)

       65.3        68.5        65.3        80.9        81.7

The Fidelis Partnership commissions ratio(4)

       15.7        6.3        12.3              

General and administrative expenses ratio(5)

       4.8        4.3        4.5        11.0        11.3

Combined ratio(6)

       85.8        79.1        82.1        91.9        93.0

Net realized and unrealized investment gains/(losses)

     $ (9.0      $ 2.8        $ 4.9        $ (33.7      $ 13.5  

Net investment return(7)

     $ 32.0        $ 23.2        $ 124.4        $ 7.0        $ 34.1  

Debt to total capitalization ratio(8)

       16.8        21.0        17.1        20.3        20.0

Fully diluted book value per share(9)

     $ 21.22        $ 17.19        $ 20.69        $ 9.91        $ 10.05  

Operating EPS(10)

     $ 0.74        $ 0.85        $ 3.49        $ 0.45        $ 0.29  

ROAE(11)

       3.3        89.3        96.3        2.6        3.4

Operating ROAE(12)(13)

       3.5        5.1        18.8        4.5        2.9

 

(1)

Calculated by dividing losses and loss adjustment expenses by NPE.

(2)

Calculated by dividing policy acquisition expenses (third party) by NPE.

(3)

Calculated by dividing losses and loss adjustment expenses and policy acquisition expenses (third party) by NPE, or equivalently, by adding the loss ratio and the policy acquisition expenses (third party) ratio.

(4)

Calculated by dividing TFP commission expenses by NPE.

(5)

Calculated by dividing general and administrative expenses by NPE.

(6)

Calculated by adding losses and loss adjustment expenses, policy acquisition expenses and general and administrative expenses by NPE, or equivalently, by adding the underwriting ratio, TFP commissions ratio and general and administrative expenses ratio.

(7)

Net investment return includes net investment income plus net realized and unrealized investment gains and losses.

(8)

Ratio, in percent, of total long-term debt and preference securities to total capitalization. The total capitalization comprises shareholders’ equity including non-controlling interests plus total long-term debt and preference securities.

(9)

Represents the equity attributable to Fidelis Insurance Group Common Shareholders divided by the sum of the Common Shares outstanding and the dilutive impact of “in the money” outstanding warrants and RSUs.

(10)

Operating EPS is a non-GAAP measure that represents a valuable measure of profitability and is calculated by dividing operating net income by the weighted average diluted Common Shares outstanding. See “—Reconciliation of Operating EPS” for a reconciliation to the most directly comparable financial measure stated in accordance with U.S. GAAP.

(11)

Calculated by dividing net income by average common shareholders’ equity.

(12)

Calculated as operating net income divided by adjusted average common shareholders’ equity.

(13)

Operating ROAE is a non-GAAP measure. See Item 5. Operating and Financial Prospects—A. Operating Results—Performance Measures and Non-GAAP Financial Measures of the 2023 Annual Report and Management’s Discussion and Analysis of Financial Condition and Results of Operations—Performance Measures and Non-GAAP Financial Measures of Exhibit 99.2 of the Q1 2024 Quarterly Report for a reconciliation to the most directly comparable financial measures stated in accordance with U.S. GAAP.

 

25


Table of Contents

RECONCILIATION OF OPERATING EPS

Operating EPS is a non-GAAP financial measure that represents a valuable measure of profitability and enables investors, analysts, rating agencies and other users of its financial information to more easily analyze Fidelis Insurance Group’s results in a manner similar to how management analyzes Fidelis Insurance Group’s underlying business performance. It is calculated by dividing operating net income by the weighted average diluted common shares outstanding.

The table below sets out the calculation of Operating EPS for the three months ended March 31, 2024 and 2023, and for the years ended December 31, 2023, 2022 and 2021.

 

     Three Months Ended
March 31,
    Year Ended December 31,  
     2024     2023     2023     2022     2021  
     ($ in millions, except for per share amounts)  

Net income available to common shareholders

     81.2       1,732.6       2,132.5       52.6       68.3  

Adjustment for net gain on distribution of The Fidelis Partnership

     —        (1,639.1     (1.639.1     —        —   

Adjustment for net realized and unrealized investment (gains)/losses

     9.0       (2.8     (4.9     33.7       (13.5

Adjustment for net foreign exchange (gains)/losses

     (2.5     1.5       4.1       (6.8     0.4  

Adjustment for corporate and other expenses

     —        1.5       4.1       20.5       2.7  

Income tax effect of the above items (1)

     (0.4     —        (97.8     (10.5     0.8  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Operating net income

   $ 87.3     $ 93.7     $ 398.9     $ 89.5     $ 58.7  
  

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Weighted average Common Shares outstanding

     117,658,016       110,771,897       114,313,971       194,290,180       195,491,804  

Share-based compensation plans

     690,368       —        10,712       5,033,674       4,888,437  

Weighted average diluted Common Shares outstanding

     118,348,384       110,771,897       114,324,683       199,323,854       200,380,241  

Earnings per diluted Common Share

   $ 0.69     $ 15.64     $ 18.65     $ 0.26     $ 0.34  

Operating EPS

   $ 0.74     $ 0.85     $ 3.49     $ 0.45     $ 0.29  

 

(1)

Income tax (benefit)/expense on adjustments to net income available to holders of Common Shares. The 2023 income tax benefit includes the establishment of a net deferred tax asset of $90.0 million related to the implementation of the Bermuda corporate income tax.

 

26


Table of Contents

RISK FACTORS

Investing in the Common Shares involves risks. Prospective investors should carefully consider the risks described below and those discussed in Item 3. Key Information—D. Risk Factors of the 2023 Annual Report which is incorporated by reference in this prospectus, our other SEC filings incorporated by reference in this prospectus as well as other information contained in this prospectus before making an investment decision. The risks described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially and adversely affect us in the future. Any of the following risks could materially adversely affect our business, prospects, financial condition, results of operations or cash flows and could impact any forward-looking statements. See “Cautionary Note Regarding Forward-Looking Statements.” In such case, the trading price of the Common Shares may decline and investors may lose all or part of their original investments.

Risks Relating to the Common Shares and this Offering

The price per Common Share may change significantly following this offering, and investors may not be able to resell their Common Shares at or above the price they paid or at all, and investors could lose all or part of their investment as a result.

The Selling Shareholders and the underwriters will negotiate the offering price of the Common Shares to be offered pursuant to this prospectus. Investors may not be able to resell their Common Shares at or above the offering price due to a number of factors, such as those listed in this “Risk Factors” section, and Item 3. Key Information—D. Risk Factors of the 2023 Annual Report and the following:

 

   

comments by securities analysts or other third parties, including blogs, articles, message boards, social media and other media;

 

   

occurrence of a large catastrophic loss;

 

   

results of operations that vary from the expectations of securities analysts and investors;

 

   

results of operations that vary from those of Fidelis Insurance Group’s competitors compared to market expectations;

 

   

changes in expectations as to Fidelis Insurance Group’s future financial performance, including financial estimates and investment recommendations by securities analysts and investors;

 

   

changes in market valuations of, or earnings and other announcements by, companies in the (re)insurance industry;

 

   

declines in the market prices of stocks generally, particularly those in the (re)insurance industry;

 

   

announcements by Fidelis Insurance Group or its competitors of significant contracts, new products or technologies, acquisitions, joint ventures, other strategic relationships or capital commitments;

 

   

changes in general economic or market conditions or trends in the (re)insurance industry or the economy as a whole and, in particular, in the softening of rates;

 

   

changes in business or regulatory conditions which adversely affect the (re)insurance industry, Fidelis Insurance Group or TFP;

 

   

future issuances, exchanges or sales, or expected issuances, exchanges or sales of the Common Shares or other securities of FIHL;

 

   

investor perceptions, of or the investment opportunity associated with, the Common Shares relative to other investment alternatives;

 

   

the market’s reaction to Fidelis Insurance Group’s outsourced underwriting arrangements with TFP, which is a novel structure among Fidelis Insurance Group’s peers;

 

27


Table of Contents
   

the market’s reaction to Fidelis Insurance Group’s reduced disclosure and other requirements as a result of being treated as a “foreign private issuer”;

 

   

the public’s response to press releases or other public announcements by Fidelis Insurance Group or third parties, including Fidelis Insurance Group’s filings with the SEC;

 

   

guidance, if any, that Fidelis Insurance Group provides to the public, any changes in this guidance or Fidelis Insurance Group’s failure to meet this guidance;

 

   

the development and sustainability of an active trading market for our Common Shares; and

 

   

other events or factors, including those resulting from informational technology system failures and disruptions, natural disasters, war, acts of terrorism or responses to these events.

Furthermore, the stock market has experienced and is likely to continue to experience extreme volatility and significant price and volume fluctuations that, in some cases, have been and may be unrelated or disproportionate to the operating performance of particular companies. These broad market and industry fluctuations may adversely affect the market price of our Common Shares, regardless of our actual operating performance. In addition, price volatility may be greater if the public float and trading volume of our Common Shares continues to be low. The Common Shares began trading on the NYSE on June 28, 2023 and as such, are newly listed, have a limited public float and a short trading history to date.

Following periods of market volatility, shareholders in U.S. listed groups from time to time may institute securities class action litigation. If Fidelis Insurance Group were to become involved in securities litigation, it could have a substantial cost and divert resources and the attention of executive management from our business regardless of the outcome of such litigation.

If securities or industry analysts do not publish research or reports about Fidelis Insurance Group’s business or if they downgrade the Common Shares or the (re)insurance industry generally, or if there is any fluctuation in Fidelis Insurance Group’s ratings, the price of the Common Shares and trading volume could decline.

The trading market for our Common Shares relies in part on the research and reports that industry or financial analysts publish about Fidelis Insurance Group and its business. Fidelis Insurance Group does not control these analysts. Furthermore, if one or more of the analysts who do cover Fidelis Insurance Group downgrade the Common Shares or the (re)insurance industry, or the stock of any of Fidelis Insurance Group’s competitors, or publish inaccurate or unfavorable research about Fidelis Insurance Group’s business, the price of Common Shares could decline. If one or more of these analysts stop covering Fidelis Insurance Group or fail to publish reports on it regularly, we could lose visibility in the market, which in turn could cause the price or trading volume of the Common Shares to decline.

Additionally, any fluctuation in Fidelis Insurance Group’s ratings may impact Fidelis Insurance Group’s ability to access debt markets in the future or increase the cost of future debt, which could have a material adverse effect on Fidelis Insurance Group’s operations and financial condition, which in return may adversely affect the trading price of the Common Shares.

If FIHL, the Selling Shareholders or other existing shareholders sell additional Common Shares after this offering or are perceived by the public markets as intending to sell additional Common Shares, the market price of the Common Shares could decline.

The sale of Common Shares in the public market by the Company in a primary offering or its existing shareholders in a secondary offering, including sales pursuant to this prospectus, or the perception that such sales could occur, could harm the prevailing market price of the Common Shares. Such sales, the perception that the holders of a large number of Common Shares intend to sell Common Shares or the possibility that such sales may occur, also might make it more difficult for FIHL to sell Common Shares in the future at a time and at a

 

28


Table of Contents

price that it deems appropriate. Sales or resales of a substantial number of Common Shares in the public market could occur at any time and may cause the market price of our securities to drop significantly, even if our business is doing well. We are unable to predict the effect that such sales may have on the prevailing market price of the Common Shares.

All of our Common Shares currently outstanding, including the Common Shares sold in this offering, are freely tradable without restriction or further registration under the Securities Act so long as they are held by persons other than our “affiliates,” as that term is defined under Rule 144 of the Securities Act, and certain executives of Fidelis Insurance Group and TFP. Certain existing holders of our Common Shares, who are also our “affiliates” as that term is defined under Rule 144 of the Securities Act, have registration rights, pursuant to the Registration Rights Agreement, subject to some conditions, to require us to file registration statements covering the sale of their Common Shares or to include their Common Shares in registration statements that we may file for ourselves or other shareholders in the future. In the event that we register the Common Shares for the holders of registration rights, they can be freely sold in the public market upon issuance. See “Shares Eligible for Future Sales,” as well as Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions and Item 19. Exhibits—Exhibit 2.1 Description of Securities of the 2023 Annual Report.

The Common Shares being offered pursuant to this prospectus by the Selling Shareholders represent approximately 7.699% of FIHL’s outstanding Common Shares as of May 17, 2024. As restrictions on resale end and certain lock-up agreements entered into in relation to the initial public offering of Common Shares expire, the volatility of the market price of the Common Shares could increase or a significant reduction of the market price of the Common Shares could occur if the holders sell such Common Shares or are perceived by the market as intending to sell such Common Shares. These factors could also make it more difficult for us to raise additional funds through offerings of Common Shares or other securities.

A decline in the price of our Common Shares may impede our ability to raise capital through the issuance of additional Common Shares or other equity securities. See “Shares Eligible for Future Sales” and Item 19. Exhibits—Exhibit 2.1 Description of Securities of the 2023 Annual Report.

Future offerings of debt or equity securities which would rank senior to the Common Shares may adversely affect the market price of the Common Shares.

If, in the future, FIHL decides to issue debt or equity securities that rank senior to the Common Shares, it is likely that such securities will be governed by an indenture or other instrument containing covenants restricting Fidelis Insurance Group’s operating flexibility. Additionally, any convertible or exchangeable securities that FIHL may issue in the future may have rights, preferences and privileges more favorable than those of the Common Shares and may result in dilution to owners of the Common Shares. FIHL and, indirectly, its shareholders, will bear the cost of issuing and servicing such securities.

Fidelis Insurance Group takes a proactive approach to capital management based on opportunities presented and sought out. Fidelis Insurance Group may therefore seek to raise additional funds through opportunistic financings in order to take advantage of market conditions and opportunities to write more business. FIHL may raise such funds by issuing further securities including equity and debt, whether senior or subordinated in ranking.

Because the decision to issue debt or equity securities in any future offering will depend on market conditions and other factors beyond Fidelis Insurance Group’s control, Fidelis Insurance Group cannot predict or estimate the amount, timing or nature of such future offerings. Thus, holders of Common Shares will bear the risk of future offerings reducing the market price of the Common Shares and diluting the value of their holdings in FIHL.

 

29


Table of Contents

We are currently listed on the NYSE. If we are unable to maintain listing of the Common Shares on the NYSE or any stock exchange, our stock price could be adversely affected and the liquidity of the Common Shares and our ability to obtain financing could be impaired and it may be more difficult for our shareholders to sell their Common Shares.

Although our Common Shares are currently listed on the NYSE, we may not be able to continue to meet the NYSE’s minimum listing requirements or those of any other national securities exchange. The listing rules of the NYSE require listed issuers to comply with certain standards in order to remain listed on its exchange. If, for any reason, we should fail to maintain compliance with these listing standards and the NYSE should delist the Common Shares from trading on its exchange and we are unable to obtain listing on another national securities exchange, a reduction in some or all of the following may occur, each of which could have a material adverse effect on our shareholders:

 

   

the liquidity of the Common Shares;

 

   

the market price of the Common Shares;

 

   

our ability to obtain financing for the continuation of our operations;

 

   

the number of investors that will consider investing in the Common Shares;

 

   

the number of market makers in the Common Shares;

 

   

the availability of information concerning the trading prices and volume of the Common Shares; and

 

   

the number of broker-dealers willing to execute trades in the Common Shares.

 

30


Table of Contents

USE OF PROCEEDS

The Selling Shareholders will receive all of the net proceeds from the sale of the Common Shares offered pursuant to this prospectus. We are not selling any Common Shares under this prospectus and will not receive any proceeds from the sale of Common Shares, including from any exercise by the underwriters of their option to purchase additional Common Shares. The Selling Shareholders participating in this offering are described under the section titled “Principal and Selling Shareholders.”

 

31


Table of Contents

DIVIDEND POLICY

The declaration, amount and payment of any dividends on our Common Shares will be at the sole discretion of the Board, which may take into account general and economic conditions, our financial condition and results of operations, our available cash and current and anticipated cash needs, capital requirements, contractual, legal, tax and regulatory restrictions and implications on the payment of dividends by us to our shareholders or by our subsidiaries to us, including restrictions under any of our then outstanding indebtedness, and such other factors as the Board may deem relevant. If we elect to pay dividends in the future, we may reduce or discontinue entirely the payment of such dividends at any time. At the Board’s discretion, we declare and pay a dividend quarterly on the Series A Preference Securities, which rank senior to and have priority over the Common Shares. The Board approved a dividend of $225.00 per Series A Preference Security with a record date of February 15, 2024, paid on March 15, 2024. For a more detailed description of the Series A Preference Securities see Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions of the 2023 Annual Report.

On February 29, 2024, we announced (i) the adoption of a dividend program for the Common Shares under which FIHL intends to pay a quarterly cash dividend and (ii) an initial dividend to be paid pursuant to the dividend program, in an amount of $0.10 per Common Share, which was paid on March 29, 2024 to holders of Common Shares of record on March 15, 2024.

On May 8, 2024, we announced that the Board of Directors approved a dividend of $0.10 per Common Share, payable on June 28, 2024 to holders of Common Shares of record on June 14, 2024.

FIHL is a holding company and, as such, has no substantial operations of its own. FIHL does not expect to have any significant operations or assets other than ownership of the shares of operating subsidiaries. Dividends and other permitted distributions and loans from operating subsidiaries are expected to be the sole source of funds to meet ongoing cash requirements, including payment of dividends to shareholders holding Series A Preference Securities, debt service payments and other expenses and to pay dividends, if any, to holders of the Common Shares. Fidelis Insurance Group’s operating subsidiaries are subject to significant regulatory restrictions limiting their ability to declare and pay dividends and make loans to other Group companies. FIHL’s ability to pay dividends on Common Shares is also dependent on the availability of distributable reserves. In addition, FIHL’s ability to pay dividends is subject to the restrictive covenants of our existing and outstanding indebtedness and may be limited by covenants of any future indebtedness we incur.

 

32


Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and are intended to qualify for the safe harbor for liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are intended to enhance the reader’s ability to assess our future financial and business performance. These statements are based on the beliefs and assumptions of our management, and are subject to known and unknown risks and uncertainties. Generally, statements that are not about historical facts, including statements concerning our possible or assumed future actions or results of operations, are forward-looking statements. Forward-looking statements include, but are not limited to, statements that represent our beliefs, expectations or estimates concerning future operations, strategies, financial results or performance, financings, investments, acquisitions, expenditures or other developments and anticipated trends and competition in the markets in which we operate.

Forward-looking statements can also be identified by the use of forward-looking terminology such as “may,” “believes,” “intends,” “anticipates,” “plans,” “estimates,” “targets,” “potential,” “will,” “can have,” “likely,” “continue,” “expects,” “should,” “could” or similar expressions. Forward-looking statements are not guarantees of performance and we caution prospective investors not to rely on them. We qualify all of our forward-looking statements by these cautionary statements, because these forward-looking statements are based on estimates and assumptions that are subject to significant business, economic and competitive uncertainties, many of which are beyond our control or are subject to change. Actual results or other outcomes could differ materially from those expressed or implied in our forward-looking statements, as a result of several factors, including the following:

 

   

changes to our strategic relationship with TFP HoldCo or the termination by TFP HoldCo or any of its subsidiaries of any of the Framework Agreement, the Delegated Underwriting Authority Agreements or the Inter-Group Services Agreement;

 

   

market sentiment amongst clients, brokers and reinsurers and other trading partners to our strategic relationship with TFP HoldCo;

 

   

our dependence on the Delegated Underwriting Authority Agreements for our underwriting and claims-handling operations;

 

   

our ability to manage risks associated with macroeconomic conditions resulting from any public health crisis, rising energy prices, inflation and interest rates, current or anticipated military conflict or terrorism, including the ongoing Ukraine Conflict and the escalation of conflict in the Middle East, sanctions and other geopolitical events globally;

 

   

our financial targets, any changes in those targets or actual results differing from such targets;

 

   

our ability to successfully implement our long-term strategy;

 

   

our limited operating history;

 

   

fluctuations in the results of our operations;

 

   

our ability to compete successfully with more established competitors and increased competition relating to consolidation in the reinsurance and insurance industries;

 

   

our developing losses exceeding our loss reserves;

 

   

downgrades, potential downgrades or other negative actions by rating agencies;

 

   

our dependence on key executives and ability to attract qualified personnel, particularly in very competitive hiring conditions, or the potential loss of Bermudian personnel as a result of Bermuda employment restrictions;

 

   

our dependence on letter of credit facilities that may not be available on commercially acceptable terms;

 

33


Table of Contents
   

our potential inability to pay dividends or distributions in accordance with our current dividend policy, due to changing conditions;

 

   

our potential need for additional capital in the future and the potential unavailability of such capital to us on favorable terms or at all;

 

   

our dependence on clients’ evaluation of risks associated with such clients’ insurance underwriting;

 

   

the suspension or revocation of our subsidiaries’ insurance licenses;

 

   

FIHL potentially being deemed an investment company under U.S. federal securities laws;

 

   

the potential characterization of us and/or any of our subsidiaries as a passive foreign investment company, or PFIC;

 

   

risks associated with our investment strategy;

 

   

changes in the regulatory environment and the potential for greater regulatory scrutiny of the Group as a result of the outsourcing arrangements;

 

   

heightened risk of cybersecurity incidents and their potential impact on our business;

 

   

a cyclical downturn of the (re)insurance industry;

 

   

the impact of inflation or deflation in relevant economies in which we operate;

 

   

our ability to evaluate and measure our business, prospects and performance metrics and respond accordingly;

 

   

the failure of our risk management policies and procedures to be adequate to identify, monitor and manage risks, which may leave us exposed to unidentified or unanticipated risks;

 

   

operational failures, including the operational risk associated with outsourcing to TFP, failure of information systems or failure to protect the confidentiality of customer information, including by service providers, or losses due to defaults, errors or omissions by third parties and affiliates;

 

   

FIHL’s status as a foreign private issuer means that it will be subject to Exchange Act reporting obligations that, to some extent, are more lenient and less frequent than those of a U.S. domestic public company (including, for example, that FIHL is not subject to the reporting obligations established by the U.S. proxy rules);

 

   

risks relating to our ability to identify and execute opportunities for growth or our ability to complete transactions as planned or realize the anticipated benefits of our acquisitions or other investments;

 

   

our ability to maintain effective internal controls over financial reporting and procedures under the applicable corporate governance requirements of the Sarbanes-Oxley Act, the rules adopted by the SEC and the NYSE corporate governance rules and listing standards and correctly apply U.S. GAAP;

 

   

our ability to maintain the listing of our Common Shares on the NYSE or another national securities exchange;

 

   

our potentially becoming subject to U.S. federal income taxation;

 

   

reporting requirements under the U.S. Foreign Account Tax Compliance Act, or FATCA, provisions or Bermuda corporate income taxation; and

 

   

the other risks identified in this prospectus, including, without limitation, those under the sections titled “Risk Factors” and “Business” herein and Item 3. Key Information—D. Risk Factors of the 2023 Annual Report.

Consequently, such forward-looking statements should be regarded solely as our current plans, estimates or belief as of the date of this prospectus. We do not intend, and do not undertake, any obligation to update any forward-looking statements to reflect future events or circumstances after the date of this prospectus. Given such limitations, prospective investors should not rely on these forward-looking statements in deciding whether to invest in our Common Shares.

 

34


Table of Contents

In addition, statements that contain “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this prospectus. While we believe that this information provides a reasonable basis for these statements, this information may be limited or incomplete. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements.

Prospective investors should review carefully the section captioned “Risk Factors” in this prospectus and the documents incorporated by reference for a more complete discussion of risks and uncertainties relating to an investment in our Common Shares.

 

35


Table of Contents

BUSINESS

Our History; Then to Now

Fidelis Insurance Group is a global specialty insurer, leveraging strategic partnerships to offer innovative and tailored insurance solutions. We have a highly diversified portfolio focused on three segments: Specialty, Bespoke, and Reinsurance, which we believe allows us to take advantage of the opportunities presented by evolving (re)insurance markets, proactively shift our business mix, and produce superior underwriting returns across market cycles. Headquartered in Bermuda, with subsidiaries located in Ireland and the UK, Fidelis Insurance Group operating companies have a financial strength rating of A from AM Best, A- from S&P and A3 from Moody’s, as of May 17, 2024.

FIHL was formed under the principles of a focused, process-driven and disciplined underwriting and risk selection, strong client and broker relationships and nimble capital deployment. Fidelis completed its initial funding and began underwriting business in June 2015 under the direction of an innovative and experienced management team.

Since then, FIHL has assembled a diversified global book of (re)insurance business and achieved scale with GPW of $3.6 billion and NPE of $1.8 billion for the year ended December 31, 2023. Between 2018 and 2023, our GPW and NPE have grown at compounded annual rates of 38.9% and 44.5%, respectively, and we have delivered an average loss ratio of 45.1% and an average combined ratio of 85.8% over the same period.

The Separation Transactions

On January 3, 2023, the Separation Transactions were completed and two distinct holding companies and businesses were created: FIHL and TFP HoldCo. FIHL, the parent holding company for Fidelis Insurance Group, owns the insurance operating subsidiaries of Fidelis, comprised of Fidelis Insurance Bermuda Limited (“FIBL”), Fidelis Underwriting Limited (“FUL”) and Fidelis Insurance Ireland DAC (“FIID”). Fidelis Insurance Group also has its own service company, FIHL (UK) Services Limited, with a branch in Ireland (“FIHL (UK) Services”).

TFP HoldCo is the parent holding company for the managing general underwriting platform (“TFP”) that carries on origination and underwriting activities on behalf of Fidelis Insurance Group. TFP HoldCo’s principal operating subsidiaries are Pine Walk Capital Limited (“Pine Walk Capital”), Pine Walk Europe SRL (“Pine Walk Europe”) and Shelf Opco Bermuda Limited (“TFP Bermuda”). The underwriting activities of each of the licensed insurance carriers of Fidelis Insurance Group (FIBL, FUL and FIID) are outsourced to the corresponding operating subsidiaries of TFP on a jurisdictional basis (TFP Bermuda, Pine Walk Capital and Pine Walk Europe, respectively). Each of the operating subsidiaries of TFP has delegated underwriting authority to source and bind contracts for and on behalf of each of FIBL, FUL and FIID, respectively. See Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions of the 2023 Annual Report.

On December 20, 2022, FIHL and TFP HoldCo entered into a rolling 10-year framework agreement (the “Framework Agreement”) that governs the ongoing relationship between the two groups of companies (see “Summary—Our Corporate Structure” for additional details).

Following the consummation of the Separation Transactions, FIHL can access the underwriting expertise of TFP while enabling TFP to attract and retain highly sophisticated underwriting talent by allowing them to focus their time and expertise on underwriting activities. We believe that the Separation Transactions and the Framework Agreement have structural benefits for both groups of companies, including increased flexibility to quickly respond to evolving insurance and reinsurance market conditions and to help sustain our strong underwriting results through access to top talent. Our objective following the completion of the Separation Transactions remains to further solidify Fidelis Insurance Group’s position as a leading specialty, bespoke and reinsurance underwriter.

 

36


Table of Contents

Our Company

Fidelis Insurance Group is a global specialty insurer focused on three segments: Specialty, Bespoke and Reinsurance. The Specialty and Bespoke segments together accounted for 82.8% of total GPW in 2023.

Fidelis Insurance Group is led by Mr. Daniel Burrows who has more than 35 years of experience in the insurance industry and is supported by a highly experienced management team that manages the operations of Fidelis Insurance Group based on our founding principles.

We have an exclusive right of first access to TFP’s underwriting business via the Framework Agreement where FIHL collaborates closely with TFP to match what we believe are superior priced risks with efficient sources of capital to produce attractive returns for shareholders. Through this operating model, we believe we are well positioned to be nimble, thoughtful, and efficient decision-makers, and we believe that we are able to respond quickly to an ever-changing world and a constantly evolving marketplace. Furthermore, FIHL’s strong capital position provides flexibility to underwrite attractive opportunities and make strategic capital allocation decisions.

We focus on nimble underwriting designed to capitalize on current market trends and dislocations as well as emerging risk solutions. The team of underwriters at TFP continues to maintain the processes and technology that have been key to Fidelis Insurance Group’s historical success at ensuring its underwriting efforts capture recent market developments. We believe this close coordination reduces the likelihood of siloed underwriting and gives us a competitive advantage in our underwriting, risk assessment and ability to offer as many products as possible to clients. A crucial and distinguishing part of those processes is the daily UMCC. Members of Fidelis Insurance Group attend and participate in the UMCC on a daily basis, together with TFP practice leads and key members of TFP senior management (including risk modeling, actuarial, legal, compliance, contract wordings and claims representatives) to provide live market insights and multiple perspectives to allow underwriters to quickly assess emerging opportunities, achieve strong underwriting and cross-sell across our product range. See “—Our Competitive Strengths” below for further detail.

Our scale and access to the highly selective underwriting capabilities of TFP via our strategic relationship allows us to capitalize on current insurance market trends and continue focusing on delivering growth coupled with strong underwriting results.

Since we began underwriting business in 2015, Fidelis Insurance Group has grown in scale in specialty and bespoke insurance and property reinsurance markets while delivering robust results. Our GPW grew from $0.7 billion for the year ended December 31, 2018 to $3.6 billion for the year ended December 31, 2023, a compound annual growth rate of 38.9%, compared to our peers’ average compounded annual growth rate for GPW of 22.1% for the same period. During that same period, we delivered an average combined ratio of 85.8%, compared to our peers’ average combined ratio of 100.2%. Our average loss ratio was 45.1% during that same period.

Our NPE grew from $0.3 billion for the year ended December 31, 2018 to $1.8 billion for the year ended December 31, 2023, a compound annual growth rate of 44.5%, compared to our peers’ average of 31.9%. Our GPW and NPE continued to grow to $1,514.3 million and $488.0 million, respectively, for the three months ended March 31, 2024, compared to $1,245.3 million and $386.0 million, respectively, for the three months ended March 31, 2023.

Our loss and combined ratio for the three months ended March 31, 2024 were 37.4% and 85.8%, respectively, compared to our peers’ average loss and combined ratios of 60.0% and 91.0%, respectively. Our loss ratio was 60.1%, 55.3% and 38.1% in 2021, 2022 and 2023, respectively, compared to our peers’ average loss ratios of 64.7%, 62.7% and 61.8%, respectively. Over the same period, our combined ratio was 93.0%, 91.9% and 82.1%, compared to our peers’ average combined ratios of 100.1%, 96.1% and 93.8%. Our peer group includes Beazley (“BEZ”), Lancashire (“LRE”), Conduit (“CRE”), Hamilton (“HG”), Everest (“EG”), Axis

 

37


Table of Contents

(“AXS”), Berkley (“WRB”) and Markel (“MKL”). For information on how peer group data is included or excluded, see “About this Prospectus—Market and Industry Data and Forecasts.”

Fidelis Insurance Group is subject to varying degrees of regulation and supervision in the jurisdictions in which it operates. In particular, the businesses of our three insurance operating subsidiaries, FIBL, FUL and FIID, are authorized by, and subject to insurance laws and regulations that are administered and enforced by, a number of different governmental and non-governmental self-regulatory authorities and associations in each of their respective jurisdictions and internationally. For a summary of the regulatory environment of our insurance operating subsidiaries, primarily in their respective jurisdictions of Bermuda, U.K. and Ireland, see Item 4. Information on the Company—B. Business Overview—Regulatory Matters of the 2023 Annual Report.

As of the date of this prospectus, Fidelis Insurance Group was assigned an “A” (Excellent) financial strength rating by A.M. Best, the third-highest of 13 rating levels, with a stable outlook on all entities. A.M. Best’s ratings range from “A+” to “D.” Each A.M. Best rating category from “A+” to “C” may be designated either an additional plus (+) or a minus (-) sign as a rating notch that reflects a gradation of financial strength within the rating category. Additionally, A.M. Best assigned a “BBB” long-term issuer credit rating to FIHL (with stable outlook), which indicates a good ability to meet ongoing senior financial obligations and a financial strength rating of “A” (Excellent) and the long-term issuer credit rating of “A” (Excellent) to each of FIBL, FUL and FIID (with stable outlook).

As of the date of this prospectus, Fidelis Insurance Group was assigned an “A-” financial strength rating by S&P Global Ratings (“S&P”), with a stable outlook, which indicates strong capacity to meet financial commitments but somewhat more susceptibility to the adverse effects of changes in circumstances and economic conditions than those in higher-rated categories. S&P’s ratings range from “AAA” to “D.” Each S&P rating category from “AA” to “CCC” may be modified by the addition of a plus (+) or minus (-) sign to show relative standing within the rating categories. Additionally, S&P has assigned a “BBB” long-term issuer rating to FIHL, which indicates adequate capacity to meet financial commitments but greater susceptibility to adverse economic conditions.

As of the date of this prospectus, Moody’s Investor Service (“Moody’s”) assigned a “Baa2” long-term issuer rating to FIHL and “A3” insurance financial strength ratings to FIBL, FUL and FIID. The outlook for FIHL is stable. Moody’s generic rating classifications range from “Aaa” to “C.” Each Moody’s generic rating classification from “Aa” to “Caa” may be modified to append numerical modifiers 1, 2, or 3 to show relative position within the rating categories. See Item 4. Information on the Company—B. Business Overview—Insurer Financial Strength Rating of the 2023 Annual Report for further discussion of ratings assigned to Fidelis Insurance Group’s insurance operating subsidiaries.

Strategic Relationship with TFP

We believe the insurance industry is evolving rapidly and is primed for further value chain disaggregation which will allow specialist underwriters to benefit from access to clients and risks and to provide access to alternate forms of capital.

Following the consummation of the Separation Transactions, TFP HoldCo became a minority investor in FIHL (holding 9.9% of the Common Shares) and entered into the Framework Agreement with FIHL to build a long-term agency relationship that provides strong economic and strategic alignment between the two groups of companies. Pursuant to the Framework Agreement, TFP manages underwriting, origination, certain outwards reinsurance placements, actuarial and claims services with close review and oversight from Fidelis Insurance Group to ensure adherence with the agreed upon annual plans, which set out our underwriting parameters and risk tolerances in respect of our three segment underwriting strategy on a gross / net basis for each annual period. For more details on our outsourcing arrangements with TFP, see Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions—Framework Agreement of the 2023 Annual Report.

 

38


Table of Contents

Pursuant to our outsourcing arrangements with TFP, we leverage their sophisticated underwriting technology and talent and will benefit from our shared history in underwriting principles, strategic visions, and managerial approaches. Our arrangement is governed by arm’s-length terms for origination and management consistent with industry commission levels, including market overrider commissions, and with a focus on aligning incentives for strong underwriting performance. Ceding commissions payable to TFP are charged for underwriting, claims and actuarial pricing services. Such ceding commissions are calculated based on NPW to ensure alignment on reinsurance purchasing. To avoid fee duplication, ceding commissions payable for open market business sourced by TFP are set at 11.5% and ceding commissions payable for business sourced by TFP via third-party managing general underwriters to whom underwriting authority has been sub-delegated by TFP are set at 3.0%. Business that continues to be sourced by subsidiary cells of Pine Walk Capital will continue to follow the fees and commissions set under those agreements (approximately 10%). Long-term objectives are further aligned by FIHL paying an ongoing portfolio management fee of 3.0% (the “Portfolio Management Fee”) to TFP and a 20.0% profit commission on Operating RoE (“Binder Operating RoE”) above a hurdle rate of 5.0% calculated on an aggregate basis for Fidelis Insurance Group. Binder Operating RoE is defined in the Framework Agreement as FIHL’s consolidated net underwriting margin (disregarding any business not underwritten by TFP following the date of the Framework Agreement and the effect of any FIHL Procured Outwards Reinsurance, as defined in the Framework Agreement) plus all overriders retained by Fidelis Insurance Group (disregarding the effect of any FIHL Procured Outwards Reinsurance), minus an Administrative Expenses Allowance (defined in the Framework Agreement as a sum equating to 2.3% of net premiums written), minus the proportion of FIHL’s costs of financing its debt and preference securities included in FIHL’s total capital that is deemed to be allocated to TFP, minus the total accumulated ceding commission that is payable by Fidelis Insurance Group to TFP, minus the Portfolio Management Fee relating to business underwritten by TFP, divided by the proportion of FIHL’s opening common shareholders’ equity adjusted for dividend and equity raises (as set out in year-end consolidated audited financial statements) that is deemed to be allocated to TFP. The calculation of such profit commission includes a deficit carry-forward mechanism for a maximum of three years in which the Binder Operating RoE is below zero. For a more detailed discussion of the fees and commissions payable by Fidelis Insurance Group in connection with its outsourced relationship with TFP, see Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions—Framework Agreement—Fees and Commissions of the 2023 Annual Report.

Our Commitment to Environmental, Social and Governance Matters

Fidelis Insurance Group is committed to working together with TFP to implement standards for environmental, social and governance (“ESG”) matters. We carried out a joint study on approximately $8.2 billion of premiums and 28,500 policies spanning between 2012 and 2021, which demonstrated that higher third-party ESG ratings were generally correlated with lower loss ratios. As such, we aim to embed ESG factors in our underwriting processes where appropriate, including through TFP’s existing underwriting restrictions. These underwriting restrictions include not directly insuring thermal coal (including dedicated infrastructure projects such as ports and railways), tar sand extraction, Arctic oil and gas exploration and drilling and fracking operations. Further, we do not provide cover to companies whose revenues from the above-mentioned activities account for more than 20% of their total revenues. TFP also uses policy language with the aim to minimize exposure to forced labor and modern slavery, in particular in the marine cargo line of business. Additionally, together with TFP, we are currently committed to transitioning our insurance portfolios to net-zero greenhouse gas emissions by 2050. To work towards this, to the extent possible, TFP are developing tools to measure the insurance-associated emissions of their insurance portfolios.

Furthermore, FIHL’s fixed income investment portfolio (which represents 98.6% of invested assets as of December 31, 2023) is managed in a manner that is consistent with Fidelis Insurance Group’s sustainability principles and ESG objectives. At December 31, 2023, 3.3% of Fidelis Insurance Group’s fixed income portfolio was invested in green, social and sustainable (“GSS”) bonds. The GSS Indices utilize the Bloomberg Global Aggregate Index, the Bloomberg Sustainable Finance Group’s GSS bond indicators and fields that show alignment with the International Capital Market Association Green Bond, Social Bond and Sustainability Bond Principles and

 

39


Table of Contents

Guidelines. Furthermore, the investment portfolio includes restrictions against holding securities of issuers that have a ‘poor’ MSCI ESG rating (with a rating below ‘B’ or issuers that currently have a ‘red’ MSCI controversy flag). Securities of these issuers may only be held if Fidelis determines it is appropriate to do so after considering whether the investment manager has a positive forward-looking ESG view of the issuer. Fidelis Insurance Group has also adopted negative screens to work to limit exposure to certain industries and activities in its fixed income investment portfolio. These include screens against holding securities of any issuers involved in thermal coal, oil and gas (though an issuer may derive up to 20% of its annual revenues from oil and gas) or arms (certain types of arms are completely excluded, others such as firearm sales are permitted to comprise up to 10% of annual revenues), and restrictions against those that fail animal welfare and for-profit prisons screens. As a result of such negative screens, Fidelis was able to limit the fixed income portfolio’s direct exposure to the securities of companies deriving revenues from fossil fuels to seven companies, which at December 31, 2023 comprised 0.7% of Fidelis Insurance Group’s fixed income portfolio. Furthermore, currently Fidelis Insurance Group has no direct exposure in its investment portfolio to energy companies and its exposure to corporate securities identified as “utilities” comprised 1.1% of the fixed income portfolio at December 31, 2023.

Additionally, we have taken action in each year since 2018 to more than offset our operational carbon emissions and we are committed to continuing to do so going forward. We partner with relevant industry specialists to calculate our carbon emissions.

Diversity, equity and inclusion are integral to Fidelis Insurance Group. We pursue a diversity, equity and inclusion strategy that includes accountability, representation, advancement, culture, outreach and fostering a sense of belonging for all our employees. We employ targeted recruiting strategies to identify a wide range of qualified candidates and partner with external agencies to advertise vacancies with the goal of increasing the hiring of women and ethnically diverse employees. Where available, we monitor certain diversity, equity and inclusion statistics (gender, ethnicity, age, marital status, religion, caring responsibilities and disability, each as provided by candidates on a voluntary basis) both at the outreach/interview stage and for our employee population so that we can see progress with respect to the composition of our qualified candidate pools. Comparative data on diverse candidate sourcing available to us demonstrates a diversity mix of approximately 48% female identifying applicants, and approximately 70% of applicants identifying as people of a diverse ethnicity. During the period from March 2023 to February 2024, approximately 82% of open roles for which the Company recruited achieved a short list including diverse candidates.

Our Business; Overview

Our business comprises three segments: “Specialty,” “Bespoke” and “Reinsurance.” We believe our strategy and capabilities allow us to take advantage of the opportunities presented by evolving (re)insurance markets and to proactively shift our business mix across market cycles to generate strong returns. We have built a diverse portfolio of over 100 products within our 11 lines of business across our three segments, serving numerous industries, types of exposure, and geographies.

The Specialty segment comprises a portfolio of Aviation and Aerospace, Energy, Marine, Property, Property D&F business and Other Specialty risks.

The Bespoke segment is highly specialized in nature providing customized risk solutions for clients which includes Credit & Political Risk and Other Bespoke risk transfer opportunities.

The Reinsurance segment includes Property Reinsurance, Retrocession and Whole Account reinsurance.

Specialty

For the year ended December 31, 2023, the Specialty segment accounted for 62.6% of our GPW and 65.7% of our NPE with an underwriting ratio of 72.5% and a loss ratio of 48.5%. In 2023, the Specialty segment

 

40


Table of Contents

generated $331.1 million in underwriting income. GPW in the Specialty segment grew from $44.1 million for the year ended December 31, 2018 to $2.2 billion for the year ended December 31, 2023, a compound annual growth rate of 119.4%. During the period from 2018 to 2023, our average underwriting ratio was 68.1%. For the three months ended March 31, 2024 our Specialty GPW grew to $1,034.0 million compared to $834.1 million for the three months ended March 31, 2023. Our Specialty segment from 2018 to 2023 accounted for 6.4%, 12.1%, 36.6%, 40.0%, 53.6%, and 62.6%, respectively, of our GPW. Property D&F accounted for 25%, Marine 19%, Aviation and Aerospace 10%, Energy 4%, Property 3% and Other Specialty 2% of our GPW for the twelve months ended March 31, 2024.

The Specialty segment comprises a portfolio of tailored risks across specialty business lines. “Hard” market conditions following years of compound rate increases across multiple business lines within the Specialty segment have provided opportunities for targeted growth and the ability to leverage leadership and scale. This, combined with long established relationships, has enabled Fidelis Insurance Group to build across specialty classes. Given the current market environment we have increasingly used our Specialty segment to deploy capital targeted to natural catastrophe exposure through the Property D&F line of business rather than through our Reinsurance segment. This allows a more selective approach to managing aggregate exposure. We further capitalized on market dislocations and associated rate increases in key classes such as Marine and Aviation and Aerospace to increase the amount of business written. Our Aviation and Aerospace, Property D&F and Marine businesses are among the leading franchise positions in the London market. The Specialty segment benefits from a program of reinsurance protections which are tailored across product lines. The program incorporates facultative covers as well as proportional and non-proportional treaties including aggregate, occurrence, per risk and parametric products such as cat bonds and industry loss warranties, which reduce the impact of frequency and severity claims, and protect capital.

Our Specialty segment provides us with access to more capital-efficient business and facilitates diversification of our exposures. In the Specialty segment, our underwriters work closely with TFP’s experts to develop collaborative relationships with brokers and clients and offer them the full suite of our existing products as well as working with them to innovate new product ideas. We have consistently demonstrated a sophisticated ability to adapt to constantly evolving market dynamics by developing specialized and tailored pricing and aggregation models while maintaining a disciplined underwriting approach. We typically seek out capacity-driven layers with attractive pricing, often focusing on dislocated markets, and look to ensure successful and sustainable growth in this segment through developing and maintaining an excellent broker network. This relationship-driven, flexible approach enables underwriters to identify additional underwriting opportunities from existing clients for providing cover on other related lines of business.

Bespoke

For the year ended December 31, 2023, the Bespoke segment accounted for 20.2% of our GPW and 20.5% of our NPE with an underwriting ratio of 61.9% and a loss ratio of 24.5%. In 2023, the Bespoke segment generated $143.2 million in underwriting income. GPW in the Bespoke segment grew from $320.5 million for the year ended December 31, 2018 to $720.4 million for the year ended December 31, 2023, a compound annual growth rate of 17.6%, despite our GPW in 2020 remaining at the same level as in 2019 due to a cautious approach to underwriting in light of political and economic uncertainties arising from the COVID-19 pandemic. During the period from 2018 to 2023, our average underwriting ratio was 59.8%. For the three months ended March 31, 2024, our Bespoke GPW was $153.5 million, compared to $150.8 million for the three months ended March 31, 2023. Credit & Political Risks accounted for 12% and Other Bespoke risk 7% of our GPW for the twelve months ended March 31, 2024.

The Bespoke segment business focuses primarily on highly tailored, innovative and specialized products, where the buying motivation is often driven by regulatory capital relief, capital efficiency or transaction facilitation versus more traditional drivers of insurance needs. The portfolio includes policies covering Credit & Political Risk and Other Bespoke risk transfer opportunities, including political violence and terrorism, limited

 

41


Table of Contents

cyber reinsurance, tax liabilities, title, transactional liabilities and other bespoke solutions to fit our clients’ needs. Given the increased global conflict and national economies shifting further to intellectual property driven value, we believe that the Bespoke segment continues to see significant opportunity for beneficial pricing, terms and conditions and growth. The relationships we have formed with clients and brokers, the underwriting expertise required, and nature of the underlying risks create a higher barrier to entry and help us maintain our position as a leader in the industry. Typically, these lines do not follow the established (re)insurance cycle and are largely influenced by prevailing economic conditions at a given time. As such, these products require highly specialized pricing and other models tailored to the risk profile. For example, for certain significant risk transfer transactions, pricing is largely driven by counterparty credit quality which has low correlation with the current (re)insurance cycle and high correlation with the overall economy and macro events. As a result, Bespoke policies follow a different and diversified loss pattern relative to our Specialty and Reinsurance segments.

The Bespoke portfolio has several economic features that we believe are financially attractive. The contracts often have multi-year tenors, and the products are generally expected to have low and stable attritional loss ratios over the exposure period. The combination of longer tenor and lower expected loss experience creates the potential to capture additional embedded value as premiums are earned over the exposure period under U.S. GAAP. Additionally, the contracts are highly capital-efficient as these risks tend to have little or no correlation to peak natural catastrophe perils driving a higher return on equity than other lines. Furthermore, the contracts typically have customized provisions rather than standard market contractual provisions, creating opportunities to optimize pricing and establish proprietary, recurring relationships with clients. The custom and direct nature of the business have allowed us to lead on substantially all of our contracts creating tailored terms, conditions and pricing.

The Bespoke segment benefits from a program of reinsurance protections which are tailored across product lines. The program incorporates facultative covers as well as proportional and non-proportional treaties including aggregate, occurrence and per risk products, which reduce the impact of frequency and severity claims, and protect capital.

Reinsurance

For the year ended December 31, 2023, the Reinsurance segment accounted for 17.2% of our GPW and 13.8% of our NPE with an underwriting ratio of 36.5% and a loss ratio of 9.3%. In 2023, the Reinsurance segment generated $161.0 million in underwriting income. GPW in the Reinsurance segment grew from $328.0 million for the year ended December 31, 2018 to $617.3 million for the year ended December 31, 2023, a compound annual growth rate of 13.5%. During the period from 2018 to 2023, our average underwriting ratio was 76.9%. For the three months ended March 31, 2024 our Reinsurance GPW was $326.8 million compared to $260.4 million for the three months ended March 31, 2023. Our Reinsurance segment from 2018 to 2023 accounted for 47.3%, 45.7%, 41.7%, 38.7%, 20.1% and 17.2%, respectively, of our GPW. Property Reinsurance accounted for 17% and other reinsurance 1% of our GPW for the twelve months ended March 31, 2024.

Our Reinsurance segment consists of an actively managed, primarily residential property catastrophe reinsurance book, with closely controlled aggregates using FireAnt, TFP’s proprietary aggregation and analytics system, to monitor exposures in real time. The Reinsurance segment also includes property retrocession and a limited amount of composite and multi-class asset reinsurance. In the context of excess of loss reinsurance products, we focus on underwriting attachment points largely exposed only to true catastrophe events. The portfolio is global in nature with a strong North American concentration and smaller exposures in Japan, Europe, Australasia and elsewhere throughout the world. The Reinsurance segment benefits from a program of retrocession protections which are tailored across product lines. The program incorporates proportional and non-proportional treaties including aggregate, occurrence and parametric products such as cat bonds and industry loss warranties, which reduce the impact of frequency and severity claims, and protect capital. We believe our strategy of pursuing closely controlled aggregates and focusing on residential portfolios in the Reinsurance segment helps keep volatility lower than a portfolio with a greater focus on commercial occupancies.

 

42


Table of Contents

We benefit from TFP’s sophisticated analytics capabilities and live aggregation tools, excellent relationships with a blend of regional and nationwide carriers (both in the United States and internationally), and strong retail and wholesale broker relations in the distribution of our products. Since 2021, we have developed a view of risk informed by thorough analysis and discussions with weather and forecasting experts. We have concluded that the effects of climate change on perils such as hurricanes, convective storms, floods and wildfires are not currently represented adequately in current vendor models. As such, we have superimposed our own expectations of frequency and severity on third-party vendor models, to form a base for exposure and aggregation tracking.

We have taken proactive steps to reduce volatility and reshape our Reinsurance portfolio to focus only on clients with stronger financial and loss adjustment capabilities and the resources to adjust and manage high volumes of claims in-house. As a consequence, the property reinsurance portfolio was reduced in 2022 and remained at reduced levels throughout 2023. We are increasingly deploying reinsurance capital across large-scale, well-resourced national accounts away from smaller regional underwriters, who we believe are less able to adjust and manage large catastrophe events. We have reduced our exposure to the middle layers of treaty accounts which are more exposed to increased frequency and severity of losses as a result of climate change and secondary perils associated with floods and wildfires without commensurate increases in rates. We expect the impact of these changes to improve the quality of our natural catastrophe-exposed portfolios and reduce volatility. As ever, we will continue to leverage a nimble underwriting approach to adapt to constantly evolving market dynamics to source business when favorable market conditions are present. If there is an increase in property catastrophe rates, as well as favorable terms and conditions, we would intend to capitalize on those trends and dislocations.

Underwriting and Reinsurance Purchasing

We purchase reinsurance to cover the potential accumulation or aggregation of exposures and to cover specific business written when warranted. At December 31, 2023 we had reinsurance balances recoverable on reserves for losses and loss adjustment expenses of $1,108.6 million (December 31, 2022: $976.1 million) and reinsurance balances recoverable on paid losses of $182.7 million (December 31, 2022: $159.4 million). The reinsurance we purchase takes the form of quota share, aggregate, stop loss and excess of loss programs, catastrophe bonds and industry loss warranties. We evaluate the financial condition of our reinsurers regularly and monitor concentrations of credit risk with reinsurers. All our reinsurance premiums ceded have been placed with reinsurers that are rated “A-” or higher by A.M. Best or S&P, other than four reinsurers that are rated “B++”. Where an insurer does not have a credit rating, Fidelis Insurance Group generally receives collateral, including letters of credit and trust accounts. In some cases, TFP will be afforded discretion to purchase reinsurance for us from a non-rated source, subject to full collateralization of policy limits ceded under such reinsurance (for example, through purchase of industry loss warranties) or to seek direct access to capital markets (for example, through catastrophe bonds). At December 31, 2023 the three largest balances by reinsurer accounted for 24.0%, 7.9% and 5.5%, compared to 25.3%, 6.0% and 5.0% at December 31, 2022, of the total balance recoverable from reinsurers on paid and unpaid losses. Under the Framework Agreement, we have delegated authority to design and place such outwards reinsurance to TFP in conjunction with the overall management of our book of business.

The amount of reinsurance we desire to purchase and our reasons for purchasing reinsurance will vary over time. We may purchase reinsurance to manage our capital and the volatility of our underwriting results more effectively or otherwise to facilitate the exit of certain business. This may include, inter alia, increasing our protection from underwriting risks, increasing our overall ability to deploy meaningful line sizes, reducing and spreading the risk of loss on our insurance and reinsurance business and limiting our exposure to multiple claims arising from a single occurrence.

On at least an annual basis, FIHL and TFP agree specific parameters in respect of which TFP may procure outwards reinsurance cover on behalf of FIHL (the “Outwards Reinsurance Strategy”). TFP is delegated authority to purchase and alter outwards reinsurance cover for and on behalf of the applicable operating

 

43


Table of Contents

subsidiary, provided that (i) the proposed outwards reinsurance cover is consistent with the parameters set out in the Outwards Reinsurance Strategy; and (ii) the underwriting performance of the insurance business in the applicable year is within the pre-agreed parameters set out in the Outsourced TFP Subsidiary Specific Underwriting Plan. However, prior to effecting such outwards reinsurance cover, TFP must obtain the approval of the relevant operating subsidiary’s Chief Underwriting Officer, who must respond to such proposal within two business days. Placements outside of the Outwards Reinsurance Strategy will be subject to a longer turnaround time as there is more substantive review to be conducted.

When we purchase reinsurance protection, we cede to reinsurers a portion of our risks and pay premiums based upon the transferred risk or perils of the subject, right or interest protected by the reinsurance. Although the reinsurer will be liable to us in respect of the business ceded, we retain the ultimate liability in the event the reinsurer is unable to meet its obligations at some later date.

When purchasing outwards reinsurance, TFP is obliged to ensure that the placement of outwards reinsurance is within the defined terms of our counterparty risk appetite in respect of both the related credit exposure and aggregate exposure. They are also obliged to ensure that the outwards reinsurance purchased is in line with the Solvency II eligibility requirements for risk mitigation techniques, including but not limited to:

 

   

the contractual arrangements and transfer of risk are legally effective and enforceable in all relevant jurisdictions;

 

   

all appropriate steps have been taken to ensure the effectiveness of the arrangement and to address the risks related to that arrangement; Fidelis Insurance Group is able to monitor the effectiveness of the arrangement and the related risks on an ongoing basis;

 

   

Fidelis Insurance Group has, in the event of a default, insolvency or bankruptcy of a counterparty or other credit event set out in the transaction documentation for the arrangement, a direct claim on that counterparty;

 

   

that there is effective transfer of risk; and

 

   

the requirements relating to collateral arrangements and guarantees.

Furthermore, Fidelis Insurance Group has the right to arrange additional outwards reinsurance protections for its own behalf, separate and in addition to the outwards reinsurance purchased by TFP in respect of Fidelis Insurance Group.

Underwriting and Risk Management

Our approach is to underwrite (re)insurance business within a process-driven, disciplined innovative and analytical framework with a focus on profitability while also delivering superior solutions for clients and brokers.

Key considerations within this process include (i) adequacy of underlying rates for each class of business and territory based upon our in-house proprietary view of risk; (ii) the reputation of the proposed (re)insured; (iii) the geographic area in which the (re)insured does business, together with our catastrophe exposures and our aggregate exposures in that area; (iv) historical loss data for the (re)insured and, where available, for the industry as a whole in order to compare the historical loss experience to industry averages; (v) projections of future loss frequency and severity; (vi) if relevant, the perceived financial strength of the (re)insured; as well as (vii) certain ESG factors.

The Outsourced TFP Underwriting Plan, the Framework Agreement and the Delegated Underwriting Authority Agreements set out the parameters within which TFP ensures the overall balance of the (re)insurance portfolio is aligned with our strategic objectives. The annual business planning process is a collaborative process between us and TFP and is subject to multiple levels of review and challenge.

 

44


Table of Contents

We focus on four key principles governing our underwriting and risk selection approach and strategy, which govern the risk appetite and tolerances outlined in the Outsourced TFP Underwriting Plan:

 

  (1)

Discipline. We will leverage TFP’s disciplined, analytical underwriting approach within a comprehensive framework of underwriting controls, which is focused on real time pre-quote peer review and portfolio management through the daily UMCC. Members of Fidelis Insurance Group attend and participate in the UMCC on a daily basis, together with TFP practice leads and key members of TFP senior management, including risk modeling, actuarial, legal, compliance, contract wordings and claims representatives. This provides live market insights and multiple perspectives to allow underwriters to quickly assess emerging opportunities, achieve strong underwriting performance and cross-sell our product range. Coming together in this way on a daily call means that there is no siloed underwriting, there is management oversight over all underwriting decisions, and there is cohesive portfolio optimization across all business lines and segments.

 

  (2)

Clients and Brokers. We aim to deliver superior solutions for our clients and broker partners. Working together with TFP, our ability to move quickly in the changing market enables us to deliver products meeting our clients’ demands. Our model is built on the balance of long-term relationships with quality clients and respect for the core broker distribution model, including by leveraging TFP’s strong broker relationships. We encourage multi-tier engagement with brokers using consistent data points to measure performance and identify opportunities.

 

  (3)

Innovation. We recognize that in an ever-changing and competitive market, we must put a lot of emphasis on creativity in bringing new products to market. We benefit from TFP’s strong ability in development and innovation when creating new products and client-led solutions.

 

  (4)

Risk and capital management. In order to optimize our risk and return, we will allow TFP flexibility within clearly defined risk appetites and tolerances to allocate risk and capital to those classes that optimize our risk-adjusted return.

Investment Operations

Our investment strategy is focused on delivering attractive and stable investment income and an above average risk-adjusted total return through all market cycles while maintaining appropriate investment portfolio liquidity and credit quality to meet the requirements of our clients, rating agencies and regulators and support our underwriting activities.

Our investments are principally managed by two external investment managers through individual investment management agreements. Our Chief Investment Officer monitors activity and performance of the external managers on a regular basis and reports to the Board on at least a quarterly basis. At December 31, 2023, our investments consisted primarily of a diversified portfolio of fixed maturity securities (including U.S. Treasuries, non-U.S. government bonds, government agency bonds, corporate bonds, mortgage and other asset-backed securities), and a small allocation to other investments. See Item 18. Financial Statements—Note 5. Investments of the 2023 Annual Report.

The Investment Committee of our Board establishes investment policies and guidelines and supervises our investment activity. The Investment Committee regularly monitors our overall investment results and performance against our investment objectives, benchmarks, risk appetite and guidelines contained in the investment policy. Our current investment policy contains a prescriptive set of permitted investments and prohibited asset classes, guidelines specifying minimum criteria on the overall credit quality (in addition to individual issuer credit quality), ESG parameters, designed to be value accretive, and liquidity characteristics of the portfolio and includes limitations on the size of certain holdings and restrictions on purchasing certain types of securities and other investments. Any material changes to our investment objectives, risk appetite and guidelines would require Board approval, and the Board will also be required to consider the impact of any such proposed changes in light of their general compatibility with Fidelis Insurance Group’s business plan. See Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions of the 2023 Annual Report.

 

45


Table of Contents

Our management team and the Investment Committee review our investment performance and assess credit and market risk concentrations and exposures to issuers. We follow an investment strategy designed to emphasize the preservation of capital and provide sufficient liquidity for the prompt payment of claims. Our investment portfolio is diversified across sectors and issuers, and we have taken a number of steps to ensure that we hold sufficient cash available to meet our obligations. At December 31, 2023, 22.4% of our total cash, cash equivalents and investments was held in cash and cash equivalents (including restricted cash and cash equivalents) and 76.5% of our total cash, cash equivalents and investments was invested in fixed maturity securities and short-term investments (with 13.3% of our total cash, cash equivalents and investments rated “BBB” and one security (0.2%) which was rated “BB”).

Claims Management

Under the terms of the Framework Agreement and the respective Delegated Underwriting Authority Agreements, claims management activities are partially delegated to TFP, with Fidelis Insurance Group retaining an oversight function and ultimate approval authority in respect of all claims relating to large losses. TFP employs a staff of experienced claims professionals who are obliged to operate within the parameters set forth in the Framework Agreement and the respective Delegated Underwriting Authority Agreements, which provide for a delegated claims authority up to a maximum monetary threshold. Claims that exceed the delegation threshold must be referred back to us for oversight and involvement in resolution within predefined timelines, and claims subject to coverage disputes and/or litigation will be handled by a separately agreed procedure.

The claims professionals employed by TFP work closely with its underwriting team to achieve consistency and efficiencies across all lines of business. We are committed to offering prompt and professional claims service to policyholders and service providers and TFP has, on our behalf, developed processes and internal business controls for identifying, tracking and settling claims.

The key responsibilities of the claims management departments include:

 

   

Processing, managing and resolving reported insurance or reinsurance claims efficiently and accurately to ensure the proper application of intended coverage and expense;

 

   

Making timely payments in the appropriate amount on those claims for which Fidelis Insurance Group is legally obligated to pay;

 

   

Selecting appropriate counsel and experts for claims, managing claims-related litigation and regulatory compliance;

 

   

Contributing to the underwriting process by collaborating with the underwriting teams and senior management in terms of the evolution of policy language and endorsements and providing claim-specific feedback and education regarding legal activity; and

 

   

Contributing to the analysis and reporting of financial data and forecasts by collaborating with the finance and actuarial functions relating to the drivers of actual claim reserve developments and potential for financial exposures on known claims.

Reserves for Losses and Loss Adjustment Expenses

Reserve estimates are derived by us after extensive consultation with the underwriters and actuaries employed by TFP, actuarial analysis of the loss reserve development, comparison with industry benchmarks and preliminary contract level loss reserve estimates prepared by TFP. The reserves for losses and loss adjustment expenses include an amount determined from reported claims and estimates based on historical loss experience and industry statistics for IBNR losses using a variety of actuarial methods. For additional discussion of our reserves, refer to Item 18. Financial Statements—Note 12. Reserves for Losses and Loss Adjustment Expenses of the 2023 Annual Report.

 

46


Table of Contents

Loss reserves represent estimates, at any given time, of what we ultimately expect to pay on claims, are based on facts and circumstances then known, and it is probable that the ultimate liability may exceed or be less than such estimates. Even actuarially sound methods can lead to subsequent adjustments to reserves that are both significant and irregular due to the nature of the risks written. Loss reserves are inherently subject to uncertainty. In establishing the reserves for losses and loss adjustment expenses, we make various assumptions relating to the pricing of reinsurance contracts and insurance policies and also considering available historical industry experience and current industry conditions. The timing and amounts of actual claim payments related to recorded reserves vary based on many factors, including large individual losses and changes in the legal environment, as well as general market conditions. The ultimate amount of the actual claim payments could differ materially from our estimated amounts. Certain lines of business have loss experience characterized as low frequency and high severity. This may result in significant variability in loss payment patterns and, therefore, may impact the related investment management process in order to be in a position, if necessary, to make these payments. The unpaid reported reserves for losses and loss adjustment expenses are established by management based on reports from brokers, ceding insurers and insureds and represent the estimated ultimate cost of events or conditions that have been reported to, or specifically identified by us. Generally, it is anticipated that reserves will be established without regard to whether we may subsequently contest the claim. Fidelis Insurance Group carries out its reserving process with input provided by TFP’s claims and actuarial teams. Ultimate ownership and sign-off responsibility over our reserving remains with us. The reserves for IBNR losses and loss adjustment expenses are established by our management based on actuarially determined estimates of ultimate losses and loss adjustment expenses, and other related data and analysis to be provided to us by TFP. Inherent in the estimate of ultimate losses and loss adjustment expenses are expected trends in claim severity and frequency and other factors which may vary significantly as claims are settled, and accordingly, ultimate losses and loss adjustment expenses may differ.

These estimates are reviewed regularly and, as experience develops and new information becomes known, the reserves are adjusted as necessary. Such adjustments, if any, will be recorded in losses and loss adjustment expenses in the period in which they become known. IBNR reserves are calculated on a best estimate basis and are established by our management based on a combination of management’s professional judgment and various actuarial methods, growing loss experience, historical (re)insurance industry loss experience, estimates of pricing adequacy trends and other related data and analysis to be provided by TFP. Due to the limited historical data available, and limited loss experience available to us due to our relatively short period of operations, reliance is placed upon industry data and a review of individual policies. Estimates are calculated at the lowest level line of business, separately for gross and ceded, and for attritional, large and catastrophic claims.

The reserve estimates contain an inherent level of uncertainty, and actual results may vary, potentially significantly, from the estimates we have made. Reserves are reviewed on a quarterly basis and estimates are adjusted to reflect emerging claims experience. We are supported by an external loss reserve specialist, which reviews our reserves annually.

Other principal actuarial methods, and associated key assumptions, used to perform our loss reserve analysis include paid and incurred chain ladder, paid and incurred Bornhuetter-Ferguson method and credible claims reserves. We may however employ a number of different reserving methods depending on the segment, the line of business, the availability of historical loss experience and the stability of that loss experience. Over time we may determine to give additional weight to our historical loss experience in our reserving process due to the then-applicable maturation of our reserves, and the increased availability and credibility of the historical experience.

Insurance Regulations

Our insurance operating subsidiaries are subject to insurance and reinsurance laws and regulations in the jurisdictions in which they operate, the most significant of which are Bermuda, Ireland and the United Kingdom. We hold capital in excess of the minimum statutory capital and surplus requirements in each of those locations. Please refer to Item 18. Financial Statements—Note 16. Statutory Requirements and Dividend Restrictions of the 2023 Annual Report for further details of the requirements in each jurisdiction.

 

47


Table of Contents

Insurance Market Conditions

We believe we have significant market opportunities given our ability to innovate and adapt to evolving market conditions. Global economic and industrial development, population increases, greater product awareness and distribution, as well as inflation continue to drive increased need for insurance and reinsurance. The current insurance and reinsurance market environment has experienced a prolonged period of rate increases, structural enhancements and continued improvement of terms and conditions. In 2022, following a period of higher loss ratios due to the frequency and severity of catastrophes, many of our competitors reevaluated and reduced their catastrophe reinsurance business, leading to a decrease in available capacity and a hardening of rates, which persisted into 2023 across both property reinsurance and D&F lines. Specialty markets such as aviation, marine and cyber have seen significant rate hardening in recent years driven by underperformance and market and geopolitical uncertainty. We believe that this combination of factors is driving a sustainable and favorable market environment, with a focus on risk management, disciplined risk selection, improved terms and profitable business, which presents significant market opportunities for us. Property D&F pricing is at the mature phase of the cycle, with rating at the highest levels in the past two decades. Marine cargo prices are elevated and pricing in aviation lines remain hard. We believe the favorable rate environment should persist for the near future across the lines of business on which FIHL focuses.

We believe that the following prevailing factors will contribute to sustained pricing levels across multiple lines:

 

   

Climate Change. The frequency and severity of catastrophes is rising as seen by the increases in catastrophe losses globally in more recent years, requiring rate increases to keep pace. The period between 2017 and 2023, for example, saw 67% more weather events in the United States that cost in excess of $1 billion and 59% higher losses caused by these severe events as compared to the period between 2011 and 2016. We believe that the impact of a warming climate and increased atmospheric moisture and changing weather patterns will result in increased frequency and severity of elemental catastrophe losses (elemental risks related to the elements i.e., weather related hail and storms etc.). 2023 was the warmest year on record and, despite no individual loss exceeding $7 billion, produced catastrophe losses of over $100 billion. The frequent incidence of annual industry-wide natural catastrophe losses in excess of $100 billion in the aggregate during the period from 2017 to 2023 has led us to reshape our portfolio and reduce our exposure to certain perils, thereby reducing the volatility traditionally associated with the property reinsurance classes. Many of our competitors have reevaluated their levels of premiums written against catastrophe reinsurance (see “—Competition”). Decreased participation created a lack of supply of reinsurance capacity causing upward pressure on price in the 2022 and 2023 renewal periods. The adjustment to terms, conditions and attachment points meant that due to the lack of significant catastrophe losses in 2023, most reinsurers were able to achieve improved terms. This market adjustment has led to more orderly and measured renewal conditions for 2024. However, given the continued frequency and severity of events, and the significant loss levels prior to 2023, we expect a level of discipline to remain, allowing TFP to underwrite select attractive policies on our behalf and position us to deliver strong risk-adjusted returns.

 

   

Casualty. We believe reserves across the industry remain deficient for accident years from 2013 to 2019 given the levels of claims inflation and nuclear verdicts, with several casualty underwriters seeing prior year adverse developments. Additional concerns have arisen with respect to adequacy of reserves for more recent accident years 2021 to 2023. Further adverse developments and actual loss payouts may deplete competitors’ capital and impair their ability to underwrite. Given Fidelis Insurance Group has made the strategic decision not to write the traditional casualty classes such as general liability, financial lines, directors and officers, and errors and omissions, it is not affected by these potential capital constraining issues, which we believe provides us with a competitive advantage due to our continued position of strength.

 

   

Cost Inflation. Numerous countries including the United States are experiencing inflation in wages, materials and parts. Real inflation for expert loss adjusters and building materials, exacerbated following a catastrophe, is causing an increase in loss costs for many insurers and complicating future estimates. This effect is increasing losses for multiple areas of the Excess & Surplus, Property & Casualty and reinsurance

 

48


Table of Contents
 

markets leading to rate increases and decreased appetite. Fidelis Insurance Group incorporates a specific cost inflation factor in its risk modeling to mitigate the effects of inflation. In addition, social inflation driven by changes in societal views on litigation aimed at insurers is a recent and developing risk highlighted by industry leaders and leading to larger claims. See Item 5. Operating and Financial Review and Prospects—D. Trend Information of the 2023 Annual Report.

 

   

Geopolitical Tensions and Conflicts. The escalation of geopolitical tensions, including conflict in the Middle East and the ongoing Ukraine Conflict, has created uncertainty and potential losses for both global direct insurers and reinsurers. Some lines of business, exacerbated by war and armed conflict, are likely to see reduced supply and/or accelerated rate changes. Fidelis Insurance Group continues to monitor such geopolitical tensions and conflicts to determine the ultimate impact from lines of business which may be exposed.

We believe that these market conditions have led to compelling dislocated underwriting opportunities.

Strengths

We believe that our competitive advantages are based on the following key strengths:

 

   

High quality, mature and well positioned specialty insurance portfolio. We believe our scale achieved since inception and our access to TFP’s sophisticated underwriting analytics and technology platform provides us a competitive advantage. Since we started underwriting in 2015, we have grown our insurance book significantly through organic business expansion including through increased client penetration, new product development, long-term relationships and new reinsurance partnerships. Between 2018 and 2023, we had strong growth with a compound annual growth rate of 38.9% for GPW and compound annual growth rate of 44.5% for NPE. Our GPW continued to grow in the three months ended March 31, 2024 to $1.5 billion compared with $1.2 billion in the three months ended March 31, 2023.

 

   

Strong premium growth in attractive lines capitalizing on market conditions. Our business comprises three segments: Specialty, Bespoke, and Reinsurance. We believe our strategy and capabilities allow us to take advantage of the opportunities presented by evolving (re)insurance markets and to proactively shift our business mix across market cycles to generate strong returns. We have built a diverse portfolio of over 100 products across our three segments serving numerous industries, types of exposure, and geographies. Within our 11 core lines of business we try to take lead positions where possible, and together with TFP, our ability to price and aggregate bespoke risks, adapt to evolving market dynamics in the specialty market, and continually optimize in reinsurance markets uniquely positions us to continue to grow a profitable portfolio. The breadth of our portfolio offering in conjunction with our strategic relationship with TFP also allows us to adjust line sizes and retention rates based on prevailing market conditions and achieve optimal economics for the overall portfolio. The three-segment strategy is central to our growth as it allows us to deliver attractive risk-adjusted returns to shareholders in the long term by managing through (re)insurance cycles and deploying to the most favorable market conditions across the three segments.

We focus on building first mover advantages across our markets. Our product portfolio evolves in response to client demand for tailored products and our market-driven, real-time assessment of risk.

 

   

We have a nimble approach and focus on bottom line. We take pride in making reasoned decisions to actively enter and grow or reduce and exit specific lines of business as opportunity arises or diminishes. We believe our nimble approach and firm focus on bottom-line profitability (i.e., net income, as opposed to top-line growth) of each line of business is key to our strategy and success. Through our oversight of underwriting operations and participation at the UMCC, we are able to identify areas of underperformance quickly and work with our underwriting partners to remediate.

Our strategy is to increase line sizes where appropriate, take the lead in requiring rate changes and establish ourselves as the “go to” market for solutions through our in-force portfolio and new classes of specialty and bespoke products. Depending on market conditions, we exercise discretion in coordination with TFP, where applicable, to increase retention by reducing outwards quota shares to take further advantage of the

 

49


Table of Contents

continued hardening of rates. Similarly, we may also coordinate with TFP to increase line sizes as conditions warrant. We intend to grow specialty classes by writing meaningful line sizes to further push rate increases, achieve differential pricing through leadership and access new classes where there is significant market dislocation. We expect to grow our specialty and bespoke products through a combination of organic growth of our already well-established footprint, systematic cross-selling to clients and innovative new products while maintaining quality underwriting information, high-quality risk selection and multi-line aggregation tools and technology.

 

   

Proven track record of delivering compelling combined ratios, supported by “First choice” access to one of the best underwriting teams in the industry. Fidelis Insurance Group has a proven track record of delivering profitable underwriting results, as evidenced through FIHL’s combined ratio. Between 2018 and 2023, Fidelis Insurance Group achieved strong underwriting performance with an average loss ratio of 45.1% and an average combined ratio of 85.8%. In the year ended December 31, 2023 our loss ratio was 38.1% and combined ratio was 82.1%, respectively.

The performance of our business portfolio written by TFP is primarily driven by the capabilities of the TFP management team, led by Richard Brindle, who is the Chairman and CEO of TFP. Mr. Brindle brings 40 years of experience in the insurance industry and is known for his track record of outperformance across Lloyd’s syndicates and Lancashire under his leadership. We secured a long term agency relationship with TFP under the Framework Agreement, with right of first access to its underwriting business, and strong economic and strategic alignment between the two businesses.

 

   

Robust capital position. We have a strong balance sheet and are committed to preserving our financial strength. At December 31, 2023, our total assets were $10.0 billion and our cash and cash equivalents, restricted cash and cash equivalents, and investments totaled $4.3 billion, primarily highly rated, liquid fixed maturity assets. Our $3.0 billion total capitalization as of December 31, 2023 (which comprises shareholders’ equity plus preference securities and long term debt) provides us with the flexibility to engage in attractive underwriting opportunities and scale quickly when market conditions warrant increased business.

 

   

Highly experienced management team. Our management team consists of industry veterans with many years of relevant experience in insurance, providing FIHL with the necessary functional support, supplemented by the services stipulated under the Framework Agreement and Inter-Group Services Agreement. We are led by Mr. Daniel Burrows, who, prior to joining Fidelis Insurance Group in 2015, was the co-CEO of Aon Benfield’s Global Re Specialty (“GRS”) division. Prior to assuming the CEO role at FIHL, Mr. Burrows had been leading Fidelis Insurance Group’s Bermuda operations and was most recently the Executive Chairman of FIBL and Group Managing Director. The other members of the management team are a mix of experienced individuals who have had held key roles at Fidelis Insurance Group and have long histories of working with TFP, along with other experienced professionals from other industry peers.

 

   

Embedded ESG initiatives that are core to our business. Fidelis Insurance Group is committed to working together with TFP to implement standards for ESG matters. TFP incorporates an ESG assessment into its underwriting on our behalf and is continually refining its process for reviewing individual insurance risks. TFP in the U.K. market has promoted the use of a forced labor clause prohibiting the use of any form of forced labor in marine cargo business and is cooperating with the U.K. Independent Anti-Slavery commissioner and Anti-Slavery International, a non-profit organization to develop a commitment to which insurers and brokers can sign up.

Fidelis Insurance Group and TFP are both members of ClimateWise. The ClimateWise Principles require members to disclose their assessment of the risks and opportunities of climate change and are aligned with the Task Force on Climate-related Financial Disclosure framework. Further, TFP was a founding member of The Poseidon Principles on Marine Insurance, which pledges a net zero marine hull insurance portfolio by 2050. We actively support the transition to a net zero global economy by making renewable energy one of our classes of underwriting through TFP, including the construction of offshore wind turbine farms.

We maintain underwriting and investment restrictions that align with our ESG principles as well as those principles that are consistent with leading to long-term value, such as excluding a number of sectors that we believe pose risks of harm to people, animals and the environment. Furthermore, FIHL’s investment

 

50


Table of Contents

portfolio is managed in a manner that is consistent with Fidelis Insurance Group’s sustainability principles and its ESG objectives. The fixed maturity portfolio has a minimum requirement for investments that meet ESG thresholds, prohibits investing in issuers with poor ESG ratings, and restricts exposure to certain industries and behaviors.

Further, the ERG works to enhance employee engagement by providing opportunities that match their workplace values. We believe that this voluntary, employee-driven initiative encourages community, support, and advocacy, involving diversity, equity, inclusion, employee engagement, environmental concerns, and philanthropy. In 2024, the ERG is prioritizing charitable causes aligned with our company values and community impact, which we hope to result in impactful grants, more cultural exchanges, and enhanced educational resources on diversity.

Our Strategy

We are set up to be nimble, thoughtful, and efficient decision-makers and we believe that we are able to respond quickly to an ever-changing world and a constantly evolving marketplace. We believe these attributes allow us to target opportunities that we expect to offer a compelling balance of risk and reward that creates long-term value through the cycle by delivering consistent returns to shareholders. We intend to scale our business to reflect market conditions and pursue prudent capital management and profitable underwriting on a loss ratio and combined ratio basis in pursuance of our financial targets.

Our strategy involves the following:

 

   

Profitable underwriting. We will continue to focus on underwriting profitably through (re)insurance cycles. As our insurance portfolio matures and scales, we believe we will also have an opportunity to increase our underwriting leverage. We seek to direct capital to attractively priced opportunities based on market conditions to address client needs.

We seek to manage volatility over the cycle in our underwriting result by writing a balanced and diversified portfolio of predominantly specialty business, maintaining strict underwriting and pricing discipline and strategic reinsurance protection. Our strategy has frequently generated better risk-adjusted returns than many of our competitors who focus on specific niches exclusively or have large exposure to natural catastrophe reinsurance. We have taken measures to actively manage and in many cases reshape our natural catastrophe exposure in light of greater severity and frequency of catastrophe events and concerns around global climate change.

We leverage our relationship with TFP to continue disciplined underwriting with the use of TFP’s integrated technology solutions, including monitoring real-time market conditions to best capture unique opportunities. TFP’s daily processes, which we actively participate in, will enable it, on our behalf, to maintain a live, dynamic picture of the current underwriting environment that drives daily underwriting decisions, including the daily UMCCs. We believe that our risk selection as a result of these processes should allow us to deploy significant line sizes that in turn allow us to be a “rate maker” rather than a “rate taker.”

 

   

Expand our presence in the specialty insurance market. The Specialty segment has benefited from a hard pricing environment over recent years which has generated profitable growth. To take advantage of mature hard market conditions, following year-on-year compound rate increases across specialty lines we will seek to grow our top-line income and maintain leading market positions that facilitate differential pricing terms and conditions through a disciplined and nimble approach to underwriting in conjunction with our underwriting partners who are carefully selected based on their underwriting performance. We expect to continue to leverage our access to TFP’s long-standing and trusted relationships with brokers and clients, built over the years by key executives, some of whom have almost 40 years of experience in insurance, both specialty and bespoke markets. The continued access to such long-standing and trusted relationships coupled with TFP’s extensive expertise will provide significant opportunity to quote, underwrite and bind attractive niche specialty insurance policies in an efficient manner. By leveraging the UMCC, where all

 

51


Table of Contents
 

lines of business are considered in real time, we expect to be able to pivot quickly to the most attractive opportunities. By focusing on markets in which we have expertise and in which we can provide innovative new products, we believe we have a strong ability to capture profitable business.

A recent example of such innovation is the cooperation between Fidelis Insurance Group and TFP to launch Itasca MGA, an aviation-focused managing general agent (“MGA”) of Pine Walk, a wholly owned subsidiary of TFP. Itasca MGA specializes in underwriting, structuring and managing risks associated with secured commercial aviation financing. We believe with the experience and expertise of the Itasca MGA team and their partnerships with established market participants that they are positioned to become one of the key solution providers for global airlines and the broader aviation market.

Furthermore, in March 2024, Fidelis Insurance Group jointly announced with TFP the launch of Syndicate 3123. Fidelis Insurance Group’s participation in Syndicate 3123 includes a 9.9% contribution of Syndicate 3123’s total capital requirement for the second half of 2024, and a variable quota share of the book of business underwritten by Syndicate 3123. TFP is also contributing 9.9% of Syndicate 3123’s capacity, further demonstrating alignment of interest between the parties, with individual members at Lloyd’s and other investors providing the remainder of the capital requirements.

 

   

Manage and develop strategic partnerships. We aim to optimize underwriting results via comprehensive management and oversight of our strategic underwriting partners. Our business model enables us to focus on building relationships with first in class underwriting teams while also achieving operational excellence through collaboration, enhanced efficiencies and effective oversight processes.

We have an exclusive right of first access to TFP’s underwriting business during the term of the Framework Agreement. Based on Fidelis’ historical experience, we expect this long-term partnership to deliver strong returns to our shareholders, primarily driven by our underwriting results. We aim to be good stewards of capital by effectively balancing capital deployment across market opportunities with capital distributions to our shareholders.

Subject to the exclusivity obligations set out in the Framework Agreement (see Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions—Framework Agreement—Exclusivity, Rights of First Offer and Rights of First Refusal of the 2023 Annual Report), we continue to explore additional avenues for the deployment of capital into new underwriting opportunities by targeting strategic partners across lines of business which support our growth strategy, in order to achieve diversification and meet return criteria.

 

   

Uphold a strong balance sheet. We believe as interest rates remain elevated, we will continue to have opportunities to earn a higher yield while maintaining an appropriately conservative investment portfolio to support our business. We maintain robust procedures for setting our reserves for losses and loss adjustment expenses and actively managing risk in our portfolio. From January 1, 2018 to December 31, 2023, we had net favorable prior year reserve development of $192.6 million from our reserves for losses and loss adjustment expenses. We believe a robust balance sheet best positions us to be a provider of choice for policyholders and take advantage of large or sudden market pricing dislocations.

 

   

Active capital management. We invest and manage our capital proactively with a goal of maximizing value for our shareholders by growing book value, generating consistent returns and optimizing capital management.

We maintain a strong, highly rated balance sheet with total capital of $3.0 billion as of December 31, 2023. We have had net favorable prior year reserve development every year since inception, demonstrating our consistent and prudent approach to reserving. In addition, our focus is on short-tail lines with carefully managed catastrophe exposure and no longer tail casualty business. This approach, and our minimal exposure to social inflation risk, reinforces our confidence that we can avoid meaningful reserve volatility moving forward. Further, we continue to strategically use reinsurance, including our 20% whole account quota share with Travelers that recently renewed for a second year, as a flexible and aligned source of capital.

 

52


Table of Contents

Looking ahead, our primary focus remains capitalizing on the attractive growth opportunities to deliver profitable returns while also continuing to explore ways to optimize our capital structure and create value for shareholders. Our strategic capital management priorities include: allocating capital back into the business and deploying capital into attractive underwriting opportunities; reassessing our outwards reinsurance purchasing program; and returning capital to shareholders through a combination of the Share Repurchase Program and our dividend policy (see “Dividend Policy”).

In relation to the Share Repurchase Program, we reported in Exhibit 99.2 of the Q1 2024 Quarterly Report that during the three months ended March 31, 2024, we repurchased 357,602 Common Shares for $5.0 million. Subsequently, from April 1, 2024, to May 17, 2024, we repurchased an additional 1,026,968 Common Shares for $18.9 million.

 

   

Foster a strong employee culture: Operate a supportive and respectful performance led culture of openness, honesty, challenge and inclusiveness. Key to our strategy is the development of a culture that reflects the shared values, behaviors and standards that contribute to a workplace environment which encourages and supports performance and ethical behaviors. Our employee values are as follows:

 

   

Autonomy: Fidelis Insurance Group cultivates a culture of empowerment, accountability and self-direction within our organization. We foster an environment where individuals have the freedom to exercise their judgement, set ambitious goals, and work towards achieving them in ways that they deem most effective.

 

   

Connected: We foster an inclusive and community orientated culture which recognizes that strength lies in unity and a shared sense of purpose among all stakeholders. We recognize that our purpose is to create tangible benefit for customers, shareholders and society at large, reflecting a commitment to ethical and socially responsible business practices.

 

   

Expert: Our Group values expertise, encourages intellectual curiosity and fosters a dynamic environment where individuals can push boundaries to explore new possibilities. We cultivate a culture of creative thinking, experimentation with new ideas, and a willingness to embrace change to drive progress and innovation within our organization.

Competition

The (re)insurance industry is highly competitive and we compete with major insurers, reinsurers and alternative capital managers. While there is no one direct competitor for us given our business strategy, and we may have other categories of peer groups or competitors, our competitors may include multi-line property and specialty (re)insurers such as AXIS Capital Holdings Limited, Beazley plc, Conduit Holdings Limited, Everest Group Ltd, Hamilton Insurance Group Ltd, Hiscox Ltd, Lancashire Holdings Limited, Markel Group Inc, and W.R. Berkley Corporation. The industry has seen and continues to see a trend of consolidation, and we believe that our unique business model and focus on quality, service and experience over scale differentiates us from our competitors seeking growth from mergers or acquisitions. See “Risk Factors” and Item 3. Key InformationD. Risk Factors of the 2023 Annual Report.

Employees

At March 31, 2024, we employed 79 persons on a full time basis, of which 21 were in Bermuda, 46 were in the United Kingdom, and 12 were in Ireland. Of these, 16 worked primarily in (re)insurance business related functions, such as actuarial, claims, risk and underwriting; 20 worked primarily in operational functions, such as business operations, facilities, office management and IT; 23 worked primarily in finance functions, such as finance and investments; and 20 worked primarily in support and other functions, such as chief executive office, audit, compliance, HR, and legal.

Facilities

We lease office space in Bermuda, Ireland and the United Kingdom. We renew and enter into new leases in the ordinary course of business.

 

53


Table of Contents

Information Technology

We require complex and extensive IT systems to run our business and are reliant on third parties, including TFP, for the provision of important services, including finance systems and processes and IT infrastructure including software, claims management and investment management services. We have autonomy over our financial and regulatory reporting, with use of dedicated Oracle Fusion general ledger and Solvency II reporting tools.

The technology platforms were transferred to TFP as part of the Separation Transactions. Although the proprietary tools and systems including the Prequel Policy Administration system, the Jarvis Data Warehouse, and the FireAnt analytics system are owned by TFP, they are licensed for use by us as appropriate pursuant to the outsourcing arrangements. See Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions—Other—Licensing Arrangements of the 2023 Annual Report.

Legal Proceedings

Similar to the rest of the insurance and reinsurance industry, we are from time to time subject to litigation and arbitration in the ordinary course of business. We may also be subject to other potential litigation, disputes and regulatory or governmental inquiry from time to time in the ordinary course of business. While it is not feasible to predict or determine the ultimate outcome of the pending or threatened proceedings, management does not believe that the outcome of these proceedings, including those discussed below, will have a material adverse effect on the financial condition of Fidelis Insurance Group, after consideration of any applicable reserves.

Following Russia’s invasion of Ukraine on February 24, 2022, government sanctions were introduced prohibiting various commercial and finance activities in Russia, including leasing of aircraft in the aviation industry to any person in Russia, or for use in Russia. Aircraft lessors issued notices to airlines and lessees in Russia purporting to terminate the leasing of aircraft (and other parts such as spare engines) and requiring that the airlines return the assets. Many of the relevant aviation authorities where the aircraft are registered have also since suspended the certificates of airworthiness of such aircraft. Some aircraft are yet to be returned and aircraft lessors filed various insurance claims under their insurance policies for loss of the unreturned aircraft. The insurers have denied the claims and the lessors have instituted proceedings in the U.K., the U.S. and Ireland against upwards of 60 (re)insurers, including certain Group entities. Provision has been made in Fidelis Insurance Group’s reserves for losses and loss adjustment expenses for potential exposures relating to the Ukraine Conflict, a considerable majority of which are reserves reflecting our estimate for potential loss claims relating to leased aircraft within Russia, including the related litigation proceedings. See Item 5. Operating and Financial Review and Prospects—Operating Results—Recent Developments—Russia-Ukraine Conflict.

This is an unprecedented event, which, as of the date of this prospectus, is anticipated to continue for a protracted period of time and presents unique circumstances and coverage issues in respect of both the gross loss and consequent extent of the reinsurance recoveries, which will continue to be unresolved until the multiple courts rule on the merits of the lawsuits. The situation is continuously evolving, including with respect to explorative discussions ongoing between Western leasing firms and Russian airline operators for the sale of some of the unreturned aircraft to the Russian operators. Such discussions, if successful, may lead to a reduction in any potential exposures under the relevant insurance policies. See Item 5. Operating and Financial Review and Prospects—Operating Results—Recent Developments—Russia-Ukraine Conflict, Item 3. Key Information—D. Risk Factors—Risks Relating to Recent Events—The full extent of the impacts of the ongoing Ukraine Conflict on the (re)insurance industry and on the Group’s business, financial condition and results of operations, including in relation to claims under the Group’s (re)insurance policies, are uncertain and remain unknown and Item 3. Key Information—D. Risk Factors—We are subject to litigation which could adversely affect our business and results of operations, of the 2023 Annual Report.

 

54


Table of Contents

MANAGEMENT AND CORPORATE GOVERNANCE

The following are the directors and senior managers of Fidelis Insurance Group as of the date of this prospectus.

 

Name

    

Position

  

Date Appointed to Role

Helena Morrissey

     Chair and Non-Executive Director    January 3, 2023

Daniel Burrows

     Group Chief Executive Officer and Executive Director    January 3, 2023

Allan Decleir

     Group Chief Financial Officer and Executive Director    January 3, 2023

Matthew Adams

     Non-Executive Director    October 25, 2023

Daniel Brand

     Non-Executive Director    July 26, 2021

Charles Collis

     Non-Executive Director    May 15, 2023

Christine Dandridge

     Non-Executive Director    October 25, 2023

Cathy Iberg

     Non-Executive Director    November 2, 2016

Daniel Kilpatrick

     Non-Executive Director    November 15, 2022

Dana LaForge

     Non-Executive Director    March 19, 2021

Hinal Patel

     Non-Executive Director    January 3, 2023

Warrick Beaver

     Group Chief People Officer    March 1, 2023

Denise Brown-Branch

     Group Chief Operating Officer    July 1, 2021

Ian Houston

     Group Chief Underwriting Officer    January 16, 2023

Michael Pearson

     Group Chief Risk Officer    January 3, 2023

Jonathan Strickle

     Group Chief Actuarial Officer    January 3, 2023

Janice Weidenborner

     Group Chief Legal Officer    January 23, 2023

Biographical Information

Biographical information on our directors and senior managers is set forth below.

Directors

Baroness Helena Morrissey DBE. Baroness Morrissey has held the position of chair of the Board since January 3, 2023. She has over three decades of experience in the financial services sector and has served in several leadership roles throughout her career. In addition to acting as chair of the Board of Fidelis Insurance Group, Baroness Morrissey currently holds the position of director on the boards of a number of other organisations. Since February 2023, Baroness Morrissey has acted as chair of the Board of Altum Group. She also serves as an advisory board member of All Perspectives Ltd, Edelman Communications, Anthemis and UK Fintech Growth Fund and is chair of the Nominations and Governance Committee of McKinsey Investment Office. Prior to her current positions, Baroness Morrissey was lead non-executive director at the Foreign & Commonwealth Office between July 2020 and September 2020, transferring to lead non-executive director of the Foreign, Commonwealth & Development Office until June 2022. Between January 2020 and May 2021, Baroness Morrissey was a non-executive director of St James’ Place. Prior to this, she was head of personal investing at Legal & General Investment Management between May 2017 and December 2019. From 2001 to 2016, she was CEO of Newton Investment Management. Baroness Morrissey began her career as a global bond analyst at Schroders in the 1980s, later becoming a global bond fund manager. Baroness Morrissey holds a Master of Arts in Philosophy from Cambridge University. Other prior experience includes: chair of the Investment Association from July 2013 to May 2017; founder of the 30% Club campaign; non-executive director of Green Park Limited from August 2020 to March 2023; and non-executive director of the board of AJ Bell plc from July 2021 to April 2023, acting as chair of the board from January 2022 to April 2023. Baroness Morrissey is chair of the Diversity Project, a trustee of the Lady Garden Foundation and a fellow and Chair of the Endowment Committee of Eton College. Baroness Morrissey has served as a director of Helena Morrissey Ltd since February 2017. We believe Baroness Morrissey is qualified to serve as a member of our Board based on our review of her experience, qualifications, attributes and skills, including her executive leadership experience in the financial sector.

 

55


Table of Contents

Daniel Burrows. Mr. Burrows has been a director of FIHL since April 2022 and has held the position of Group Chief Executive Officer of FIHL since January 3, 2023. He is also Chief Underwriting Officer of FIBL and an executive director of FIBL. Mr. Burrows joined Fidelis Insurance Group in 2015. Prior to joining Fidelis Insurance Group, Mr. Burrows was co-CEO of Aon Benfield’s Global Re Specialty (GRS) division from 2013 to 2015. Specializing in non-marine retrocession and the aviation, marine and energy sectors, among others, Mr. Burrows supported Aon Benfield’s business hubs across North America, Europe, the Middle East, Africa and Asia Pacific. Prior to this, he was Deputy CEO of the GRS division from 2008 until 2013. Mr. Burrows began his career as a non-marine property broker at Greig Fester in the 1980s, later joining the retrocession team and then leading that team following a merger with Benfield in 1997. We believe Mr. Burrows is qualified to serve as a member of our Board based on our review of his experience, qualifications, attributes, and skills, including his extensive insurance background and executive leadership experience.

Allan Decleir. Mr. Decleir has held the position of Group Chief Financial Officer of FIHL since January 3, 2023. Mr. Decleir is also Chief Executive Officer of FIBL and an executive director of FIBL. Prior to assuming these executive positions, Mr. Decleir was a consultant to FIBL from June 1, 2022. He has over 27 years of experience in the (re)insurance industry. From June 2015 to December 2022, Mr. Decleir was an independent consultant for ThreeSeas Consulting Ltd, providing management consulting services in the Bermuda (re)insurance market. Mr. Decleir was also a Listings Manager at the Canadian Securities Exchange from February 2019 until March 2022. Prior to this, he was Executive Vice President & Chief Financial Officer of Platinum Underwriters Holdings, Ltd. (“Platinum”) from June 2010 until March 2015, overseeing SEC, financial and regulatory reporting. He first joined Platinum’s Class 4 reinsurance subsidiary, Platinum Underwriters Bermuda, Ltd. (“Platinum Bermuda”), in 2003, and, from 2005 until his promotion to Platinum’s Group CFO, served as Senior Vice President and Chief Financial Officer. Prior to joining Platinum Bermuda, Mr. Decleir was the Chief Financial Officer of Stockton Reinsurance Limited from June 1996 to May 2003. He began his career at Ernst & Young in 1988, taking on various positions in Canada and Bermuda. Mr. Decleir was granted a National Association of Corporate Directors governance fellowship in 2017 and achieved the “Directorship Certified” designation in 2022, and earned the Associate in Reinsurance designation from the Insurance Institute of America in 2000. Mr. Decleir holds a Bachelor of Business Administration from Wilfrid Laurier University and is a Chartered Professional Accountant (Chartered Accountant). We believe Mr. Decleir is qualified to serve as a member of our Board based on our review of his experience, qualifications, attributes, and skills, including his extensive financial accounting background, corporate governance and executive leadership experience in the financial and insurance industries.

Matthew Adams. Mr. Adams has held the position of non-executive director of FIHL since October 25, 2023. Mr. Adams built a long-standing practice with PricewaterhouseCoopers (“PwC”), largely concentrated in the insurance industry. He served as a lead account partner for PwC, auditing and advising many of PwC’s largest and most complex global insurance clients. From 2015-2021, he led PwC’s U.S. Insurance Practice and was a member of PwC’s global insurance practice leadership team. Mr. Adams retired from PwC in June 2023, following a 38-year career with the firm. Mr. Adams’ leadership of PwC’s U.S. Insurance Practice has exposed him to many diverse aspects of the insurance sector, and he has significant experience managing the strategic, operational, profitability and human capital challenges of leading a large, quickly growing business. Mr. Adams has participated in numerous audit and other board committee meetings during his career, providing broad perspectives on board governance priorities. Mr. Adams earned a B.S. in Economics and an M.B.A. from the Wharton School of the University of Pennsylvania, and is a certified public accountant in New York. Mr. Adams serves as chair of the Board’s Audit Committee. We believe Mr. Adams is qualified to serve as a member of our Board based on our review of his experience, qualifications, attributes, and skills, including his extensive financial accounting, audit and corporate governance background in the insurance sector.

Daniel Brand. Mr. Brand is the CVC non-executive director nominee of FIHL and has held this position since 26 July 2021. Mr. Brand joined CVC in 2009 and is a partner leading CVC’s U.S. private equity activities in financial services and co-leading CVC’s U.S. private equity activities in business services. Mr. Brand also represents CVC on the boards of directors of CFGI, Medrisk, Republic, Teneo and Worldwide Express. Prior to

 

56


Table of Contents

joining CVC, Mr. Brand worked at DLJ Merchant Banking Partners and Credit Suisse in the investment banking division covering financial institutions. Mr. Brand holds a B.A. in Economics with a Certificate in Finance from Princeton University, and an M.B.A. from Harvard Business School. We believe Mr. Brand is qualified to serve as a member of our Board based on our review of his experience, qualifications, attributes, and skills, including his extensive financial background and directorial experience.

Charles Collis. Mr. Collis has held the position of non-executive director of FIHL since May 15, 2023. Mr. Collis is a director of Conyers Dill & Pearman (“Conyers”). Mr. Collis works in the corporate department of the Bermuda office of Conyers and headed up the Bermuda Insurance Practice for more than fifteen years. Mr. Collis joined Conyers in 1990 and became a partner in 1998. Mr. Collis specializes in insurance and reinsurance, advising on corporate and regulatory matters. Mr. Collis holds a Bachelor of Laws from University College London and a Bachelor of Arts from the University of Toronto. We believe Mr. Collis is qualified to serve as a member of our Board based on our review of his experience, qualifications, attributes, and skills, including his extensive legal background and experience in the insurance industry.

Christine Dandridge. Ms. Dandridge has held the position of non-executive director of FIHL since October 25, 2023. Ms. Dandridge is a veteran of the specialty insurance market, with experience spanning more than four decades. Ms. Dandridge began her career in 1978 as a broker at Stewart Wrightson, before joining the underwriting team at Posgate and Denby Syndicate in 1980 and becoming one of the first female underwriters at Lloyd’s. Ms. Dandridge was one of the founding members of Atrium Underwriting. She served as active underwriter of Syndicate 609 from 1997 to 2007, was part of numerous Lloyd’s market committees and was a member of the Council of Lloyd’s from 2004 to 2007. Since then, she has held several non-executive directorships and currently acts as non-executive director on the boards of Equitas Limited, Hive Underwriting Limited, Managing Agency Partners Limited and Track My Risks Ltd. She graduated from University College, London with a BSc (Hon) in Anthropology and is an associate of the Chartered Insurance Institute. Ms. Dandridge serves on the Board’s Risk Committee. We believe Ms. Dandridge is qualified to serve as a member of our Board based on our review of her experience, qualifications, attributes, and skills, including her extensive underwriting background and executive leadership and directorial experience in the insurance sector.

Cathy Iberg. Ms. Iberg has held the position of non-executive director of FIHL since November 2, 2016. Ms. Iberg is Vice President of Investments at the St David’s Foundation, a charitable foundation dedicated to providing and supporting nonprofit health-related programs in the US, including the largest scholarship program in Texas for aspiring health professionals, and the largest mobile dental program in the country. Ms. Iberg joined the St David’s Foundation in December 2015. Prior to her role at the Foundation, Ms. Iberg was UTIMCO’s (University of Texas Investment Management Company) President and Deputy CIO and retired in August 2014. At UTIMCO she was responsible for investment oversight of $30 billion in investment assets in addition to the management of public equity, fixed income and hedge fund investments. Her employment with the organization dates back to April of 1991 when she joined the U.T. System Office of Asset Management, the predecessor to UTIMCO. Previous to joining U.T. System, Ms. Iberg practiced in the area of public accounting for 15 years. She has a B.Sc. degree in accounting from the Southern Illinois University and was a Certified Public Accountant. We believe Ms. Iberg is qualified to serve as a member of our Board based on our review of her experience, qualifications, attributes, and skills, including her financial accounting background and executive leadership experience in the investments sector.

Daniel Kilpatrick. Mr. Kilpatrick is the Crestview director nominee and has held this position since November 15, 2022. Mr. Kilpatrick joined Crestview in August 2009 and is a partner and member of the Crestview Investment Committee. He is also the head of the financial services strategy. Mr. Kilpatrick also is on the boards of directors of AutoLenders, Congruex, DARAG Group, Modern Wealth Management, WildOpenWest, LLC and Venerable Holdings. He was previously on the boards of Accuride Corporation, Camping World Holdings, ICM Partners, Industrial Media, NYDJ Apparel, Protect My Car and Symbion. Prior to joining Crestview, Mr. Kilpatrick worked at the Yale Investments Office. Mr. Kilpatrick received an M.B.A. from Stanford Graduate School of Business and a B.A. from Yale University. We believe Mr. Kilpatrick is

 

57


Table of Contents

qualified to serve as a member of our Board based on our review of his experience, qualifications, attributes, and skills, including his extensive financial background and directorial experience.

Dana LaForge. Mr. LaForge is the Pine Brook director nominee and has held this position since March 19, 2021. Mr. LaForge joined Pine Brook in June 2020 and is a partner on the financial services investment team and a member of Pine Brook’s Investment Committee. Mr. LaForge also represents Pine Brook on the boards of directors of Amedeo Capital Limited, Belmont Green Limited, Syndicate Holding Corp., and Clear Blue Financial Holdings. He also serves as a director of a venture philanthropy fund, the Myeloma Investment Fund. Prior to joining Pine Brook, he was the founder and managing director of Colonnade Financial Group from 2002-2020, a spin-out from Deutsche Bank created to manage a private equity portfolio. Prior to Colonnade, from 1985-2002 Mr. LaForge served in numerous senior executive roles at Deutsche Bank and its predecessor companies, Bankers Trust and BT Alex. Brown, also serving as the head of the North American financial institutions group in investment banking. Mr. LaForge holds a Bachelor of Science in Commerce and Accounting from Washington & Lee University and a Master of Business Administration from Harvard Business School. We believe Mr. LaForge is qualified to serve as a member of our Board based on our review of his experience, qualifications, attributes, and skills, including his extensive financial background and directorial experience.

Hinal Patel. Mr. Patel is the TFP HoldCo director nominee. Mr. Patel acted as Group Chief Actuary of Fidelis Insurance Group from September 2015 to July 2017 and as Group Chief Financial Officer of Fidelis Insurance Group from July 2017 until January 3, 2023, following which Mr. Patel left Fidelis Insurance Group to become the Chief Financial Officer of the TFP HoldCo. Mr. Patel has held the position of non-executive director of FIHL since January 3, 2023. During his time as Group Chief Financial Officer of Fidelis Insurance Group, Mr. Patel was responsible for the finance, investment, actuarial and corporate finance functions. Prior to joining Fidelis Insurance Group, Mr. Patel spent 12 years at Catlin, where he served in a variety of positions, including Bermuda Chief Actuary overseeing actuarial, catastrophe modelling and capital functions for the Bermuda entity. Prior to joining Catlin, Mr. Patel worked at a number of actuarial consultancies and has over 20 years of experience. Mr. Patel graduated from the London School of Economics and is also Fellow of the Institute of Actuaries. We believe Mr. Patel is qualified to serve as a member of our Board based on our review of his experience, qualifications, attributes, and skills, including his extensive financial accounting background, corporate governance and executive leadership experience in the insurance industry.

Senior Management

Warrick Beaver. Mr. Beaver became Chief People Officer of Fidelis Insurance Group in March 2023. Prior to that, Mr. Beaver worked as Head of HR at Fidelis Insurance Group, which he joined in August 2022 and, following the completion of the Separation Transactions, TFP. From March 2019 until July 2022, Mr. Beaver was an independent consultant for Stonehouse HCC Ltd, providing management consulting services to private equity-backed specialty (re)insurance brokers. Prior to that, Mr. Beaver worked for Thomson Reuters Corporation from November 2010 to December 2018, where he held a number of global Head of HR positions, as well as Managing Director of the Global Financial Crime and Reputational Risk Proposition and Modern-Day Slavery Initiative from November 2014. Mr. Beaver began his career in 1995, taking on various HR leadership positions in South Africa, the United States and the United Kingdom. Mr. Beaver graduated with a Bachelor of Arts (Psychology) from University of the Witwatersrand in 1994 and in 2001 became a Chartered Member of the Institute of Personnel and Development.

Denise Brown-Branch. Ms. Brown-Branch has held the position of Chief Operating Officer of Fidelis Insurance Group since July 2021. Ms. Brown-Branch is also CEO of FUL and an executive director of FUL. Before becoming Group Chief Operating Officer, Ms. Brown-Branch served in the roles of Strategic Program Manager (as an independent contractor from July 2015 to September 2020) and Director of Operations (from September 2020 to June 2021) within Fidelis Insurance Group. Ms. Brown-Branch has over 25 years of experience in strategic program delivery and business change management. Prior to joining Fidelis Insurance Group, Ms. Brown-Branch was a consultant at Bluefin Solutions from August 2011 to July 2015 where she

 

58


Table of Contents

managed a program of work for Catlin Insurance. Ms. Brown-Branch began her career in the consumer goods industry, where she focused on marketing, IT and global service delivery. Ms. Brown-Branch holds an MBA from Northeastern University and Bachelor of Science degrees in Accounting and Information Systems from Virginia Commonwealth University. She is also certified as a project management professional by the Project Management Institute.

Ian Houston. Mr. Houston joined Fidelis Insurance Group as Group Chief Underwriting Officer on January 16, 2023. Mr. Houston has over two decades of experience in the insurance industry. Prior to joining FIHL, from January 2018 until January 2023, Mr. Houston was general manager of Partner Re Europe. From August 2010 until April 2016, he was Deputy Head of Specialty Lines and Chief Underwriting Officer at PartnerRe. In this role, he was responsible for the strategy, risk appetite framework, portfolio shaping, and transaction referrals for the specialty lines portfolio. Mr. Houston began his career at various insurance carriers in the late 1980s in London. He is an associate of Chartered Insurance Institute and has attended various training courses such as the ZFS EXED Training course at IBM in Lausanne and Converium’s Executive Management course in Vitznau and Washington D.C. and Henley Business School. Mr. Houston holds a BA.Hons degree in Business Studies from South Bank University.

Michael Pearson. Mr. Pearson became Group Chief Risk Officer of Fidelis Insurance Group on January 3, 2023. Prior to this, Mr. Pearson was a consultant to FUL from May 2022, a senior independent non-executive director of FUL from October 2015 to December 2020 and chairman of the FUL board from January 2021 until January 2023. He has over 35 years of experience in the insurance industry and was the Chief Risk Officer at Lancashire from March 2010 until February 2013. Mr. Pearson has held roles as Head of Internal Audit in both the Lloyd’s and company markets and Chief Risk Officer roles in the U.K. and Bermuda. He is a chartered accountant and a fellow of the Chartered Insurance Institute.

Jonathan Strickle. Mr. Strickle has held the position of Group Chief Actuarial Officer of Fidelis Insurance Group since January 3, 2023, prior to which he was Group Actuary of Fidelis Insurance Group from October 2021. Mr. Strickle also held the roles of U.K. Chief Actuary and Group Head of Reserving over the course of his career at Fidelis Insurance Group, which he joined in March 2020. He joined Fidelis Insurance Group after having spent three years as Head of Reserving for China Re’s Lloyd’s syndicate, from January 2017. Between September 2009 and January 2017, Mr. Strickle worked as a consultant at EY on a number of actuarial projects. Mr. Strickle is a Fellow of the Institute and Faculty of Actuaries, and holds both a Bachelor’s and a Master’s degree from the University of Warwick.

Janice Weidenborner. Ms. Weidenborner joined Fidelis Insurance Group as Group Chief Legal Officer on January 23, 2023. Previously, Ms. Weidenborner was Chief Operating Officer and General Counsel at Weston Insurance Management LLC from December 2021 to December 2022. Ms. Weidenborner was Executive Vice President, Group General Counsel and Secretary at Third Point Reinsurance Ltd. between January 2016 and March 2021, adding the role of Head of Human Resources in 2019. Ms. Weidenborner continued on as Executive Vice President overseeing Human Resources at SiriusPoint from March 2021 to July 2021 during a planned integration period following its merger with Third Point Re. From January 2013 to December 2015, Ms. Weidenborner served as General Counsel of Ariel Reinsurance Ltd. Prior to Ariel Re, Ms. Weidenborner served in a number of senior legal roles at the ACE Group of Companies (now Chubb), including Senior Vice President and General Counsel, ACE Financial Solutions International Ltd., Senior Vice President and Associate General Counsel, ACE Bermuda Insurance Ltd and ACE Tempest Re, and Associate General Counsel, ACE USA. Ms. Weidenborner has a Bachelor of Science from Embry-Riddle Aeronautical University, a Master of Business Administration in Finance from Fordham University and a Juris Doctor from Rutgers University School of Law.

Director Independence

As foreign private issuer, under the listing requirements and rules of the NYSE we are not required to have independent directors on our board of directors, except to the extent that our audit committee is required to

 

59


Table of Contents

consist fully of independent directors, subject to certain phase-in schedules. The listing standards of the NYSE require that, subject to specified exceptions, each member of a listed company’s audit, compensation and nominating and corporate governance committees be independent, following a phase-in period. In addition, the listing standards of the NYSE require that audit committee members satisfy independence criteria set forth in Rule 10A-3 under the Exchange Act and that compensation committee members satisfy independence criteria set forth in the NYSE Listed Company Manual. Nevertheless, the listing standards further provide that a director will only qualify as an “independent director” if, in the opinion of that company’s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

The Board has affirmatively determined that each of Matthew Adams, Christine Dandridge, Charles Collis, Cathy Iberg, Daniel Brand, Daniel Kilpatrick, Dana LaForge and Helena Morrissey meet the definition of “independent director” under the applicable rules of the NYSE Listed Company Manual. In making this determination, the Board considered the relationships that each such non-employee director has with FIHL and all other facts and circumstances that the Board deemed relevant in determining such director’s independence, including beneficial ownership of Common Shares. As a result, in accordance with listing standards of the NYSE, a majority of our directors are independent.

Family Relationships

There is no family relationship between any director or senior manager of Fidelis Insurance Group and any other director or senior manager or any person nominated to become a director or senior manager. As explained in Item 6. Directors, Senior Management and Employees—A. Directors and Senior Management—Family Relationships of the 2023 Annual Report, each of the Founders and TFP HoldCo has the right to nominate one individual to serve as a director on the Board. Other than these arrangements, there are no arrangements or understandings with major stockholders, customers, suppliers or others pursuant to which any director or senior manager of Fidelis Insurance Group was selected for such position.

Board Composition

FIHL’s business and affairs are managed under the direction of the Board.

The Amended and Restated Bye-Laws provide that the Board will be divided into three classes, designated Class I, Class II and Class III, as nearly equal in number as possible, with the directors in each class serving staggered three-year terms, and one class being elected each year. Our current directors are divided among the three classes as follows:

 

   

the Class I Directors are Charles Collis, Cathy Iberg, Christine Dandridge and Hinal Patel, who were re-elected at the annual general meeting held on May 8, 2024, and their terms will expire at the third annual general meeting to be held after the consummation of this offering;

 

   

the Class II Directors are Allan Decleir, Daniel Brand, Daniel Kilpatrick and Matthew Adams, and their initial terms will expire at the first annual general meeting to be held after the consummation of this offering; and

 

   

the Class III Directors are Daniel Burrows, Dana LaForge and Helena Morrissey, and their initial terms will expire at the second annual general meeting to be held after the consummation of this offering.

The classified board will remain in place until the annual general meeting occurring in 2030, following which, all of the directors shall be of one class and shall serve for a term ending at the next following annual general meeting.

 

60


Table of Contents

See Item 19. Exhibits—Exhibit 2.1 Description of Securities of the 2023 Annual Report.

When considering whether directors and nominees have the experience, qualifications, attributes or skills, taken as a whole, to enable the Board to satisfy its oversight responsibilities effectively in light of our business and structure, the Board focused primarily on each person’s background and experience as reflected in the information discussed in each of the directors’ individual biographies set forth in “—Biographical Information” above. The effectiveness of the Board is reviewed annually. We continue to believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business.

Role of the Board in Risk Oversight

The Board is responsible for overseeing our risk management process. The Board focuses on our general risk management strategy and the most significant risks facing us, as well as oversees the implementation of risk mitigation strategies by management. Our Chief Executive Officer and other executive officers regularly report to our non-executive directors and the audit committee to ensure effective and efficient oversight of our activities and to assist in proper risk management and the ongoing evaluation of management controls.

Foreign Private Issuer Exemption

As a “foreign private issuer,” as defined by the SEC, FIHL is permitted to follow, and does follow, home country corporate governance practices instead of certain corporate governance practices required for U.S. domestic issuers, provided that FIHL discloses which requirements it is not following and the equivalent requirement in Bermuda (i.e., its home country). FIHL intends to maintain compliance as a foreign private issuer under the applicable corporate governance requirements of the Sarbanes-Oxley Act, the rules adopted by the SEC, and the NYSE corporate governance rules and listing standards.

FIHL relies on the foreign private issuer exemption to certain of the NYSE’s corporate governance standards with respect to matters related to its independent director oversight of executive compensation, proxy solicitation, quorum and shareholder approval. FIHL may decide to rely upon the foreign private issuer exemption for purposes of opting out of some or all of the corporate governance rules applicable from time to time to U.S. domestic companies.

Because FIHL is a foreign private issuer, its directors and senior management will not be subject to short-swing profit and insider trading reporting obligations under Section 16 of the Exchange Act. All shareholders, however, will be subject to the obligations to report changes in share ownership under Section 13 of the Exchange Act and related SEC rules.

Committees of the Board

The Board has an audit committee, compensation committee, investment committee, risk committee, and nominating and corporate governance committee. The Board may have such other committees as it shall determine from time to time. Each of the standing committees of the Board has the composition and responsibilities described below. Copies of each committee’s charter are posted on our website, www.fidelisinsurance.com/investors. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus.

Audit Committee

The Audit Committee is formed of the following directors: Matthew Adams (Committee Chair), Cathy Iberg, Dana LaForge, and Helena Morrissey, each of whom is independent for purposes of the NYSE rules and Rule 10A-3 under the Exchange Act.

 

61


Table of Contents

Pursuant to its terms of reference, the Audit Committee’s role is one of oversight. Its responsibilities include appointing and evaluating the performance and independence of the Company’s independent auditor. Additionally, the Audit Committee also reviews the financial statements and annual audits of the Company, oversees the internal audit function, reviews and discusses with the Board earnings press releases, reviews procedures for handling complaints in relation to accounting, internal accounting controls or auditing matters and assists the Board in assessing and providing oversight regarding the Company’s internal controls and risk management systems. The Audit Committee is responsible for reviewing its terms of reference on an annual basis and shall review its own performance at least once per year.

The Board determined that each of the members of the Audit Committee is financially literate as such term is defined by applicable NYSE and SEC requirements. In addition, the Board has determined that Mr. Matthew Adams qualifies as having accounting or related financial management expertise pursuant to the NYSE requirements and is an “audit committee financial expert” pursuant to the rules and regulations of the SEC.

Compensation Committee

As a foreign private issuer, we are not required to have a compensation committee or a compensation committee consisting only of independent directors. However, our Board has established the compensation committee (the “Compensation Committee”), which consists entirely of independent directors for the purposes of the NYSE rules. The Compensation Committee is formed of the following directors: Helena Morrissey (Committee Chair), Daniel Brand, Charles Collis, Christine Dandridge, Daniel Kilpatrick and Dana La Forge.

Pursuant to its terms of reference, the Compensation Committee is responsible for reviewing, assessing and making recommendations to the Board regarding the Company’s incentive-based and equity-based compensation plans (including long-term incentive plans) and the Company’s processes and procedures for considering and determining the compensation of its directors and senior executives. The Compensation Committee is also responsible for developing and recommending to the Board one or more policies for the recovery or clawback of erroneously paid compensation, monitoring compliance with such policies and making any necessary revisions to such policies as may be required from time to time. The Compensation Committee is responsible for reviewing its terms of reference on an annual basis and shall review its own performance at least once per year.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee is formed of the following directors: Helena Morrissey (Committee Chair), Matthew Adams, Daniel Brand, Charles Collis, Christine Dandridge, Cathy Iberg and Daniel Kilpatrick, each of whom is independent for purposes of the NYSE rules.

Pursuant to its terms of reference, the Nominating and Corporate Governance Committee is responsible for overseeing FIHL’s corporate governance and procedures by developing a set of guidelines and making recommendations to the Board to ensure compliance with laws and regulations. The Nominating and Corporate Governance Committee also reviews Fidelis Insurance Group’s leadership needs by preparing and recommending nominees it thinks necessary based on vacancies and plans for succession in respect of directorship and management, using recommended selection criteria. Additionally, the Nominating and Corporate Governance Committee develops, recommends and oversees the process of annual self-evaluation for the Board as well as its own performance on an annual basis, subject to approval by the Board.

Investment Committee

The Board has established an investment committee, which consists of Cathy Iberg (Committee Chair), Daniel Brand, Dana LaForge, Hinal Patel, Daniel Burrows and Allan Decleir. Pursuant to its written charter, the investment committee is responsible for, among other things: (i) recommending investment strategy, investment risk appetite and investment risk limits to the FIHL Board; (ii) reviewing and approving new material changes to

 

62


Table of Contents

the investment policy or investment managers; (iii) overseeing investment policies, guidelines and benchmarks; (iv) delegation of investment related authorities and responsibilities to sub-committees and management; and (v) monitoring investment risk, compliance, portfolio composition, investment performance and activity.

Risk Committee

The Board has established a risk committee, which consists of Daniel Kilpatrick (Committee Chair), Hinal Patel, Christine Dandridge, Matthew Adams, Daniel Burrows and Allan Decleir. Pursuant to its written charter, the risk committee is responsible for, among other things: (i) evaluating FIHL’s risk appetite and tolerances; (ii) overseeing risk management and related policies and guidelines; (iii) establishing risk policies and guidelines; and (iv) overseeing the Board’s responsibilities related to risk management exposure.

Compensation Committee Interlocks and Insider Participation

None of our executive officers currently serves, or in the past fiscal year has served, as a member of the board or compensation committee of another entity that has one or more executive officers serving on the Board or our compensation committee.

Code of Business Conduct and Ethics

The Board has adopted a code of business conduct and ethics applicable to our employees, directors and officers, including our Chief Executive Officer, Chief Financial Officer and other executive and senior officers, in accordance with applicable U.S. federal securities laws and the corporate governance rules of the NYSE. This code is a “code of ethics,” as defined in Item 406(b) of Regulation S-K under the Securities Act. Our code of ethics is available on our website, www.fidelisinsurance.com/investors/. We make any legally required disclosures regarding amendments to, or waivers of, provisions of our code of ethics on our website. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus.

 

63


Table of Contents

PRINCIPAL AND SELLING SHAREHOLDERS

The following table sets forth certain information regarding the beneficial ownership of Common Shares at May 17, 2024 by (i) each person who is known by us to beneficially own more than 5.0% of the Common Shares; (ii) all of our directors and senior managers as a group; and (iii) the Selling Shareholders (as defined below).

Beneficial ownership for the purposes of the following table is determined in accordance with the rules and regulations of the SEC. These rules generally provide that a person is the beneficial owner of securities if such person has or shares the power to vote or direct the voting of such securities, or to dispose or direct the disposition of such securities, or has the right to acquire such securities or such powers within 60 days.

To our knowledge, except as disclosed in the footnotes to the following table and subject to applicable community property laws, we believe that each beneficial owner identified in the table possesses sole voting and investment power over all Common Shares shown as beneficially owned by such beneficial owner.

For purposes of the table below, the percentage ownership calculations for beneficial ownership are based on 116,898,062 Common Shares outstanding at May 17, 2024. Such beneficial ownership information is presented on the following basis:

 

   

prior to the consummation of this offering; and

 

   

following the consummation of this offering.

The information in the table and the footnotes below with respect to each Selling Shareholder has been obtained from that Selling Shareholder. When we refer to the “Selling Shareholders” in this prospectus, we mean the individuals and entities listed in the table below as offering Common Shares as well as the pledgees, donees, assignees, transferees, successors and others who may hold any of the Selling Shareholders’ interest.

Unless otherwise indicated in the table or footnotes below, the address for each beneficial owner listed under “Directors and Senior Managers” is Wellesley House South, 90 Pitts Bay Road, Pembroke, HM08, Bermuda.

 

    Common Shares Prior
to this Offering
    Common Shares
Offered Hereby
    Common Shares After
this Offering
    Common Shares After
this Offering

Including Full Option
Exercise
 
    Number      %      Number      %      Number      %      Number      %   

Names of Beneficial Owners

5.0% Shareholders

               

Crestview Funds (1)

    17,014,423       14.555     2,177,725       1.863     14,836,698       12.692     14,510,039       12.413

Capital Z Partners (Fidelis) L.P. (2)

    4,026,736       3.445     515,393       0.441     3,511,343       3.004     3,434,034       2.938

CVC Falcon Holdings Limited (3)

    18,506,328       15.831     2,368,678       2.026     16,137,650       13.805     15,782,349       13.501

Pine Brook Feal Intermediate, L.P. (4)

    8,454,329       7.232     1,082,094       0.925     7,372,235       6.307     7,209,921       6.168

Platinum Ivy B 2018 RSC Limited (5)

    13,869,151       11.864     1,775,152       1.518     12,093,999       10.346     11,827,726       10.118

SPFM Holdings, LLC (6)

    8,445,456       7.225     1,080,958       0.925     7,364,498       6.300     7,202,354       6.161

TFP HoldCo (7)

    11,507,581       9.844     —        —        11,507,581       9.844     11,507,581       9.844

 

64


Table of Contents
    Common Shares Prior
to this Offering
    Common Shares
Offered Hereby
    Common Shares After
this Offering
    Common Shares After
this Offering

Including Full
Option

Exercise
 
    Number      %      Number      %      Number      %      Number      %   

Directors and Senior Managers  (8)

               

All directors and senior managers as a group (17 persons)

    724,081       *       —        —        724,081       *       724,081       *  

 

(*)

Less than 1%.

(1)

Represents 11,493,953 Common Shares held by Crestview FIHL Holdings, L.P. and Crestview FIHL TE Holdings, Ltd. (together, “Crestview Fund III”) and 5,520,470 Common Shares held by Crestview IV FIHL Holdings, L.P. and Crestview IV FIHL TE Holdings, LLC (together, “Crestview Fund IV” and, together with Crestview Fund III, the “Crestview Funds”). Crestview Fund III is owned by investment funds the general partner of which is Crestview Partners III GP, L.P. (“Crestview III GP”), each of which may be deemed beneficial owners of the shares held by Crestview Fund III. Crestview Fund IV is owned by investment funds, the general partner of which is Crestview Partners IV GP, L.P. (“Crestview IV GP”), each of which may be deemed beneficial owners of the shares held by Crestview Fund IV. Crestview III GP has voting and investment control over shares held by Crestview Fund III, and Crestview IV GP has voting and investment control over shares held by Crestview Fund IV. Decisions by each of Crestview III GP and Crestview IV GP to vote or dispose of such shares require the approval of a majority of members of its respective investment committee and the chairman of such investment committee, each of which is composed of the following individuals: Barry S. Volpert (chairman), Thomas S. Murphy, Jr., Robert V. Delaney, Jr., Brian P. Cassidy, Adam J. Klein, Daniel G. Kilpatrick and Bradford R. Williams. None of the foregoing persons has the power individually to vote or dispose of such shares. Each of the foregoing individuals disclaims beneficial ownership of all such shares. The address of each of the foregoing is c/o Crestview, 590 Madison Avenue, 42nd Floor, New York, NY 10022.

(2)

The general partner of Capital Z Partners (Fidelis) LP (“Capital Z”) is Capital Z Partners (Cayman) GP, LP. Its general partner is Capital Z Partners III GP, Ltd. The general partner has appointed Capital Z Partners Management, LLC as the investment manager (the “Investment Manager”) of Capital Z Partners (Fidelis), LP with effective control under the investment management agreement. Each member of the Investment Manager disclaims ownership of the Common Shares held by Capital Z Partners (Fidelis) LP, except to the extent that such member has a pecuniary interest therein through an investment in the general partner. The mailing address of Capital Z Partners (Fidelis) LP is 4851 Tamiami Trail N, Suite 200, Naples, FL 34103.

(3)

Represents 18,506,328 Common Shares held by CVC Falcon Holdings Limited. CVC Falcon Holdings Limited is wholly owned by CVC Capital Partners VI (A) L.P, CVC Capital Partners VI (B) L.P, CVC Capital Partners VI (C) L.P, CVC Capital Partners VI (D) S.L.P, CVC Capital Partners VI Associates L.P and CVC Capital Partners Investment Europe VI L.P (collectively, “CVC Fund VI”). CVC Capital Partners VI Limited is the sole general partner of each of the limited partnerships comprising CVC Fund VI. As a result, each of the foregoing entities may be deemed to share beneficial ownership of the securities held by CVC Falcon Holdings Limited. The board of directors of CVC Falcon Holdings Limited exercises voting and investment authority with respect to the subject ordinary shares. CVC Capital Partners VI Limited is managed by a four member board of directors. Each of the foregoing persons disclaims beneficial ownership of the securities beneficially owned by CVC Falcon Holdings Limited. The registered address of CVC Falcon Holdings Limited is at 27 Esplanade, St Helier, Jersey JE1 1SG.

(4)

The general partner of Pine Brook Feal Intermediate, L.P. (“Pine Brook”) is PBRA (Cayman) Company. Any of (i) PBRA (Cayman) Company, (ii) Pine Brook Road Advisors, L.P., which provides investment advice to Pine Brook, (iii) PBRA, LLC, general partner of Pine Brook Road Advisors, L.P. or (iv) Mr. Howard H. Newman, who serves as the managing member of PBRA, LLC, may be deemed to have voting or dispositive power over the shares owned by Pine Brook. The registered address for Pine Brook is PO Box 309, Ugland House, Grand Cayman, KY1-1104 Cayman Islands.

(5)

Represents 13,869,151 Common Shares owned by Platinum Ivy B 2018 RSC Limited (“Platinum Ivy”), which is a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”). By reason of its ownership of Platinum Ivy and pursuant to the rules and regulations of the SEC, ADIA may be deemed to share investment and voting power over and, therefore, beneficial ownership of, the Common Shares held directly by Platinum Ivy. ADIA is an independent public investment institution owned by the Emirate of Abu Dhabi, founded in 1976, that manages a diversified global investment portfolio across more than two dozen asset classes and sub-categories, including quoted equities, fixed income, real estate, private equity, alternatives and infrastructure. The mailing address of Platinum Ivy is Level 26, Al Khatem Tower, Abu Dhabi Global Market Square, Al Maryah Island, Abu Dhabi, United Arab Emirates.

(6)

SPFM Holdings, LLC (“SPFM”) is a Delaware limited liability company, which is governed by a board of directors that has the authority to dispose of and vote the Common Shares held by SPFM. The ultimate parent of SPFM is The Travelers Companies, Inc., which may be deemed to beneficially own the Common Shares directly held by SPFM. The mailing address of SPFM Holdings, LLC is One Tower Square, Hartford, CT 06183.

(7)

TFP HoldCo is a wholly owned subsidiary of Shelf Bidco Limited, which in turn is a wholly owned subsidiary of Shelf Midco Limited, which in turn is a wholly owned subsidiary of Shelf Holdco Limited, the ultimate holding company. As a result, each of the foregoing entities may be deemed to share beneficial ownership of the securities held by TFP HoldCo. The mailing address of TFP HoldCo is Waterloo House, 100 Pitts Bay Road, Pembroke HM08, Bermuda.

(8)

The directors and senior managers listed in this table will not sell any of their Common Shares in this offering.

 

65


Table of Contents

MATERIAL CONTRACTS AND RELATED PARTY TRANSACTIONS

Repurchase Agreement with TFP HoldCo

In connection with the adoption by our Board of a Common Share repurchase program of up to $50.0 million of Common Shares, on March 19, 2024 we entered into a repurchase agreement with one of our shareholders, TFP HoldCo (the “Repurchase Agreement”), following approval by our Audit Committee. Under the terms of the Amended and Restated Common Shareholders Agreement, upon any proposed repurchase of Common Shares by FIHL, if TFP HoldCo, acting reasonably and in good faith, determines that, as a result of such proposed repurchase it (i) would become consolidated with FIHL for accounting purposes, (ii) would hold more than 9.9% of the Common Shares and/or (iii) would become a controller of any of FIHL’s subsidiaries which are regulated pursuant to applicable regulatory law, in each case, as a result of such proposed repurchase, then it shall have the right, at its election, to (x) have a sufficient portion of its Common Shares repurchased by the Company, on the same terms as the proposed repurchase (each such election, a “Repurchase Election”) or (y) undertake a permitted transfer in respect of a sufficient portion of its Common Shares. Following written notice from FIHL that the adoption of the brokered repurchase plan under the repurchase (the “Brokered Repurchase Plan”) program might result in TFP HoldCo holding more than 9.9% of Common Shares, TFP HoldCo has elected to exercise one or more Repurchase Elections in order to avoid circumstances where TFP HoldCo would hold more than 9.9% of Common Shares. Under the Repurchase Agreement, on each day that FIHL repurchases Common Shares under the Brokered Repurchase Plan, it shall repurchase a certain number of Common Shares from TFP HoldCo at a price equal to the average price per Common Share paid by FIHL on such day under the Brokered Repurchase Plan. The repurchase mechanic follows a prescribed format designed to keep TFP HoldCo’s ownership of FIHL to below 9.8752%. As of May 17, 2024, FIHL has repurchased 101,701 Common Shares from TFP HoldCo.

We have agreed for a period of 90 days not to consent to any request by TFP HoldCo to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise dispose of, directly or indirectly, any of our common shares for a period of 90 days after the date of this prospectus, subject to the Repurchase Election under the Amended and Restated Common Shareholders Agreement.

Launch of Lloyd’s Syndicate 3123

On March 28, 2024, FIHL announced its participation in the launch of a new Lloyd’s Syndicate 3123 which is being sponsored by TFP HoldCo. It is expected that TFP Holdco’s managing agent will underwrite a diverse book of risks within Syndicate 3123 across multiple insurance and reinsurance classes, including property catastrophe, credit, political, violence, marine and aviation. Syndicate 3123 has received in principle approval from Lloyd’s, with underwriting expected to begin on July 1, 2024, subject to final approval from Lloyd’s.

FIHL intends to participate in Syndicate 3123 as a co-investor, alongside TFP HoldCo and third party private capital sourced by Hampden Agencies Limited, pursuant to which it would contribute approximately 9.9% of Syndicate 3123’s initial total capital requirement in respect of the 2024 underwriting year of account. Consistent with the Framework Agreement, the Group also intends to reinsure a variable quota share of specified lines of business underwritten by Syndicate 3123.

For a disclosure of other related party transactions, refer to Item 7. Major Shareholders and Related Party TransactionsB. Related Party Transactions of the 2023 Annual Report.

 

  66  


Table of Contents

COMPARISON OF SHAREHOLDER RIGHTS

Prospective investors should be aware that the Bermuda Companies Act 1981 (the “Companies Act”), which applies to us, differs in certain material respects from laws generally applicable to U.S. companies incorporated in the State of Delaware and their shareholders. The following is a summary of certain significant differences between the Companies Act (including modifications adopted pursuant to our Amended and Restated Bye-Laws) and Bermuda common law applicable to us and our shareholders, on the one hand, and the provisions of the Delaware General Corporation Law applicable to U.S. companies organized under the laws of Delaware and their shareholders, on the other hand.

Duties of Directors

The Companies Act authorizes the directors of a company, subject to its bye-laws, to exercise all powers of the company except those that are required by the Companies Act or the company’s bye-laws to be exercised by the shareholders of the company. Our Amended and Restated Bye-Laws provide that our business is to be managed and conducted by the Board. In accordance with Bermuda common law, members of a board of directors owe a fiduciary duty to the company to act in good faith in their dealings with or on behalf of the company and exercise their powers and fulfill the duties of their office honestly. This duty includes the following essential elements:

 

  1.

a duty to act in good faith in the best interests of the company;

 

  2.

a duty not to make a personal profit from opportunities that arise from the office of director;

 

  3.

a duty to avoid situations in which there is an actual or potential conflict between a personal interest or the duties owed; and

 

  4.

a duty to exercise powers for the purpose for which such powers were intended.

The Companies Act imposes a duty on directors and officers of a Bermuda company:

 

  1.

to act honestly and in good faith with a view to the best interests of the company; and

 

  2.

to exercise the care, diligence and skill that a reasonably prudent person would exercise in comparable circumstances.

The Companies Act also imposes various duties on directors and officers of a company with respect to certain matters of management and administration of such company.

Under Bermuda law, directors and officers generally owe fiduciary duties to the company itself, not to the company’s individual shareholders or members, creditors, or any class of shareholders, members or creditors. Our shareholders may not have a direct cause of action against our directors.

Under Delaware law, the business and affairs of a company are managed by or under the direction of its board of directors. In exercising their powers, directors are charged with a fiduciary duty of care to protect the interests of the company and a fiduciary duty of loyalty to act in the best interests of its shareholders. The duty of care requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances. Under this duty, a director must inform himself of, and disclose to shareholders, all material information reasonably available regarding a significant transaction. The duty of loyalty requires that a director act in a manner he or she reasonably believes to be in the best interests of the company. He or she must not use his or her corporate position for personal gain or advantage. This duty prohibits self-dealing by a director and mandates that the best interests of the company and its shareholders take precedence over any interest possessed by a director, officer or controlling shareholder and not shared by the shareholders generally. In general, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the company. However, this presumption may be

 

67


Table of Contents

rebutted by evidence of a breach of one of the fiduciary duties. Should such evidence be presented concerning a transaction by a director, a director must prove the procedural fairness of the transaction, and that the transaction was of fair value to the company.

Interested Directors

Bermuda law provides that a transaction entered into by us in which a director has an interest will not be voidable by us and such director will not be liable to us for any profit realized pursuant to such transaction as a result of such interest, provided that the nature of the interest is disclosed at the first opportunity, either at a meeting of directors or in writing to the directors. While we are not aware of any Bermuda case law on the meaning of “first opportunity,” a Bermuda court will likely employ a practical interpretation of those words.

Subject to the NYSE rules and applicable U.S. securities laws, our Amended and Restated Bye-Laws do not require directors to recuse themselves from any discussion or decision involving any contract or proposed contract or arrangement in which the director is directly or indirectly interested so long as the nature of the interest is disclosed, and such director may be counted in the quorum for such meeting, unless the Board by resolution of a simple majority of the Board (which vote shall exclude the interested director) requires the director to abstain from any vote on the conflicted matter.

Under Delaware law, such transaction would not be voidable if: (i) the material facts as to such interested director’s relationship or interests are disclosed or are known to the board of directors and the board in good faith authorizes the transaction by the affirmative vote of a majority of the disinterested directors; (ii) such material facts are disclosed or are known to the shareholders entitled to vote on such transaction and the transaction is specifically approved in good faith by vote of the majority of shares entitled to vote on the matter; or (iii) the transaction is fair as to the company as of the time it is authorized, approved or ratified. Under Delaware law, such interested director could be held liable for a transaction in which such director derived an improper personal benefit.

Voting Rights and Quorum Requirements

Under Bermuda law, the voting rights of our shareholders are regulated by our Amended and Restated Bye-Laws and, in certain circumstances, the Companies Act. Generally, except as otherwise provided in the Amended and Restated Bye-Laws or the Companies Act, any action or resolution requiring approval of the shareholders may be passed by a simple majority of the shareholders. Any individual who is our shareholder and who is present at a meeting may vote in person, as may any corporate shareholder that is represented by a duly authorized representative at a meeting of shareholders. Our Amended and Restated Bye-Laws also permit attendance at general meetings by proxy, provided that the instrument appointing the proxy is in the form specified in the Amended and Restated Bye-Laws or such other form as the Board may determine.

Holders of the Common Shares have one vote for each Common Share held by them and are entitled to vote at all meetings of the shareholders.

In the event of the liquidation, dissolution or winding up of FIHL, the holders of the Common Shares will be entitled to share equally and ratably in our assets, if any, remaining after the payment of all our debts and liabilities, subject to the liquidation preference on any issued and outstanding preference securities, including our Series A Preference Securities.

If at any time, FIHL has more than one class of shares, the rights attaching to any class, unless otherwise provided for by the terms of issue of the relevant class, may be varied with the approval of the Board and with the consent in writing of the holders of a Simple Majority (as defined in the Amended and Restated Bye-Laws) of that class or with the sanction of a resolution passed by a Simple Majority at a separate general meeting of the holders of the shares of the class at which meeting the necessary quorum will be two persons at least holding or

 

68


Table of Contents

representing by proxy a Simple Majority. The Amended and Restated Bye-Laws specify that the creation or issuance of shares ranking pari passu or senior with existing shares will not, unless expressly provided by the terms of issue of existing shares, vary the rights attached to existing shares.

Under Delaware law, unless otherwise provided in a company’s certificate of incorporation, each shareholder is entitled to one vote for each share of stock held by the shareholder. Delaware law provides that unless otherwise provided in a company’s certificate of incorporation or bylaws, a majority of the shares entitled to vote, present in person or represented by proxy, constitutes a quorum at a meeting of shareholders. In matters other than the election of directors, with the exception of special voting requirements related to extraordinary transactions, and unless otherwise provided in a company’s certificate of incorporation or bylaws, the affirmative vote of a majority of shares present in person or represented by proxy and entitled to vote at a meeting in which a quorum is present is required for shareholder action, and the affirmative vote of a plurality of shares present in person or represented by proxy and entitled to vote at the meeting is required for the election of directors.

Amalgamations, Mergers and Similar Arrangements

The amalgamation or merger of a Bermuda company with another company or corporation (other than certain affiliated companies) requires the amalgamation or merger agreement to be approved by the company’s board of directors and by its shareholders. Unless the company’s bye-laws provide otherwise, the approval of 75% of the shareholders voting at such meeting is required to approve the amalgamation or merger agreement, and the quorum for such meeting must be two persons holding or representing more than one-third of the issued shares of the company.

Under Bermuda law, in the event of an amalgamation or merger of a Bermuda company with another company or corporation, a shareholder of the Bermuda company who did not vote in favor of the amalgamation or merger and is not satisfied that fair value has been offered for such shareholder’s shares may, within one month of notice of the shareholders meeting, apply to the Supreme Court of Bermuda to appraise the fair value of those shares.

Under Delaware law, with certain exceptions, a merger, consolidation or sale of all or substantially all the assets of a corporation must be approved by the board of directors and a majority of the issued and outstanding shares entitled to vote on such transaction. A shareholder of a company participating in certain merger and consolidation transactions may, under certain circumstances, be entitled to appraisal rights, such as having a court determine the fair value of the stock or requiring the company to pay such value in cash. However, such appraisal right is not available to shareholders if the stock received in such transaction is listed on a national securities exchange, including the NYSE.

Acquisitions

Under Bermuda law, an acquiring party is generally able to acquire compulsorily the common shares of minority holders of a company in the following ways:

 

  1.

By a procedure under the Companies Act known as a “scheme of arrangement.” The Companies Act enables the Supreme Court of Bermuda to approve a scheme of arrangement between a company and its shareholders or any class of shareholders. If the requisite majority (being a majority in number of shareholders representing 75% in value) agrees to the acquisition of their shares pursuant to the terms of the scheme, and the Supreme Court sanctions the scheme, the remaining shares can be compulsorily acquired. Schemes may provide for the target’s shares to be either transferred or cancelled, but unlike a transfer scheme, a cancellation scheme requires the company to pass a solvency test. In either case, dissenting shareholders do not have express statutory appraisal rights although shareholders have a right to appear at the hearing, and the Supreme Court will only sanction a scheme if the Supreme Court is satisfied that the scheme is fair. Shares owned by the acquirer can be voted to approve the scheme, but the Supreme Court will be concerned to see that the shareholders approving the scheme are fairly representative of the general body of shareholders.

 

69


Table of Contents
  2.

If the acquiring party is a company, by acquiring pursuant to a tender offer 90% of the shares or class of shares not already owned by, or by a nominee for, the acquiring party (the “offeror”), or any of its subsidiaries. If an offeror has, within four months after the making of an offer for all the shares or class of shares not owned by, or by a nominee for, the offeror, or any of its subsidiaries, obtained the approval of the holders of 90% or more of all the shares to which the offer relates, the offeror may, at any time within two months beginning with the date on which the approval was obtained, by notice compulsorily acquire the shares of any non-tendering shareholder on the same terms as the original offer unless the Supreme Court of Bermuda (on application made within a one-month period from the date of the offeror’s notice of its intention to acquire such shares) orders otherwise.

 

  3.

Where the acquiring party or parties hold not less than 95% of the shares or a class of shares of the company, by acquiring, pursuant to a notice given to the remaining shareholders or class of shareholders, the shares of such remaining shareholders or class of shareholders. When this notice is given, the acquiring party is entitled and bound to acquire the shares of the remaining shareholders on the terms set out in the notice, unless a remaining shareholder, within one month of receiving such notice, applies to the Supreme Court of Bermuda for an appraisal of the value of their shares. This provision only applies where the acquiring party offers the same terms to all holders of shares whose shares are being acquired.

Delaware law provides that a parent corporation, by resolution of its board of directors and without any shareholder vote, may merge with any subsidiary of which it owns at least 90% of each class of its capital stock. Upon any such merger, and in the event the parent corporation does not own all of the stock of the subsidiary, dissenting shareholders of the subsidiary are entitled to certain appraisal rights. Delaware law also provides, subject to certain exceptions, that if a person acquires 15% of voting stock of a company, the person is an “interested shareholder” and may not engage in “business combinations” with the company for a period of three years from the time the person acquired 15% or more of voting stock.

Dissenters’ Rights of Appraisal

Under Bermuda law, in the event of an amalgamation or merger of a Bermuda company with another company or corporation, a shareholder of the Bermuda company who did not vote in favor of the amalgamation or merger and who is not satisfied that fair value has been offered for such shareholder’s shares may, within one month of notice of the shareholders’ meeting, apply to the Supreme Court of Bermuda to appraise the fair value of those shares. Under Bermuda law, each share of an amalgamating or merging company carries the right to vote in respect of an amalgamation or merger whether or not it otherwise carries the right to vote.

In addition, any minority shareholder receiving notice that the holders of 95% or more of a company’s shares or class of shares intend to compulsorily acquire the minority shareholder’s shares may, within one month of receiving the notice, apply to the Supreme Court of Bermuda to appraise the value of the shares.

Appraisal rights are available under Delaware law for any class or series of common shares of a corporation in a merger or consolidation, subject to limited exceptions, such as a merger or consolidation of corporations listed on a national securities exchange in which listed stock is the offered consideration.

Shareholders’ Suits

Class actions and derivative actions are generally not available to shareholders under Bermuda law. The Bermuda courts, however, would ordinarily be expected to permit a shareholder to commence an action in the name of a company to remedy a wrong to the company where the act complained of is alleged to be beyond the corporate power of the company or illegal, or would result in the violation of the company’s memorandum of association or bye-laws.

 

70


Table of Contents

Furthermore, consideration would be given by a Bermuda court to acts that are alleged to constitute a fraud against the minority shareholders or, for instance, where an act requires the approval of a greater percentage of the company’s shareholders than that which actually approved it.

Class actions and derivative actions generally are available to shareholders under Delaware law for, among other things, breach of fiduciary duty, corporate waste and actions not taken in accordance with applicable law. In such actions, the court generally has discretion to permit the winning party to recover attorneys’ fees incurred in connection with such action.

Indemnification of Directors and Officers

Section 98 of the Companies Act provides generally that a Bermuda company may indemnify its directors, officers and auditors against any liability which by virtue of any rule of law would otherwise be imposed on them in respect of any negligence, default, breach of duty or breach of trust, except in cases where such liability arises from fraud or dishonesty of which such director, officer or auditor may be guilty in relation to the company. Section 98 further provides that a Bermuda company may indemnify its directors, officers and auditors against any liability incurred by them in defending any proceedings, whether civil or criminal, in which judgment is awarded in their favor or in which they are acquitted or granted relief by the Supreme Court of Bermuda pursuant to Section 281 of the Companies Act. Section 98 of the Companies Act further provides that a company may advance moneys to an officer or auditor for the costs, charges and expenses incurred by the officer or auditor in defending any civil or criminal proceedings against them, on condition that the officer or auditor shall repay the advance if any allegation of fraud or dishonesty is proved against them.

We have adopted provisions in our Amended and Restated Bye-Laws that provide that we shall indemnify our officers and directors in respect of their actions and omissions except in respect of fraud or dishonesty. Pursuant to our Amended and Restated Bye-Laws, our shareholders have agreed to waive any claim or right of action such shareholder may have, whether individually or by or in our right, against any director or officer on account of any action taken by such director or officer, or the failure of such director or officer to take any action in the performance of his or her duties with or for us or any of our subsidiaries, provided that such waiver does not extend to any matter in respect of any fraud or dishonesty in relation to us which may attach to such director or officer.

Under Delaware law, a corporation may include in its certificate of incorporation a provision that, subject to the limitations described below, eliminates or limits director liability to the corporation or its shareholders for monetary damages for breaches of their fiduciary duty of care. Under Delaware law, a director’s liability cannot be eliminated or limited for: (i) breaches of the duty of loyalty; (ii) acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; (iii) the payment of unlawful dividends or expenditure of funds for unlawful stock purchases or redemptions; or (iv) transactions from which such director derived an improper personal benefit.

Delaware law provides that a corporation may indemnify a director, officer, employee or agent of the corporation against any liability or expenses incurred in any civil, criminal, administrative or investigative proceeding if they acted in good faith and in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal proceeding, had no reasonable cause to believe their conduct was unlawful, except that in any action brought by or in the right of the corporation, such indemnification may be made only for expenses (not judgments or amounts paid in settlement) and may not be made even for expenses if the officer, director or other person is adjudged liable to the corporation (unless otherwise determined by the court). In addition, under Delaware law, to the extent that a director or officer of a corporation has been successful on the merits or otherwise in defense of any proceeding referred to above, he or she must be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by that party. Furthermore, under Delaware law, a corporation is permitted to maintain directors’ and officers’ insurance.

 

71


Table of Contents

Meeting of Shareholders

The Companies Act requires an annual meeting of shareholders unless waived by resolution of shareholders. Our Amended and Restated Bye-Laws provide that, subject to an election made by us in accordance with the Companies Act to dispense with the holding of annual general meetings, an annual general meeting will be held in each year at such time and place as the Board determines.

Under our Amended and Restated Bye-Laws, a special general meeting of shareholders may be held when the Board, in its judgment, decides such a meeting is necessary. In addition, the Board shall, on the requisition of shareholders holding at the date of the deposit of the requisition not less than 10% of our paid-up share capital, forthwith proceed to convene a special general meeting and the provisions of the Companies Act shall apply.

Delaware law permits the board of directors or any person who is authorized under a corporation’s certificate of incorporation or bylaws to call a special meeting of shareholders.

Notice of Shareholder Meetings

Bermuda law and our Amended and Restated Bye-Laws require that notice of an annual general meeting and special general meeting must be given to each shareholder entitled to attend and vote thereat at least five days before the date of such meeting, stating the date, place and time at which the meeting is to be held and business to be conducted at the meeting, including, for annual general meetings, the election of directors.

A general meeting shall, notwithstanding that it is called on shorter notice than that specified in the Amended and Restated Bye-Laws, be deemed to have been properly called provided that (i) in the case of an annual general meeting, with the agreement of all of the shareholders entitled to attend and vote at such meeting and (ii) in the case of a special general meeting, with the agreement of a majority in number of the shareholders entitled to attend and vote at such meeting, together holding not less than 95% in nominal value of the shares entitled to be voted at such meeting.

The accidental omission to give notice of a general meeting to, or the non-receipt of a notice of a general meeting by, any person entitled to receive notice shall not invalidate the proceedings conducted at such meeting. The Amended and Restated Bye-Laws contain detailed provisions setting out the manner in which a notice of a general meeting must be served effectively on the shareholders.

Under Delaware law, a company is generally required to give written notice of any meeting not less than ten days or more than sixty days before the date of the meeting to each shareholder entitled to vote at the meeting.

Dividends and Other Distributions

Under Bermuda law, a company may not declare or pay a dividend, or make a distribution out of contributed surplus, if there are reasonable grounds for believing that (i) it is, or would after the payment be, unable to pay its liabilities as they become due; or (ii) the realizable value of its assets would thereafter be less than its liabilities. “Contributed surplus” is defined for purposes of Section 54 of the Companies Act to include the proceeds arising from donated shares, credits resulting from the redemption or conversion of shares at less than the amount set up as nominal capital, and donations of cash and other assets to the company.

Under Delaware law, subject to any restrictions contained in the company’s certificate of incorporation, a company may pay dividends out of surplus or, if there is no surplus, out of net profits for the fiscal year in which the dividend is declared and for the preceding fiscal year. Delaware law also provides that dividends may not be paid out of net profits if, after the payment of the dividend, capital is less than the capital represented by the outstanding stock of all classes having a preference upon the distribution of assets.

 

72


Table of Contents

Inspection of Corporate Records

Members of the general public have the right to inspect our public documents available at the office of the Registrar of Companies in Bermuda. These documents include our memorandum of association and any charges on our assets. Our shareholders have the additional right to inspect our Amended and Restated Bye-Laws, minutes of general meetings and audited financial statements, all of which must be presented to the annual general meeting of shareholders.

The register of members of a company is also open to inspection by shareholders and members of the general public without charge. The register of members is required to be open for inspection for not less than two hours in any business day (subject to the ability of a company to close the register of members for not more than 30 days in a year). A company is required to maintain its share register in Bermuda but may, subject to the provisions of the Companies Act, establish a branch register outside of Bermuda. A company is required to keep at its registered office a register of directors and officers and a list of its directors must be filed with the Registrar of Companies where it will be available for public inspection. Bermuda law does not, however, provide a general right for shareholders to inspect or obtain copies of any other corporate records.

Delaware law requires that a company, within ten days before a meeting of shareholders, prepare and make available a complete list of shareholders entitled to vote at the meeting. This list must be open to the examination of any shareholder for any purpose relating to the meeting for a period of at least ten days prior to the meeting, either on a reasonably accessible electronic network or during ordinary business hours at the principal place of business of the company. Delaware law also permits a shareholder to inspect the company’s books and records if the shareholder can establish that he or she is a shareholder of the company, that the shareholder has complied with Delaware law with respect to the form and manner of making demand for inspection of corporate records, and that the inspection by the shareholder is for a proper purpose.

Shareholder Proposals

Under Bermuda law, upon the requisition in writing of such number of shareholders as is hereinafter specified and at their own expense (unless the company otherwise resolves), the company will be required to: (i) give notice to all shareholders entitled to receive notice of the annual general meeting of any resolution which may properly be moved and is intended to be moved at the next annual general meeting; and/or (ii) circulate to all shareholders entitled to receive notice of any general meeting a statement of not more than one thousand words with respect to the matter referred to in any proposed resolution or any business to be conducted at such general meeting. The number of shareholders necessary for a requisition under the foregoing sentence is (x) either any number of shareholders representing not less than 1/20th of the total voting rights of all members having at the date of the requisition a right to vote at that meeting to which the requisition relates; or (y) not less than one hundred shareholders.

Delaware law does not include a provision restricting the manner in which nominations for directors may be made by shareholders or the manner in which business may be brought before a meeting, although restrictions may be included in a Delaware corporation’s certificate of incorporation or bylaws.

Amendment of Memorandum of Association/Certificate of Incorporation

Bermuda law provides that the memorandum of association of a company may be amended by a resolution passed at a general meeting of shareholders of which due notice has been given. Certain amendments to the memorandum of association may require approval of the Bermuda Minister of Finance, who may grant or withhold approval at his or her discretion.

Under Bermuda law, the holders of an aggregate of not less than 20% in par value of a company’s issued share capital have the right to apply to the Bermuda courts for an annulment of any amendment of the memorandum of association adopted by shareholders at any general meeting, other than an amendment which

 

73


Table of Contents

alters or reduces a company’s share capital as provided in the Companies Act. When such an application is made, the amendment becomes effective only to the extent that it is confirmed by the Bermuda court. An application for an annulment of an amendment of the memorandum of association must be made within 21 days after the date on which the resolution altering the company’s memorandum of association is passed and may be made on behalf of persons entitled to make the application by one or more of their designees as such holders may appoint in writing for such purpose. No application may be made by the shareholders voting in favor of the amendment.

Under Delaware law, amendment of the certificate of incorporation, which is the equivalent of a memorandum of association, of a company must be made by a resolution of the board of directors setting forth the amendment, declaring its advisability, and either calling a special meeting of the shareholders entitled to vote or directing that the proposed amendment be considered at the next annual meeting of the shareholders. Delaware law requires that, unless a greater percentage is provided for in the certificate of incorporation, a majority of the outstanding voting power of the corporation is required to approve the amendment of the certificate of incorporation at the shareholders’ meeting. If the amendment would alter the number of authorized shares or par value or otherwise adversely affect the powers, preferences or special rights of any class of a company’s stock, the holders of the issued and outstanding shares of such affected class, regardless of whether such holders are entitled to vote by the certificate of incorporation, are entitled to vote as a class upon the proposed amendment. However, the number of authorized shares of any class may be increased or decreased, to the extent not falling below the number of shares then outstanding, by the affirmative vote of the holders of a majority of the stock entitled to vote, if so provided in the company’s original certificate of incorporation.

Amendment of Bye-Laws

Our Amended and Restated Bye-Laws provide that the Amended and Restated Bye-Laws may be amended upon a resolution approved by a simple majority of the Board and by a resolution approved by a simple majority of the shareholders, provided that any rescission, alteration or amendment to bye-laws conferring special rights on each of the Founders and TFP HoldCo (as described in more detail in Item 19. Exhibits—Exhibit 2.1 Description of Securities of the 2023 Annual Report) shall require the prior consent of each of the Founders and TFP HoldCo for so long as they each beneficially own a specified minimum percentage of our Common Shares or they have a designated director serving on the Board.

Under Delaware law, unless the certificate of incorporation or bylaws provide for a different vote, holders of a majority of the voting power of a corporation and, if so provided in the certificate of incorporation, the directors of the corporation have the power to adopt, amend and repeal the bylaws of a corporation.

Dissolution

Under Bermuda law, a solvent company may be wound up by way of a shareholders’ voluntary liquidation. Prior to the company entering liquidation, a majority of the directors are each required to make a statutory declaration, which states that the directors have made a full inquiry into the affairs of the company and have formed the opinion that the company will be able to pay its debts within a period of 12 months of the commencement of the winding-up and must file the statutory declaration with the Registrar of Companies in Bermuda. The general meeting is required to be convened primarily for the purposes of passing a resolution that the company be wound up voluntarily and appointing a liquidator. The winding-up of the company is deemed to commence at the time of the passing of the resolution.

Under Delaware law, a corporation may voluntarily dissolve (i) if a majority of the board of directors adopts a resolution to that effect and the holders of a majority of the issued and outstanding shares entitled to vote thereon vote for such dissolution; or (ii) if all shareholders entitled to vote thereon consent in writing to such dissolution.

 

74


Table of Contents

SHARES ELIGIBLE FOR FUTURE SALE

General

Future sales of substantial amounts of our Common Shares in the public market, or the perception that such sales may occur, could adversely affect the prevailing market price of our Common Shares or impair our ability to raise equity capital in the future. No prediction can be made as to the effect, if any, future sales of our Common Shares, or the availability of our Common Shares for future sales, will have on the market price of our Common Shares prevailing from time to time. The sale of substantial amounts of our Common Shares in the public market, or the perception that such sales of our Common Shares could occur, could adversely affect the prevailing market price of our Common Shares.

Sales of Restricted Securities

A total of 116,898,062 of our Common Shares were outstanding as of May 17, 2024. The Selling Shareholders are offering 9,000,000 Common Shares (or 10,350,000 Common Shares if the underwriters exercise their option to purchase additional Common Shares from the Selling Shareholders in full). After giving effect to the offering, 52,575,139 (or 53,685,686 Common Shares if the underwriters exercise their option to purchase additional Common Shares from the Selling Shareholders in full) will be freely tradable without restriction under the Securities Act, unless purchased by our “affiliates,” as that term is defined in Rule 144 under the Securities Act. The remaining Common Shares that will be outstanding after this offering are “restricted securities” within the meaning of Rule 144 under the Securities Act. Restricted securities may be sold in the public market only if registered under the Securities Act or if they qualify for an exemption from registration, including an exemption under Rule 144, Rule 701 or Regulation S, which are summarized below.

Of the 116,898,062 Common Shares outstanding immediately following this offering, 53.81% of our Common Shares (or 52.59% of our Common Shares if the underwriters exercise their option to purchase additional Common Shares from the Selling Shareholders in full) are subject to lock-up agreements as described herein. See “—Lock-up Agreement” and “—IPO Assistance and Lock-Up Agreement.”

As defined in Rule 144, an “affiliate” of an issuer is a person that directly, or indirectly through one or more intermediaries, controls, is controlled by or is under common control with the issuer.

Lock-up Agreement

Prior to the settlement of this offering, we and the Selling Shareholders, have agreed, subject to limited exceptions, not to offer, pledge, announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise dispose of, directly or indirectly, or enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Shares or such other securities for a period of 90 days after the date of this prospectus. These agreements are described below under the section captioned “Underwriting.

IPO Assistance and Lock-Up Agreement

In connection with our initial public offering, Daniel Burrows, Allan Decleir, Denise Brown-Branch and Ian Houston (collectively, the “Insurance Group Executives” and each, an “Insurance Group Executive”), Richard Brindle, Richard Coulson, Hinal Patel and Charles Mathias (collectively, the “TFP Executives” and each, a “TFP Executive”) and FIHL entered into an initial public offering assistance and lock-up agreement (the “IPO Assistance and Lock-Up Agreement”). Under the terms of the IPO Assistance and Lock-Up Agreement, (i) the TFP Executives and Daniel Burrows agreed, subject to limited exceptions, not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or

 

75


Table of Contents

warrant to purchase, lend, assign, encumber, pledge, hypothecate, or otherwise transfer or dispose of, directly or indirectly, any of their Common Shares for a period of 18 months following the effective date of our initial public offering, except that 25% of such Common Shares relating to Retention RSUs (as defined below) are released from such lock-up within 180 days after such date of vesting and (ii) the Insurance Group Executives agreed, subject to limited exceptions, not to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, assign, encumber, pledge, hypothecate, or otherwise transfer or dispose of, directly or indirectly, any of the Common Shares that they receive following the vesting of their retention restricted stock units approved by FIHL on May 15, 2023 (the “Retention RSUs”) for a period of 18 months after the date of vesting of such Retention RSUs (such period end date being October 1, 2025), except that 25% of such Common Shares relating to Retention RSUs are released from such lock-up within 180 days after such date of vesting. We have agreed not to waive or amend certain provisions of the IPO Assistance and Lock-Up Agreement for a period of 90 days after the date of this prospectus, with respect to certain of our directors and officers.

Registration Rights

Certain shareholders have the right to require us to include their Registrable Securities in any registration statement filed for the purposes of a public offering of our equity securities, subject to the terms of the Registration Rights Agreement. These Registrable Securities will represent 55.025% of our outstanding Common Shares after this offering (or 54.075% if the underwriters exercise their option to purchase additional Common Shares from the Selling Shareholders in full). See Item 7. Major Shareholders and Related Party Transactions—B. Related Party Transactions—Registration Rights Agreement of the 2023 Annual Report.

Rule 144

In general, under Rule 144 as currently in effect, beginning 90 days after the effectiveness of the registration statement of which this prospectus forms a part, a person who is not our affiliate and has not been our affiliate at any time during the preceding three months will be entitled to sell any of our Common Shares that such person has beneficially owned for at least six months, including the holding period of any prior owner other than one of our affiliates, without regard to volume limitations and subject only to the availability of current public information about us. A non-affiliated person who has beneficially owned Common Shares considered to be restricted securities under Rule 144 for at least one year would be entitled to sell such Common Shares without complying with any of the requirements of Rule 144.

Beginning 90 days after the effectiveness of the registration statement of which this prospectus forms a part, an affiliate of ours who has beneficially owned our Common Shares for at least six months would be entitled to sell, within any three-month period, a number of Common Shares that does not exceed the greater of:

 

   

one percent (1%) of our Common Shares then issued and outstanding, which will equal approximately 1,168,981 Common Shares immediately after this offering; or

 

   

the average weekly trading volume of our Common Shares on the NYSE during the four calendar weeks preceding the date on which notice of the sale is filed with the SEC.

Sales under Rule 144 by our affiliates or persons selling our Common Shares on behalf of our affiliates are also subject to any manner of sale provisions, notice requirements and the availability of current public information about us. The sale of these Common Shares, or the perception that sales will be made, could adversely affect the price of our Common Shares after this offering because a great supply of Common Shares would be, or would be perceived to be, available-for-sale in the public market.

We are unable to estimate the number of Common Shares that will be sold under Rule 144 since this will depend on the market price for our Common Shares, the personal circumstances of the shareholder and other factors.

 

76


Table of Contents

Rule 701

Any of our employees, officers or directors who acquired our Common Shares under a written compensatory plan or contract may be entitled to sell them in reliance on Rule 701. Rule 701 permits affiliates to sell their Rule 701 Common Shares under Rule 144 without complying with the holding period requirements of Rule 144. Rule 701 further provides that non-affiliates may sell these Common Shares in reliance on Rule 144 without complying with the holding period, public information, volume limitation or notice provisions of Rule 144. All holders of Rule 701 Common Shares are required to wait until 90 days after the date of this prospectus before selling such Common Shares. However, our Common Shares issued under Rule 701 that are subject to lock-up agreements will become eligible for sale only when the 90-day lock-up agreements expire.

The SEC has indicated that Rule 701 will apply to typical stock options granted by an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after a company becomes subject to the reporting requirements of the Exchange Act.

Regulation S

Regulation S under the Securities Act provides an exemption from registration requirements in the U.S. for offers and sales of securities that occur outside the U.S. Rule 903 of Regulation S provides the conditions to the exemption for a sale by an issuer, a distributor, their respective affiliates or anyone acting on their behalf, while Rule 904 of Regulation S provides the conditions to the exemption for a resale by persons other than those covered by Rule 903. In each case, any sale must be completed in an offshore transaction, as that term is defined in Regulation S, and no directed selling efforts, as that term is defined in Regulation S, may be made in the U.S.

We are a “foreign issuer” as defined in Regulation S. As a foreign issuer, securities that we sell outside the U.S. pursuant to Regulation S are not considered to be restricted securities under the Securities Act, and, subject to the offering restrictions imposed by Rule 903, are freely tradable without registration or restrictions under the Securities Act, unless the securities are held by our affiliates. Generally, subject to certain limitations, a holder of our restricted securities who is not our affiliate or who is an affiliate by virtue of his status as an officer or director may, under Regulation S, resell his restricted securities in an “offshore transaction” if none of the seller or its affiliates or any person acting on their behalf engages in directed selling efforts in the U.S. and, in the case of a sale of our restricted securities by an officer or director who is an affiliate of ours solely by virtue of holding such position, no selling commission, fee or other remuneration is paid in connection with the offer or sale other than the usual and customary broker’s commission that would be received by a person executing such transaction as agent. Additional restrictions are applicable to a holder of our restricted securities who will be an affiliate of FIHL other than by virtue of his or her status as an officer or director of FIHL.

Form S-8 Registration Statement

On July 3, 2023, we filed a registration statement on Form S-8 with the SEC, which became effective upon filing, to register 4,913,119 Common Shares issuable under our Long-Term Incentive Plan. 479,245 restricted stock units vested on April 1, 2024, resulting in the issuance of 367,878 Common Shares. As of May 17, 2024 there are no Common Shares issuable (that are not already issued) as a result of vested restricted stock units then outstanding under our Long-Term Incentive Plan. Accordingly, the Common Shares registered under such registration statement are available for sale in the open market following the effective date, unless such Common Shares are subject to vesting restrictions with us, Rule 144 restrictions applicable to our affiliates or the lock-up restrictions described herein, if applicable.

 

77


Table of Contents

CERTAIN TAX CONSIDERATIONS

The following summary of the taxation of Fidelis Insurance Group and its shareholders is based upon current U.S. and Bermuda law and is for general information only. Legislative, judicial or administrative changes may be forthcoming that could affect this summary. Prospective investors should consult their own tax advisors with respect to their particular circumstances. Prospective investors should also carefully consider the summary of taxation of Fidelis Insurance Group and its shareholders in Item. 10 Additional Information—E. Taxation of the 2023 Annual Report.

United States Taxation

Certain U.S. Tax Consequences

The following legal discussion (including and subject to the matters and qualifications set forth in such summary) is based upon the advice of Willkie Farr & Gallagher LLP. The advice of such firm does not include any factual or accounting matters, determinations or conclusions, including amounts and computations of RPII and amounts of components thereof or facts relating to Fidelis Insurance Group’s business or activities. The tax treatment of a holder of Common Shares, or of a person treated as a holder of Common Shares for U.S. federal income, state, local or non-U.S. tax purposes, may vary depending on the holder’s particular tax situation. Statements contained herein as to the beliefs, expectations and conditions of FIHL and its subsidiaries as to the application of such tax laws or facts represent the view of management as to the application of such laws and do not represent the opinions of counsel. For information on the taxation of holders of Common Shares, see Item 10. Additional Information—E. Taxation—Taxation of Shareholders of the 2023 Annual Report.

PROSPECTIVE INVESTORS SHOULD CONSULT THEIR OWN TAX ADVISORS WITH RESPECT TO THEIR PARTICULAR CIRCUMSTANCES CONCERNING THE U.S. FEDERAL, STATE, LOCAL AND NON-U.S. TAX CONSEQUENCES OF OWNING COMMON SHARES.

U.S. Tax Reform

The 2017 Act was passed by the U.S. Congress and signed into law on December 22, 2017, with certain provisions intended to eliminate certain perceived tax advantages of companies (including insurance companies) that have legal domiciles outside the United States, but have certain U.S. connections, and U.S. Persons (as defined below) investing in such companies. Among other things, the 2017 Act revised the rules applicable to PFICs and CFCs in ways that could affect the timing or amount of U.S. federal income taxes imposed on certain investors that are U.S. Persons. Further, it is possible that other legislation could be introduced and enacted by the current Congress or future Congresses that could have an adverse impact on Fidelis Insurance Group, Fidelis Insurance Group’s operations or U.S. Holders. Additionally, tax laws and interpretations regarding whether a company is engaged in a U.S. trade or business or whether a company is a CFC or a PFIC or has RPII are subject to change, possibly on a retroactive basis. The U.S. Treasury Department recently issued final and proposed regulations intended to clarify the application of the insurance income exception to the classification of a non-U.S. insurer as a PFIC and provide guidance on a range of issues relating to PFICs, and recently issued proposed regulations that would expand the scope of the RPII rules. New regulations or pronouncements interpreting or clarifying such rules may be forthcoming as well. FIHL cannot be certain if, when, or in what form such regulations or pronouncements may be provided and whether such guidance will have a retroactive effect.

U.S. Taxation of Fidelis Insurance Group

The following discussion is a summary of material U.S. federal income tax considerations relating to Fidelis Insurance Group’s operations. A non-U.S. corporation that is engaged in the conduct of a U.S. trade or business will be subject to U.S. federal income tax as described below, unless entitled to the benefits of an applicable tax

 

78


Table of Contents

treaty. Whether a trade or business is being conducted in the U.S. is an inherently factual determination. Because the Code, regulations and court decisions fail to identify definitively activities that constitute being engaged in a trade or business in the U.S., FIHL cannot be certain that the IRS will not contend successfully that it or any of its non-U.S. subsidiaries are or will be engaged in a trade or business in the U.S. A non-U.S. corporation deemed to be so engaged would be subject to U.S. income tax at regular corporate rates, as well as the branch profits tax, on its income which is treated as effectively connected with the conduct of that trade or business unless the corporation is entitled to relief under the permanent establishment provision of an applicable tax treaty, as discussed below. Such income tax on effectively connected income, if imposed, would be computed in a manner generally analogous to that applied to the income of a U.S. corporation, except that a non-U.S. corporation is generally entitled to deductions and credits only if it timely files a U.S. federal income tax return. Each of FIHL, FIBL, FIID, FIHL (UK) Services, Fidelis European Holdings Limited and FUL files protective U.S. federal income tax returns on a timely basis in order to preserve the right to claim income tax deductions and credits if it is ever determined that it is subject to U.S. federal income tax. The highest marginal federal income tax rates currently are 21% for a corporation’s effectively connected income and 30% for the additional “branch profits” tax. In addition, certain corporations with effectively connected income may be subject to a corporate alternative minimum tax of 15 percent of the corporation’s adjusted financial statement income.

If FIBL is entitled to the benefits under the income tax treaty between Bermuda and the U.S. (the “Bermuda Treaty”), FIBL would not be subject to U.S. income tax on any income found to be effectively connected with a U.S. trade or business unless that trade or business is conducted through a permanent establishment in the U.S. Similarly, if FIHL or any U.K. subsidiary of FIHL is entitled to the benefits under the U.S. income tax treaty with the U.K. (the “U.K. Treaty”) (discussed below), it would not be subject to U.S. income tax on any income found to be effectively connected with U.S. trade or business unless that trade or business is conducted through a permanent establishment in the U.S. FIBL, FIHL and the U.K. subsidiaries of FIHL each currently intend to conduct their activities so that they do not have a permanent establishment in the U.S., although FIHL cannot be certain that this result will be achieved.

An insurance enterprise resident in Bermuda generally will be entitled to the benefits of the Bermuda Treaty if (i) more than 50% of its shares are owned beneficially, directly or indirectly, by individual residents of the U.S. or Bermuda or U.S. citizens; and (ii) its income is not used in substantial part, directly or indirectly, to make disproportionate distributions to, or to meet certain liabilities of, persons who are neither residents of either the U.S. or Bermuda nor U.S. citizens. No regulations interpreting the Bermuda Treaty have been issued. FIHL cannot be certain that FIBL will be eligible for Bermuda Treaty benefits because of factual and legal uncertainties regarding the residency and citizenship of the company’s shareholders. Accordingly, FIBL intends to conduct substantially all of its operations outside the U.S. and to limit its U.S. contacts so that FIBL would not be treated as engaged in the conduct of a trade or business in the U.S.

Under the U.K. Treaty, a U.K. resident company is entitled to the benefits of the treaty only if certain requirements can be satisfied, for example where: (i) the principal class of its shares is listed or admitted to dealings on certain recognized stock exchanges and is regularly traded on one or more recognized stock exchanges, (ii) shares representing at least 50 percent of the aggregate voting power and value of such company are owned directly or indirectly by five or fewer companies entitled to the benefits of the U.K. Treaty, (iii) such company is owned more than 50 percent, by vote and by value, by “qualified persons” (broadly speaking, certain U.S. and U.K. tax residents) during a requisite portion of the relevant taxable period, or (iv) such company is engaged in the active conduct of a trade or business in the U.K. and the income, profit or gain derived from the United States is derived in connection with, or is incidental to, that trade or business, and the company satisfies certain other conditions. Provided that FIHL is successfully listed and regularly traded on the NYSE and its U.K. subsidiaries successfully carry out their intended business plan, each such entity expects to qualify for benefits under the U.K. Treaty, although FIHL cannot be certain it will achieve this result. If each of FIHL and its U.K. subsidiaries qualifies for treaty benefits, each of FIHL and its U.K. subsidiaries should be subject to U.S. federal income tax on its income found to be effectively connected with a U.S. trade or business only if such income is attributable to the conduct of a trade or business carried on through a permanent establishment in the U.S. FIHL

 

79


Table of Contents

and its U.K. subsidiaries have conducted and intend to conduct their activities in a manner so that none of them should have a permanent establishment in the U.S., although FIHL cannot be certain that they will achieve this result.

Under the U.K. Treaty, the additional U.S. branch profits tax may be imposed at a rate of up to five percent (5%) absent an applicable exception to the extent a U.K. resident company has a permanent establishment in the U.S.

Non-U.S. insurance companies carrying on an insurance business within the U.S. have a certain minimum amount of effectively connected net investment income, determined in accordance with a formula that depends, in part, on the amount of U.S. risk insured or reinsured by such companies. If FIBL or FUL is considered to be engaged in the conduct of an insurance business in the U.S. and it is not entitled to the benefits of an income tax treaty with the U.S. in general, the Code could subject a significant portion of FIBL or FUL’s investment income to U.S. income tax. In addition, while the Bermuda Treaty clearly applies to premium income, it is uncertain whether the Bermuda Treaty applies to other income such as investment income. If FIBL is considered engaged in the conduct of an insurance business in the U.S. and is entitled to the benefits of the Bermuda Treaty in general, but the Bermuda Treaty is interpreted to not apply to investment income, a significant portion of FIBL’s investment income could be subject to U.S. income tax.

Non-U.S. corporations not engaged in a trade or business in the U.S. are nonetheless subject to U.S. income tax imposed by withholding on certain “fixed or determinable annual or periodic gains, profits and income” derived from sources within the U.S. (such as dividends and certain interest on investments), subject to exemption under the Code or reduction by applicable treaties. Generally, under the U.K. Treaty the withholding rate is reduced (i) on dividends from less than ten percent (10%) owned corporations to 15%; (ii) on dividends from 10% or more owned corporations to five percent (5%) (and is eliminated in some cases); and (iii) on interest to zero percent (0%). The Bermuda Treaty does not reduce the U.S. withholding rate on U.S.-sourced investment income.

The U.S. also imposes FET on insurance premiums paid to non-U.S. insurers with respect to (i) risks of a U.S. entity or individual, located wholly or partly within the U.S. and (ii) risks of a non-U.S. entity or individual engaged in trade or business in the U.S., located within the U.S. (“U.S. Situs Risks”) and on reinsurance premiums for any reinsurance policy covering any such risks. The rates of FET applicable to premiums paid are four percent (4%) for direct property and casualty insurance premiums and one percent (1%) for reinsurance premiums or life insurance premiums, subject to elimination pursuant to a U.S. income tax treaty. The U.K. Treaty provides for the elimination of the FET on insurance or reinsurance premiums paid to U.K. residents, otherwise entitled to the benefits of the treaty, with respect to U.S. Situs Risks, provided that the U.K. resident does not cede the risks in a transaction characterized as part of a conduit arrangement for purposes of the U.K. Treaty. If FUL is entitled to the benefit of the FET exemption in the U.K. Treaty, but it cedes business with respect to U.S. Situs Risks in transactions that are characterized as conduit arrangements for purposes of the U.K. Treaty, it would not be entitled to the U.K. Treaty FET exemption with respect to these U.S. Situs Risks. The Bermuda Treaty does not eliminate the FET on premiums ceded to Bermuda residents with respect to U.S. Situs Risks.

Bermuda Taxation

Taxation of FIHL and FIBL

In response to the OECD Pillar Two initiative, Bermuda has enacted the Corporate Income Tax Act 2023 (“CIT Act”) the provisions of which will be fully effective for tax years beginning on or after January 1, 2025. Entities subject to tax under the CIT Act are the Bermuda constituent entities of multi-national groups. A multi-national group is defined under the CIT Act as a group with entities in more than one jurisdiction with consolidated revenues of at least €750 million for two of the four previous fiscal years. If Bermuda constituent entities of a multi-national group are subject to tax under the CIT Act, such tax is charged at a rate of 15 per cent

 

80


Table of Contents

of the net income of such constituent entities (as determined in accordance with the CIT Act, including after adjusting for any relevant foreign tax credits applicable to the Bermuda constituent entities).

On the basis of the foregoing, we have concluded that the CIT Act will apply to our Bermuda constituent entities (i.e. Bermuda tax resident entities and Bermuda permanent establishments) and in recognition of the transitional provisions under the CIT Act in respect of pre-commencement periods FIBL, as a Bermuda constituent entity, has recognized a deferred tax asset of $90 million.

For so long as FIHL is UK tax resident, the CIT Act will only apply to FIHL to the extent that FIHL maintains a Bermuda permanent establishment, and only then in respect of such financial accounting net income or loss as is allocated to the Bermuda permanent establishment in accordance with US GAAP (on the basis that this is the accounting standard used in the preparation of the consolidated accounts of FIHL). In any event, tax under the CIT Act only arises in respect of tax years starting on or after January 1, 2025.

At the present time, there is no other Bermuda income or profits tax, withholding tax, capital gains tax, capital transfer tax, estate duty or inheritance tax payable by FIHL or FIBL in respect of the Common Shares. FIHL has obtained an assurance from the Minister of Finance of Bermuda under the Exempted Undertakings Tax Protection Act 1966 (the “EUTP Act”) that, in the event that any legislation is enacted in Bermuda imposing any tax computed on profits or income, or computed on any capital asset, gain or appreciation or any tax in the nature of estate duty or inheritance tax, such tax will not, until March 31, 2035, be applicable to us or to any of our operations or to the Common Shares, debentures or other obligations except insofar as such tax applies to persons ordinarily resident in Bermuda or is payable by FIHL in respect of real property owned or leased by it in Bermuda. The same assurance has been obtained with respect to FIBL. Given the limited duration of any assurance by the Minister of Finance, neither FIHL nor FIBL can be certain that it will not be subject to any Bermuda taxes after March 31, 2035. In particular, in the event that FIHL and FIBL are subject to tax under the CIT Act, this would supersede the assurances received from the Minister of Finance under the EUTP Act. Each of FIHL and FIBL pays an annual Bermuda Government fee and an insurance license fee, as applicable. In addition, all entities employing individuals in Bermuda are required to pay a payroll tax and there are other sundry taxes payable, directly or indirectly, to the Bermuda Government.

Pursuant to the Payroll Tax Act 1995 and the Payroll Tax Rates Act 1995 of Bermuda (together, the “Payroll Tax Act”), an employer is required to pay payroll tax on remuneration paid by it to each employee or deemed employee for services rendered by the employee or deemed employee during that tax period wholly or mainly in Bermuda (provided that any remuneration paid by the employer to the employee or deemed employee in excess of $900,000 per annum is disregarded) and may, within certain parameters, make deductions from remuneration paid to each employee and deemed employee in each tax period in respect of a certain portion of the payroll tax paid by the employer in respect of that employee or deemed employee in that tax period. For the purposes of the Payroll Tax Act, any gain obtained by the exercise, assignment or release of any option awarded under any of our option plans will constitute actual remuneration.

In addition, the OECD has published reports and launched a global dialogue among member and non-member countries on measures to limit harmful tax competition. These measures are largely directed at counteracting the effects of tax havens and preferential tax regimes in countries around the world. According to the OECD, Bermuda is a jurisdiction that has substantially implemented the internationally agreed tax standard. However, neither FIHL nor FIBL is able to predict whether any changes will be made to this classification or whether any such changes will subject FIHL or FIBL to additional taxes.

Taxation of Shareholders

In the event any shareholder is determined to be Bermuda constituent entities of a multi-national group, they may also be subject to tax under the CIT Act. At the present time, there is no other Bermuda income or profits tax, withholding tax, capital gains tax, capital transfer tax, estate duty or inheritance tax payable by our shareholders in respect of our Common Shares.

 

81


Table of Contents

UNDERWRITING

Under the terms and subject to the conditions in an underwriting agreement dated as of the date of this prospectus, the underwriters named below, for whom Barclays Capital Inc., J.P. Morgan Securities LLC, and Goldman Sachs & Co. LLC are acting as representatives, have severally agreed to purchase, and the Selling Shareholders have agreed to sell to them, the number of Common Shares indicated below:

 

Name

   Common Shares  

Barclays Capital Inc.

  

J.P. Morgan Securities LLC

  

Goldman Sachs & Co. LLC

  

Evercore Group, L.L.C.

  

Citigroup Global Markets Inc.

  

BMO Capital Markets Corp.

  

Keefe, Bruyette & Woods, Inc.

  

UBS Securities LLC

  

Citizens JMP Securities, LLC

  

Dowling & Partners Securities, LLC

  
  

 

 

 

Total:

     9,000,000  
  

 

 

 

The underwriting agreement provides that the obligations of the underwriters are subject to certain conditions precedent, including the absence of any material adverse change in our business and the receipt of certain certificates, opinions and letters from us, our counsel and the independent auditors. The underwriters have committed to purchase all of the Common Shares offered by the Selling Shareholders if any such Common Shares are purchased. However, the underwriters are not required to take or pay for the Common Shares covered by their option to purchase additional Common Shares described below. The underwriting agreement also provides that if an underwriter defaults, the purchase commitments of non-defaulting underwriters may also be increased or the offering may be terminated. The offering of the Common Shares by the underwriters is subject to receipt and acceptance and subject to the underwriters’ right to reject any order in whole or in part.

The underwriters propose to offer the Common Shares directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $       per Common Share under the public offering price. After the offering of the Common Shares, the offering price and other selling terms may from time to time be varied by the representatives.

The Selling Shareholders have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase up to 1,350,000 additional Common Shares at the public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same percentage of the additional Common Shares as the number listed next to the underwriter’s name in the preceding table bears to the total number of Common Shares listed next to the names of all underwriters in the preceding table.

The following table shows the per Common Share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to the Selling Shareholders. These amounts are shown assuming both no exercise and full exercise of the underwriters’ option to purchase up to an additional 1,350,000 Common Shares from the Selling Shareholders. We are not selling any Common Shares in this offering and will not receive any of the proceeds from the Common Shares sold by the Selling Shareholders.

 

82


Table of Contents
          Total  
    Per
Common
Share
    No
Exercise of
Option
    Full
Exercise of
Option
 

Public offering price

                                   
 

 

 

   

 

 

   

 

 

 

Underwriting discounts and commissions to be paid by the Selling Shareholders

     
 

 

 

   

 

 

   

 

 

 

Proceeds, before expenses, to the Selling Shareholders

     

We have agreed that, without the prior written consent of Barclays Capital Inc., J.P. Morgan Securities LLC, and Goldman Sachs & Co. LLC on behalf of the underwriters, we will not, and will not publicly disclose an intention to, during the period ending 90 days after the date of this prospectus (the “restricted period”):

 

   

offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the SEC a registration statement under the Securities Act relating to, any Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares

 

   

enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common shares or any such other securities whether any such transaction described above is to be settled by delivery of Common Shares or such other securities, in cash or otherwise.

The restrictions described above do not apply to;

 

  i.

the offer, issuance, sale and disposition of the Common Shares in connection with this offering,

 

  ii.

the issuance of Common Shares or securities convertible into or exercisable for Common Shares pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of RSUs (including net settlement), in each case outstanding as of the pricing of this offering,

 

  iii.

grants of options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of Common Shares or securities convertible into or exercisable or exchangeable for Common Shares (whether upon the exercise of options or otherwise) to the Company’s employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the closing of this offering and described herein, provided that such recipients enter into a lock-up agreement with the underwriters,

 

  iv.

the issuance of up to 5% of the outstanding Common Shares, or securities convertible into, exercisable for, or which are otherwise exchangeable for, Common Shares, immediately following the closing of this offering, in acquisitions or other similar strategic transactions, provided that such recipients enter into a lock-up agreement with the underwriters, or

 

  v.

the filing of any registration statement on Form S-8 relating to securities granted or to be granted pursuant to any plan in effect as of the pricing of this offering and described herein or any assumed benefit plan pursuant to an acquisition or similar strategic transaction.

Additionally, the Selling Shareholders have agreed that, without the prior written consent of Barclays Capital Inc., J.P. Morgan Securities LLC, and Goldman Sachs & Co. LLC on behalf of the underwriters, they will not, and will not publicly disclose an intention to, during the restricted period:

 

   

offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares,

 

83


Table of Contents
   

enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares, or

 

   

make any demand for, or exercise any right with respect to, the registration of any Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares.

The restrictions described in the immediately preceding paragraph do not apply to certain transfers, dispositions or transactions, including:

 

  i.

as a bona fide gift or gifts, or for bona fide estate planning purposes,

 

  ii.

by will or intestacy,

 

  iii.

to any trust for the direct or indirect benefit of the holder or the immediate family of the holder, or if the holder is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust,

 

  iv.

to a partnership, limited liability company or other entity of which the holder and the immediately family of the holder are the legal and beneficial owner of all of the outstanding equity securities or similar interests,

 

  v.

to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (iv) above,

 

  vi.

if the holder is a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act) of the holder, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the holder or affiliates of the holder, or (B) as part of a distribution to members or shareholders of the undersigned,

 

  vii.

by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement,

 

  viii.

to the Company from an employee of the Company upon death, disability or termination of employment, in each case, of such employee

 

  ix.

as part of a sale of the holder’s Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares acquired in open market transactions after the closing of this offering,

 

  x.

to the Company in connection with the vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase Common Shares (including, in each case, by way of “net” or “cashless” exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights,

 

  xi.

pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the Board of Directors and made to all holders of the Company’s capital stock the result of which is that any “person” (as defined in Section 13(d)(3) of the Exchange Act), or group of affiliated persons, would hold at least a majority of the outstanding voting securities of the Company (or the surviving entity), or

 

  xii.

with the prior written consent of Barclays Capital Inc., J.P. Morgan Securities LLC, and Goldman Sachs & Co. LLC on behalf of the underwriters.

Barclays Capital Inc., J.P. Morgan Securities LLC, and Goldman Sachs & Co. LLC, in their sole discretion, may release the Common Shares and other securities subject to the lock-up agreements described above in whole or in part at any time. When determining whether or not to release common stock and other securities from lock-up agreements, Barclays Capital Inc. will consider, among other factors, the holder’s reasons for requesting the release, the Common Shares and other securities for which the release is being requested and market conditions at the time.

 

84


Table of Contents

We have agreed not to waive or amend certain provisions of the IPO Assistance and Lock-Up Agreement, with respect to certain of our directors and officers, or consent to any request by TFP HoldCo to offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise dispose of, directly or indirectly, any of our common shares for a period of 90 days after the date of this prospectus, subject to the Repurchase Election under the Amended and Restated Common Shareholders Agreement.

In order to facilitate the offering of the Common Shares, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the Common Shares. Specifically, the underwriters may sell more Common Shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number of Common Shares available for purchase by the underwriters by exercise of their option to purchase additional Common Shares. The underwriters can close out a covered short sale by exercising their option to purchase additional Common Shares or purchasing Common Shares in the open market. In determining the source of Common Shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of Common Shares compared to the price available under their option to purchase additional Common Shares. The underwriters may also sell Common Shares in excess of their option to purchase additional Common Shares, creating a naked short position. The underwriters must close out any naked short position by purchasing Common Shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the Common Shares in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, Common Shares in the open market to stabilize the price of the Common Shares. These activities may raise or maintain the market price of the Common Shares above independent market levels or prevent or retard a decline in the market price of the Common Shares. The underwriters are not required to engage in these activities and may end any of these activities at any time.

We estimate that our share of the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately $1.4 million. We have agreed to reimburse the underwriters for certain of their expenses in an amount up to $35,000.

We, the Selling Shareholders and the underwriters have agreed to indemnify one and another against certain liabilities, including liabilities under the Securities Act.

Our Common Shares are listed on the NYSE under the symbol “FIHL.”

A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of Common Shares to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations.

The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. In particular, affiliates of Barclays Capital Inc., BMO Capital Markets Corp. and Citigroup Global Markets Inc. provide letters of credit facilities to us. In addition, affiliates of Goldman Sachs & Co. LLC provide services in relation to the Share Repurchase Program. Affiliates of Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC provide asset- and investment management services.

In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts

 

85


Table of Contents

of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments.

Selling Restrictions

European Economic Area

In relation to each member state of the European Economic Area (each an “EEA State”), no Common Shares have been offered or will be offered pursuant to the offering to the public in that EEA State prior to the publication of a prospectus in relation to our Common Shares which have been approved by the competent authority in that EEA State or, where appropriate, approved in another EEA State and notified to the competent authority in that EEA State, all in accordance with the E.U. Prospectus Regulation, except that offers of our Common Shares may be made to the public in that EEA State at any time under the following exemptions under the E.U. Prospectus Regulation:

 

   

to any legal entity which is a qualified investor as defined under the E.U. Prospectus Regulation;

 

   

to fewer than 150 natural or legal persons (other than qualified investors as defined under the E.U. Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or

 

   

in any other circumstances falling within Article 1(4) of the E.U. Prospectus Regulation,

provided that no such offer of Common Shares shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the E.U. Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the E.U. Prospectus Regulation, and each person who initially acquires any Common Shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the representatives and us that it is a “qualified investor” within the meaning of Article 2(e) in the E.U. Prospectus Regulation.

For the purposes of this provision, the expression an “offer to the public” in relation to our Common Shares offered by this prospectus in any EEA State means the communication in any form and by any means of sufficient information on the terms of the offer and any Common Shares to be offered so as to enable an investor to decide to purchase or subscribe for any of the Common Shares offered by this prospectus and the expression “E.U. Prospectus Regulation” means Regulation (EU) 2017/1129.

United Kingdom

None of our Common Shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to our Common Shares which (i) has been approved by the Financial Conduct Authority or (ii) is to be treated as if it had been approved by the Financial Conduct Authority in accordance with the transitional provisions in Article 74 (transitional provisions) of the Prospectus Amendment etc. (EU Exit) Regulations 2019/1234, except that our Common Shares may be offered to the public in the United Kingdom at any time:

 

  a.

to any legal entity which is a qualified investor as defined under Article 2 of the U.K. Prospectus Regulation;

 

  b.

to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the U.K. Prospectus Regulation), subject to obtaining the prior consent of the underwriters for any such offer; or

 

  c.

in any other circumstances falling within Section 86 of the Financial Services and Markets Act 2000 (“FSMA”),

 

86


Table of Contents

provided that no such offer of our Common Shares shall require us or any underwriter to publish a prospectus pursuant to Section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the U.K. Prospectus Regulation. For the purposes of this provision, the expression an “offer to the public” in relation to our Common Shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any of our Common Shares to be offered so as to enable an investor to decide to purchase or subscribe for any of our Common Shares and the expression “U.K. Prospectus Regulation” means Regulation (EU) 2017/1129 as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended by the European Union (Withdrawal Agreement) Act 2020.

In addition, in the United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are “qualified investors” (as defined in the Prospectus Regulation) (i) who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005, as amended (the “Order”) and/or (ii) who are high net worth companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”) or otherwise in circumstances which have not resulted and will not result in an offer to the public of our Common Shares in the United Kingdom within the meaning of the FSMA.

Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons.

Canada

The Common Shares may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the Common Shares must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory for particulars of these rights or consult with a legal advisor.

Pursuant to section 3A.3 (or, in the case of securities issued or guaranteed by the government of a non-Canadian jurisdiction, section 3A.4) of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.

Australia

No placement document, prospectus, product disclosure statement, or other disclosure document has been lodged with the Australian Securities and Investments Commission in relation to this offering. This prospectus does not constitute a prospectus, product disclosure statement, or other disclosure document under the Corporations Act 2001 (the “Corporations Act”), and does not purport to include the information required for a prospectus, product disclosure statement, or other disclosure document under the Corporations Act.

Any offer in Australia of our Common Shares may only be made to persons (“Exempt Investors”) who are “sophisticated investors” (within the meaning of section 708(8) of the Corporations Act), “professional investors” (within the meaning of section 708(11) of the Corporations Act), or otherwise pursuant to one or more

 

87


Table of Contents

exemptions contained in section 708 of the Corporations Act so that it is lawful to offer our Common Shares without disclosure to investors under Chapter 6D of the Corporations Act.

The Common Shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the twelve-month period after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring securities must observe such Australian on-sale restrictions.

This prospectus contains general information only and does not take account of the investment objectives, financial situation, or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this prospectus is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters.

Switzerland

We have not and will not register with the Swiss Financial Market Supervisory Authority (the “FINMA”) as a foreign collective investment scheme pursuant to Article 119 of the Federal Act on Collective Investment Scheme of 23 June 2006, as amended (CISA), and accordingly the securities being offered pursuant to this prospectus have not and will not be approved, and may not be licensable, with FINMA. Therefore, the securities have not been authorized for distribution by FINMA as a foreign collective investment scheme pursuant to Article 119 CISA and the securities offered hereby may not be offered to the public (as this term is defined in Article 3 CISA) in or from Switzerland. The securities may solely be offered to “qualified investors,” as this term is defined in Article 10 CISA, and in the circumstances set out in Article 3 of the Ordinance on Collective Investment Scheme of 22 November 2006, as amended (the “CISO”), such that there is no public offer. Investors, however, do not benefit from protection under CISA or CISO or supervision by FINMA. This prospectus and any other materials relating to the securities are strictly personal and confidential to each offeree and do not constitute an offer to any other person. This prospectus may only be used by those qualified investors to whom it has been handed out in connection with the offer described herein and may neither directly nor indirectly be distributed or made available to any person or entity other than its recipients. It may not be used in connection with any other offer and will in particular not be copied or distributed to the public in Switzerland or from Switzerland. This prospectus does not constitute an issue prospectus as that term is understood pursuant to Article 652a or 1156 of the Swiss Federal Code of Obligations. We have not applied for a listing of the securities on the SIX Swiss Exchange or any other regulated securities market in Switzerland, and consequently, the information presented in this prospectus does not necessarily comply with the information standards set out in the listing rules of the SIX Swiss Exchange and corresponding prospectus schemes annexed to the listing rules of the SIX Swiss Exchange.

Japan

No registration pursuant to Article 4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as amended, the “FIEL”) has been made or will be made with respect to the solicitation of the application for the acquisition of our Common Shares.

Accordingly, our Common Shares have not been, directly or indirectly, offered or sold and will not be, directly or indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for re-offering or re-sale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan.

 

88


Table of Contents

Japan: Qualified Institutional Investors (“QII”)

Please note that the solicitation for newly issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in relation to our Common Shares constitutes either a “QII only private placement” or a “QII only secondary distribution” (each as described in Paragraph 1, Article 23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the Common Shares. The Common Shares may only be transferred to QIIs.

Japan: Non-QII Investors

Please note that the solicitation for newly issued or secondary securities (each as described in Paragraph 2, Article 4 of the FIEL) in relation to the Common Shares constitutes either a “small number private placement” or a “small number private secondary distribution” (each as is described in Paragraph 4, Article 23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article 4 of the FIEL, has not been made in relation to the Common Shares. The Common Shares may only be transferred en bloc without subdivision to a single investor.

Dubai International Finance Centre

This prospectus relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority (the “DFSA”). This prospectus is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth herein and has no responsibility for the prospectus. The Common Shares to which this prospectus relates may be illiquid or subject to restrictions on its resale. Prospective purchasers of our Common Shares offered should conduct their own due diligence on the Common Shares. If you do not understand the contents of this prospectus, you should consult an authorized financial advisor.

Hong Kong

Our Common Shares may not be offered or sold by means of any document other than (i) in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), (ii) to “professional investors” within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder, or (iii) in other circumstances which do not result in the document being a “prospectus” within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation, or document relating to our Common Shares may be issued or may be in the possession of any person for the purpose of issue (in each case, whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to our Common Shares which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder.

Singapore

This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or materials in connection with the offer or sale, or invitation for subscription or purchase, of our Common Shares may not be circulated or distributed, nor may our Common Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the “Singapore SFA”), (ii) to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions specified in Section 275 of the Singapore SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the Singapore SFA.

 

89


Table of Contents

Where our Common Shares are subscribed to or purchased under Section 275 by a relevant person which is:

 

a.

a corporation (which is not an accredited investor) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or

 

b.

a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, shares, debentures and units of shares and debentures of that corporation or the beneficiaries’ rights and interest in that trust will not be transferable for six (6) months after that corporation or that trust has acquired our Common Shares under Section 275 except:

 

  i.

to an institutional investor or to a relevant person, or to any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275 of the SFA;

 

  ii.

where no consideration is or will be given for the transfer;

 

  iii.

where the transfer is by operation of law;

 

  iv.

as specified in Section 276(7) of the SFA; or

 

  v.

as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities based Derivatives Contracts) Regulation 2018.

Solely for purposes of the notification requirements under Section 309B(1)(c) of the SFA, we have determined, and hereby notify all relevant persons, that our Common Shares are “prescribed capital markets products” (as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).

Brazil

The offer and sale of our Common Shares has not been, and will not be, registered (or exempted from registration) with the Brazilian securities commission, Comissão de Valores Mobiliários (“CVM”), and, therefore, will not be carried out by any means that would constitute a public offering in Brazil under CVM resolution No. 160, dated July 13, 2022, as amended (“CVM Resolution 160”) or unauthorized distribution under Brazilian laws and regulations. Our Common Shares will be authorized for trading on organized non-Brazilian securities markets and may only be offered to Brazilian professional investors (as defined by applicable CVM regulation), who may only acquire our Common Shares through a non-Brazilian account, with settlement outside Brazil in non-Brazilian currency. The trading of these securities on regulated securities markets in Brazil is prohibited.

China

This prospectus does not constitute a public offer of our Common Shares, whether by sale or subscription, in the People’s Republic of China (the “PRC”). Our Common Shares are not being offered or sold directly or indirectly in the PRC to or for the benefit of legal or natural persons of the PRC.

Further, no legal or natural persons of the PRC may directly or indirectly purchase any of the Common Shares offered by this prospectus or any beneficial interest therein without obtaining all prior PRC governmental approvals that are required, whether statutorily or otherwise. Persons who come into possession of this document are required by the issuer and its representatives to observe these restrictions.

France

Neither this prospectus nor any other offering material relating to our Common Shares described in this prospectus has been submitted to the clearance procedures of the Autorité des Marchés Financiers or of the competent authority of another member state of the European Economic Area and notified to the Autorité des

 

90


Table of Contents

Marchés Financiers. Our Common Shares have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus nor any other offering material relating to our Common Shares has been or will be (1) released, issued, distributed or caused to be released, issued or distributed to the public in France; or (2) used in connection with any offer for subscription or sale of our Common Shares to the public in France.

Such offers, sales and distributions will be made in France only:

 

   

to qualified investors (investisseurs estraint) and/or to a restricted circle of investors (cercle estraint d’investisseurs), in each case investing for their own account, all as defined in, and in accordance with, articles L.411-2, D.411-1, D.411-2, D.734-1, D.744-1, D.754-1 and D.764-1 of the French Code monétaire et financier;

 

   

to investment services providers authorized to engage in portfolio management on behalf of third parties; or

 

   

in a transaction that, in accordance with article L.411-2-II-1° -or-2° -or 3° of the French Code monétaire et financier and article 211-2 of the General Regulations (Réglement Général) of the Autorité des Marchés Financiers, does not constitute a public offer (appel public à l’épargne).

Our Common Shares may be resold, directly or indirectly, only in compliance with articles L.411-1, L.411-2, L412-1 and L.621-8 through L.621-8-3 of the French Code monétaire et financier.

Kuwait

Unless all necessary approvals from the Kuwait Ministry of Commerce and Industry required by Law No. 31/1990 “Regulating the Negotiation of Securities and Establishment of Investment Funds,” its Executive Regulations and the various Ministerial Orders issued pursuant thereto or in connection therewith, have been given in relation to the marketing and sale of the Common Shares, these may not be marketed, offered for sale, nor sold in the State of Kuwait. Neither this prospectus (including any related document), nor any of the information contained therein is intended to lead to the conclusion of any contract of whatsoever nature within Kuwait.

Qatar

Our Common Shares have not been, and will not be, offered, sold or delivered, at any time, directly or indirectly, in the State of Qatar (including the Qatar Financial Centre) in a manner that would constitute a public offering. This prospectus has not been, and will not be, registered with or approved by the Qatar Financial Markets Authority, the Qatar Central Bank, the Qatar Financial Centre Regulatory Authority, the Qatar Exchange or any other relevant Qatar governmental body or securities exchange, and may not be publicly distributed. This prospectus is intended for the original recipient only and must not be provided to any other person. It is not for general circulation in the State of Qatar and may not be reproduced or used for any other purpose.

Saudi Arabia

This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the board of the Saudi Arabian Capital Market Authority (the “CMA”) pursuant to resolution number 2-11-2004 dated 4 October 2004 as amended by resolution number 1-28-2008, as amended. The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this document, you should consult an authorized financial advisor.

 

91


Table of Contents

LEGAL MATTERS

Our principal legal advisors in the United States and United Kingdom are Willkie Farr & Gallagher (UK) LLP, located at CityPoint, 1 Ropemaker Street, EC2Y 9AW London, United Kingdom. Our principal legal advisors in Bermuda are Conyers Dill & Pearman Limited (“Conyers”), located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda. Certain Bermuda legal matters relating to this offering will be passed upon by Conyers. Charles Collis is a partner and director at Conyers, as well as a director of the Company. Certain legal matters relating to this offering will be passed upon for the underwriters by Latham & Watkins LLP, located at 1271 Avenue of the Americas, New York, New York 10020.

 

92


Table of Contents

EXPERTS

The consolidated financial statements of Fidelis Insurance Holdings Limited as of December 31, 2023 and 2022, and for each of the years in the three-year period ended December 31, 2023, have been incorporated by reference in this prospectus in reliance upon the report of KPMG Audit Limited, independent registered public accounting firm, and upon the authority of said firm as experts in accounting and auditing.

 

93


Table of Contents

WHERE PROSPECTIVE INVESTORS CAN FIND ADDITIONAL INFORMATION

We have filed with the SEC a registration statement on Form F-1, including exhibits, schedules and amendments thereto, of which this prospectus is a part, under the Securities Act with respect to our Common Shares covered by this prospectus. This prospectus does not contain all of the information set forth in the registration statement and exhibits and schedules to the registration statement or the documents incorporated by reference herein and therein. For further information with respect to our company and the Common Shares covered by this prospectus, reference is made to the registration statement, including the exhibits and schedules thereto and the documents incorporated by reference herein and therein. You should rely only on the information contained in this prospectus or incorporated by reference herein or therein.

Statements contained in this prospectus and the documents incorporated by reference herein and therein as to the contents of any contract or other document referred to in this prospectus are not necessarily complete and, where that contract or other document has been filed as an exhibit to the registration statement, each statement in this prospectus and the documents incorporated by reference herein and therein is qualified in all respects by the exhibit to which the reference relates.

We are subject to the informational requirements of the Exchange Act. Accordingly, we are required to file reports and other information with the SEC, including annual reports on Form 20-F and periodic reports on Form 6-K. Our SEC filings, including our registration statement, our annual and periodic reports and other information, are available, free of charge, on the SEC’s website, www.sec.gov.

We also maintain a website at https://www.fidelisinsurance.com/. We will make the information filed with or furnished to the SEC available free of charge through our website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information contained on, or accessible through our website is not incorporated by reference into and does not constitute a part of this prospectus or any other report or documents we file with or furnish to the SEC. We have included these website addresses in this prospectus solely as inactive textual references.

As a foreign private issuer, we are exempt under the Exchange Act from the rules prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.

INFORMATION INCORPORATED BY REFERENCE

The SEC allows us to “incorporate by reference” information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The SEC file number for the documents incorporated by reference in this prospectus is 001-41731. The documents incorporated by reference into this prospectus contain important information that you should read about us.

The following document is incorporated by reference into this document:

 

  a.

our Annual Report on Form 20-F for the year ended December 31, 2023, as filed with the SEC on March 15, 2024;

 

  b.

our Current Report on Form 6-K, as filed with the SEC on May 9, 2024 (only our Unaudited Consolidated Financial Statements and Management’s Discussion and Analysis of Financial Condition and Results of Operations for the three months ended March 31, 2024 and 2023 contained in Exhibit 99.2); and

 

  c.

our Current Reports on Form 6-K, as filed with the SEC on May 8, 2024 and May 10, 2024.

 

94


Table of Contents

You can obtain any of the filings incorporated by reference into this prospectus through us or from the SEC through the SEC’s website at http://www.sec.gov. We will provide to each person, including any beneficial owner, to whom a prospectus is delivered, without charge upon written or oral request, a copy of any or all of the documents that are incorporated by reference into this prospectus but not delivered with the prospectus, including exhibits which are specifically incorporated by reference into such documents. Requests should be directed to: Fidelis Insurance Holdings Limited, Attn: Investor Relations, Wellesley House South, 90 Pitts Bay Road, Pembroke, Bermuda HM08. Our telephone number is +1 (441) 279-2590. Any statement contained herein or in a document incorporated or deemed to be incorporated by reference into this document will be deemed to be modified or superseded for purposes of the document to the extent that a statement contained in this document or any other subsequently filed document that is deemed to be incorporated by reference into this document modifies or supersedes the statement.

 

95


Table of Contents

 

 

9,000,000 Common Shares

 

 

LOGO

FIDELIS INSURANCE HOLDINGS LIMITED

 

 

Prospectus dated        , 2024

 

Barclays   J.P. Morgan   Goldman Sachs & Co. LLC

 

  Evercore ISI   Citigroup  

 

BMO Capital Markets  

Keefe, Bruyette & Woods

        A Stifel Company

  UBS Investment Bank

 

Citizens JMP

 

Dowling & Partners Securities, LLC

 

 

 

 

 

 

 


Table of Contents

PART II

INFORMATION NOT

REQUIRED IN PROSPECTUS

ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS

To the extent permitted by the Companies Act, we are empowered to indemnify our directors against any liability they incur by reason of their directorship and we have entered into such an indemnification agreement with directors, a form of which is filed as an exhibit to this registration statement. We maintain directors’ and officers’ insurance to insure such persons against certain liabilities.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is theretofore unenforceable.

ITEM 7. RECENT SALES OF UNREGISTERED SECURITIES

During the past three years, we issued securities that were not registered under the Securities Act as set forth below. We believe that each of such issuances of the securities described below were exempt from registration pursuant to Section 4(a)(2) of the Securities Act as transactions by an issuer not involving a public offering or Rule 701 promulgated under the Securities Act as transactions pursuant to compensatory benefit plans and/or Regulation S under the Securities Act as offshore transactions to non-U.S. Persons.

 

   

Common Shares

 

   

On July 15, 2021, we issued 19,874,121 Common Shares for total proceeds of $318.2 million, net of issuance costs in reliance on the exemption from registration under Section 4(a)(2) of the Securities Act and/or Regulation D or Regulation S promulgated thereunder.

 

   

Other Securities

 

   

Since May 1, 2021 we have granted 740,316 warrants, consisting of 482,341 warrants at an average exercise price of $10.00 per warrant, 129,006 warrants at an average exercise price of $16.00 per warrant and 128,969 warrants at an average exercise price of $20.00 per warrant. 11,194,164 Common Shares were issued in connection with the completion of the Separation Transactions upon the exercise of our “in the money” warrants, exercised on a cashless basis at their respective exercise price and net settled for employee taxes. Of these, 4,571 Common Shares were issued as a result of the exercise of leaver warrants. No Common Shares were issued for our “out of the money” or unvested warrants, which were forfeited as part of the completion of the Separation Transactions. Since May 1, 2021 we granted 1,951,481 RSUs at a weighted average price of $0.01 to certain employees and directors pursuant to the 2015 Non-Qualified Share Option Plan and the 2018 Non-Qualified Share Option Plan (collectively, the “Prior Incentive Plans”). In connection with the completion of the Separation Transactions. 2,359,517 Common Shares were issued upon the exercise, on a cashless basis at a $0.01 exercise price and net settled for employee taxes, of vested RSUs outstanding under our Prior Incentive Plans. All of the “in the money” warrants and RSUs issued since May 1, 2021 under the Prior Incentive Plans vested and exercised for Common Shares, or were forfeited, as part of the Separation Transactions.

 

   

Since May 15, 2023, we have granted LTIP Awards, in the form of time- and performance-based restricted share units, with respect to 1,660,965 Common Shares pursuant to the Long-Term Incentive Plan (see Item 6. Directors, Senior Management and Employees—B. Compensation—Senior Management Compensation Components—2023 Share Incentive Plan of the 2023 Annual Report.

 

II-1


Table of Contents

ITEM 8. EXHIBITS

 

  (a)

Exhibits

The exhibit index attached hereto is incorporated herein by reference.

 

  (b)

Financial Statement Schedules.

All schedules have been omitted because they are not required, are not applicable or the information is otherwise set forth in the Consolidated Financial Statements and related notes thereto.

ITEM 9. UNDERTAKINGS

 

  (a)

The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser.

 

  (b)

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that, in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction, the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

  (c)

The undersigned registrant hereby further undertakes that:

 

  i.

For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

 

  ii.

For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

II-2


Table of Contents

EXHIBIT INDEX

 

Exhibit

 No. 

  

Description

1.1*    Form of Underwriting Agreement
3.1    Memorandum of Association of the Registrant (incorporated by reference to Exhibit 1.1 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
3.2    Amended and Restated Bye-laws of the Registrant (incorporated by reference to Exhibit 1.2 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
5.1*    Opinion of Conyers Dill & Pearman Limited, counsel to the Registrant, as to the validity of the Common Shares
10.1    Common Shareholder Registration Rights Agreement, dated as of June  9, 2015, by and among the Registrant and certain shareholders of the Registrant (incorporated by reference to Exhibit 3.6 to the Company’s Annual Report on Form 20-F, filed with the SEC on March  15, 2024)
10.2    First Amendment to the Common Shareholder Registration Rights Agreement, dated as of November  25, 2019, by and among the Registrant and certain shareholders of the Registrant (incorporated by reference to Exhibit 3.7 to the Company’s Annual Report on Form 20-F, filed with the SEC on March  15, 2024)
10.3    Second Amendment to the Common Shareholder Registration Rights Agreement, dated as of February  3, 2020, by and among the Registrant and certain shareholders of the Registrant (incorporated by reference to Exhibit 3.8 to the Company’s Annual Report on Form 20-F, filed with the SEC on March  15, 2024)
10.4    Third Amendment to the Common Shareholder Registration Rights Agreement, dated as of July  13, 2021, by and among the Registrant and certain shareholders of the Registrant (incorporated by reference to Exhibit 3.9 to the Company’s Annual Report on Form 20-F, filed with the SEC on March  15, 2024)
10.5**    Framework Agreement (incorporated by reference to Exhibit 4.2 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
10.6**    Bermuda Delegated Underwriting Authority Agreement (incorporated by reference to Exhibit 4.3 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
10.7**    UK Delegated Underwriting Authority Agreement (incorporated by reference to Exhibit 4.4 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
10.8**    Ireland Delegated Underwriting Authority (incorporated by reference to Exhibit 4.5 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
10.9**    Inter-Group Services Agreement (incorporated by reference to Exhibit 4.6 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
10.10    Amended and Restated Common Shareholders Agreement (incorporated by reference to Exhibit 3.5 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
10.11    Form of Indemnification Agreement for Officers and Directors (incorporated by reference to Exhibit 3.10 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
10.12    Base Senior Notes Indenture, dated as of June  18, 2020, among the Registrant and The Bank of New York Mellon (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
10.13    Supplemental Senior Notes Indenture, dated as of July  2, 2020, between the Registrant and The Bank of New York Mellon (incorporated by reference to Exhibit 3.2 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)


Table of Contents

Exhibit

 No. 

  

Description

10.14    Base Subordinated Notes Indenture, dated as of October  16, 2020, among the Registrant and The Bank of New York Mellon (incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
10.15    Supplemental Subordinated Notes Indenture, dated as of October  20, 2020, between the Registrant and The Bank of New York Mellon (incorporated by reference to Exhibit 3.4 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
10.16†    Long-Term Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company’s Annual Report on Form 20-F, filed with the SEC on March 15, 2024)
21.1*    List of subsidiaries of the Registrant
23.1*    Consent of KPMG Audit Limited, independent registered public accounting firm
23.2*    Consent of Conyers Dill & Pearman Limited (included in Exhibit 5.1)
24.1*    Power of Attorney (included in signature page to Registration Statement)
107*    Filing Fees Table

 

**

The schedules and exhibits to this agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.

Identifies management contract or compensatory plan or arrangement

*

Filed herewith


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Hamilton, Bermuda, on this 20th day of May 2024.

 

FIDELIS INSURANCE HOLDINGS LIMITED
By:  

/s/ Daniel Burrows

  Name: Daniel Burrows
  Title: Group Chief Executive Officer and Executive Director


Table of Contents

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each of the undersigned constitutes and appoints each of Allan Decleir, Daniel Burrows and Janice Weidenborner, each acting alone, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for such person and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement on Form F-1, or other appropriate form, and all amendments thereto, including post-effective amendments, of Fidelis Insurance Holdings Limited, and to file the same, with all exhibits thereto, and other document in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, each acting alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that any such attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

 

/s/ Daniel Burrows
Name: Daniel Burrows
Title: Group Chief Executive Officer and Executive Director
Date: May 20, 2024
/s/ Allan Decleir
Name: Allan Decleir
Title: Group Chief Financial Officer and Executive Director
Date: May 20, 2024
/s/ Matthew J. Adams
Name: Matthew J. Adams
Title: Director
Date: May 20, 2024
/s/ Daniel Brand
Name: Daniel Brand
Title: Director
Date: May 20, 2024
/s/ Charles Collis
Name: Charles Collis
Title: Director
Date: May 20, 2024
/s/ Christine Dandridge
Name: Christine Dandridge
Title: Director
Date: May 20, 2024
/s/ Cathy Iberg
Name: Cathy Iberg
Title: Director
Date: May 20, 2024


Table of Contents
/s/ Daniel Kilpatrick
Name: Daniel Kilpatrick
Title: Director
Date: May 20, 2024
/s/ Dana LaForge
Name: Dana LaForge
Title: Director
Date: May 20, 2024
/s/ Helena Morrissey
Name: Helena Morrissey
Title: Director
Date: May 20, 2024
/s/ Hinal Patel
Name: Hinal Patel
Title: Director
Date: May 20, 2024


Table of Contents

AUTHORIZED REPRESENTATIVE

Pursuant to the requirement of the Securities Act of 1933, the undersigned, the duly undersigned representative in the United States of Fidelis Insurance Holdings Limited, has signed this registration statement in the City of Newark, State of Delaware, on May 20, 2024.

 

By:  

/s/ Donald J. Puglisi

  Name: Donald J. Puglisi
  Title: Authorized Representative

Exhibit 1.1

FIDELIS INSURANCE HOLDINGS LIMITED

[ • ] Common Shares

Underwriting Agreement

[ • ], 2024

Barclays Capital Inc.

J.P. Morgan Securities LLC

Goldman Sachs & Co. LLC

As representatives (the “Representatives” or “you”) of the

several Underwriters listed

in Schedule 1 hereto

c/o Barclays Capital Inc.

745 Seventh Avenue

New York, New York 10019

c/o J.P. Morgan Securities LLC

383 Madison Avenue

New York, New York 10179

c/o Goldman Sachs & Co. LLC

200 West Street

New York, New York 10282

Ladies and Gentlemen:

Certain shareholders named in Schedule 2 hereto (the “Selling Shareholders”) of Fidelis Insurance Holdings Limited, an exempted company organized under the laws of Bermuda (the “Company”), propose to sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [ • ] common shares, par value $0.01 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [ • ], common shares of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares.” The common shares of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock.”


The Company and the Selling Shareholders hereby severally and not jointly confirm their agreement with the several Underwriters concerning the purchase and sale of the Shares, as follows:

1. Registration Statement. The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Securities Act”), a registration statement on Form F-1 (File No. 333-[ • ]), including a prospectus, relating to the Shares. Such registration statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule 430A under the Securities Act to be part of the registration statement at the time of its effectiveness (“Rule 430 Information”), is referred to herein as the “Registration Statement”; and as used herein, the term “Preliminary Prospectus” means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the Commission pursuant to Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information, and the term “Prospectus” means the prospectus in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the “Rule 462 Registration Statement”), then any reference herein to the term “Registration Statement” shall be deemed to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this “Agreement”) to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 5 of Form F-1 under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus.

At or prior to the Applicable Time (as defined below), the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the “Pricing Disclosure Package”): a Preliminary Prospectus dated [ • ], 2024 and each “free-writing prospectus” (as defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto.

Applicable Time” means [ • ] P.M., New York City time, on [ • ], 2024.

2. Purchase of the Shares.

(a) Each of the Selling Shareholders agrees, severally and not jointly, to sell, the Underwritten Shares to the several Underwriters as provided in this Agreement, and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of $[ • ] (the “Purchase Price”) from each of the Selling Shareholders the number of Underwritten Shares (to be adjusted by the Representatives so as to eliminate fractional shares) determined by multiplying the aggregate number of Underwritten Shares to be sold by each of the Selling Shareholders as set forth opposite their respective names in Schedule 2 hereto by a fraction, the numerator of which is the aggregate number of Underwritten Shares to be purchased by such Underwriter as set forth opposite the name of such Underwriter in Schedule 1 hereto and the denominator of which is the aggregate number of Underwritten Shares to be purchased by all the Underwriters from all of the Selling Shareholders hereunder.

 

-2-


In addition, each of the Selling Shareholders agrees, severally and not jointly, as and to the extent indicated in Schedule 2 hereto, to sell, the Option Shares to the several Underwriters as provided in this Agreement, and the Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from each Selling Shareholder the Option Shares at the Purchase Price less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares. If any Option Shares are to be purchased, the number of Option Shares to be purchased by each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule 1 hereto (or such number increased as set forth in Section 12 (Defaulting Underwriter) hereof) bears to the aggregate number of Underwritten Shares being purchased from the Selling Shareholders by the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares as the Representatives in their sole discretion shall make. Any such election to purchase Option Shares shall be made in proportion to the maximum number of Option Shares to be sold by each Selling Shareholder as set forth in Schedule 2 hereto.

The Underwriters may exercise the option to purchase Option Shares at any time in whole, or from time to time in part, on or before the thirtieth day following the date of the Prospectus, by written notice from the Representatives to the Direct Selling Shareholders (as defined below) and the Attorney-in-Fact (as defined below). Such notice shall set forth the aggregate number of Option Shares as to which the option is being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section 12 (Defaulting Underwriter) hereof). Any such notice shall be given at least two business days prior to the date and time of delivery specified therein.

(b) The Selling Shareholders understand that the Underwriters intend to make a public offering of the Shares, and initially to offer the Shares on the terms set forth in the Pricing Disclosure Package. The Selling Shareholders acknowledge and agree that the Underwriters may offer and sell Shares to or through any affiliate of an Underwriter.

(c) Payment for the Shares shall be made by wire transfer in immediately available funds to the accounts specified by the Selling Shareholders (or, in the case of a Non-Direct Selling Shareholders, by the Attorney-in-Fact or any of them) to the Representatives in the case of the Underwritten Shares, at the offices of Latham & Watkins LLP, 1271 Avenue of the Americas, New York, New York 10020 at 10:00 A.M. New York City time on May [ • ], 2024, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives, the Company and the Selling Shareholders (or, in the case of a Non-Direct Selling Shareholder, as the Attorney-in-Fact) may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the Representatives in the written notice of the Underwriters’ election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares is referred to herein as the “Closing Date”, and the time and date for such payment for any of the Option Shares, if other than the Closing Date, is herein referred to as the “Additional Closing Date.”

 

-3-


Payment for the Shares to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made against delivery to the Representatives for the respective accounts of the several Underwriters of the Shares to be purchased on such date, with any transfer or similar taxes payable in connection with the sale of such Shares duly paid by the Selling Shareholders. Delivery of the Shares shall be made through the facilities of The Depository Trust Company (“DTC”) unless the Representatives shall otherwise instruct.

(d) Each of the Company and each Selling Shareholder acknowledges and agrees that the Representatives and the other Underwriters are acting solely in the capacity of an arm’s length contractual counterparty to the Company and the Selling Shareholders with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company, the Selling Shareholders or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company, the Selling Shareholders or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company and the Selling Shareholders shall consult with their own advisors concerning such matters and each shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and, except as set forth in this Agreement, neither the Representatives nor the other Underwriters shall have any responsibility or liability to the Company or the Selling Shareholders with respect thereto. Any review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Representatives and the other Underwriters and shall not be on behalf of the Company or the Selling Shareholders. Moreover, each Selling Shareholder acknowledges and agrees that, although the Representatives may be required or choose to provide certain Selling Shareholders with certain Regulation Best Interest and Form CRS disclosures in connection with the offering, the Representatives and the other Underwriters are not making a recommendation to any Selling Shareholder to participate in the offering, enter into a “lock-up” agreement, or sell any Shares at the price determined in the offering, and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriter is making such a recommendation.

 

-4-


3. Representations and Warranties of the Company. The Company represents and warrants to each Underwriter and the Selling Shareholders that:

(a) Preliminary Prospectus. No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and no Preliminary Prospectus, at the time of filing thereof, contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 9(c) (Indemnification of the Company and the Selling Shareholders) hereof.

(b) Pricing Disclosure Package. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 9(c) (Indemnification of the Company and the Selling Shareholders) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included in the Prospectus has been omitted therefrom.

(c) Issuer Free Writing Prospectus. Other than the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any “written communication” (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication by the Company or its agents and representatives (other than a communication referred to in clause (i) below) an “Issuer Free Writing Prospectus”) other than (i) any document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii) the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the Representatives. Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken together with the Preliminary Prospectus accompanying, or delivered prior to delivery of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 9(c) (Indemnification of the Company and the Selling Shareholders) hereof.

 

-5-


(d) Testing-the-Waters Materials. The Company (i) has not alone engaged in any Testing-the-Waters Communications (as defined below) other than Testing-the-Waters Communications with the consent of the Representatives with potential investors that are persons reasonably believed to be “qualified institutional buyers” (“QIBs”) as defined in Rule 144A under the Securities Act or institutions that are “accredited investors” within the meaning of Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8) (a)(9), (a)(12) or (a)(13) under the Securities Act (“IAIs”) and otherwise in compliance with the requirements of Rule 163B under the Securities Act and (ii) has not authorized anyone other than the Representatives to engage in Testing-the-Waters Communications. The Company reconfirms that the Representatives has been authorized to act on its behalf in undertaking Testing-the-Waters Communications by virtue of a writing substantially in the form of Exhibit A hereto. The Company has not distributed or approved for distribution any Written Testing-the-Waters Communications (as defined below) other than those listed on Annex B hereto. “Testing-the-Waters Communication” means any oral or written communication with potential investors undertaken in reliance on either Section 5(d) of, or Rule 163B under, the Securities Act. “Written Testing-the-Waters Communication” means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Securities Act. Any individual Written Testing-the-Waters Communication does not conflict in any material respect with the information contained in the Registration Statement or the Pricing Disclosure Package, complied in all material respects with the Securities Act, and when taken together with the Pricing Disclosure Package as of the Applicable Time, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading.

(e) Registration Statement and Prospectus. The Registration Statement has been declared effective by the Commission. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section 8A of the Securities Act against the Company or related to the offering of the Shares has been initiated or, to the Company’s knowledge, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied and will comply in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the Additional Closing Date, as the case may be, the Prospectus will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section 9(c) (Indemnification of the Company and the Selling Shareholders) hereof.

 

-6-


(f) Incorporated Documents. The documents incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, when they were filed with the Commission conformed in all material respects to the requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading.

(g) Financial Statements. The financial statements (including the related notes thereto) of the Company and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply as to form in all material respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly, in all material respects, the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) applied on a consistent basis throughout the periods covered thereby (except for any normal year-end adjustments, the adoption of new accounting principles, and as otherwise noted therein), and except in the case of unaudited financial statements, which are subject to normal period-end adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission, and any supporting schedules included or incorporated by reference in the Registration Statement present fairly, in all material respects, the information required to be stated therein; and the other financial information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly, in all material respects, the information shown thereby; all disclosures included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus regarding “non-U.S. GAAP financial measures” (as such term is defined by the rules and regulations of Commission) comply with Regulation G of the Exchange Act, and Item 10 of Regulation S-K of the Securities Act, to the extent applicable.

 

-7-


(h) No Material Adverse Change. Since the date of the most recent financial statements of the Company (including the related notes thereto) included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i) there has not been any change in the share capital (other than the issuance of common shares of the Company upon exercise of options, restricted stock units and warrants described as outstanding in, and the grant of options and awards under equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of share capital (other than (i) quarterly dividends declared and paid or payable on the Company’s 9.00% non-convertible and cumulative preferred securities, par value $0.01 per share (the “Series A Preferred Securities”) and (ii) ordinary course dividends paid on the Company’s common shares, each as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus), or any material adverse change, or any development that could reasonably be expected to result in a prospective material adverse change, in or affecting the business, properties, management, financial position, shareholders’ equity or results of operations of the Company and its subsidiaries taken as a whole; (ii) neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii) neither the Company nor any of its subsidiaries has sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

(i) Organization and Good Standing. The Company and each of its “significant subsidiaries” (as such term is defined in Rule 1-02(w) of Regulation S-X under the Exchange Act) (the “significant subsidiaries”) have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization (to the extent the concept of good standing or an equivalent concept is applicable in such jurisdiction), are duly qualified to do business and are in good standing (to the extent the concept of good standing or an equivalent concept is applicable in such jurisdiction) in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a material adverse effect, including any prospective material adverse effect, on the business, properties, management, financial position, shareholders’ equity or results of operations of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a “Material Adverse Effect”). The Company does not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21 to the Registration Statement.

 

-8-


(j) Non-Significant Subsidiaries. The Company’s subsidiaries, other than the significant subsidiaries, are collectively not material to the business, properties, management, financial position, shareholders’ equity or results of operations of the Company and its subsidiaries taken as a whole and an event at a subsidiary, other than a significant subsidiary, would not cause a Material Adverse Effect.

(k) Capitalization. The Company has an authorized capitalization as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; all the outstanding share capital of the Company (including the Shares to be sold by the Selling Shareholders) have been duly and validly authorized and issued and are fully paid and non-assessable and, except as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus are not subject to any pre-emptive or similar rights; except as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any share capital or other equity interest in the Company or any of its significant subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any share capital of the Company or any such significant subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the share capital of the Company conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding share capital or other equity interests of each significant subsidiary are owned, directly or indirectly, by the Company, have been duly and validly authorized and issued, are fully paid and non-assessable (except, in the case of any foreign subsidiary, for directors’ qualifying shares) and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party, except for such lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

-9-


(l) Share Options. With respect to the options or other equity awards or rights to acquire Common Shares, including, without limitation, restricted stock unit awards (together, the “Share Options”) granted pursuant to the share-based compensation plans of the Company and its subsidiaries (the “Company Share Plans”), (i) each Share Option intended to qualify as an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), so qualifies, (ii) each grant of a Share Option was duly authorized no later than the date on which the grant of such Share Option was by its terms to be effective (the “Grant Date”) by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required shareholder approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii) each such grant was made in accordance with the terms of the Company Share Plans, the Exchange Act and all other applicable laws and regulatory rules or requirements, including the rules of the New York Stock Exchange (the “NYSE”) and any other exchange on which Company securities are traded, and (iv) each such grant was properly accounted for in accordance with U.S. GAAP in the financial statements (including the related notes) of the Company and disclosed in the Company’s filings with the Commission in accordance with the Exchange Act and all other applicable laws. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company of granting, Share Options prior to, or otherwise coordinating the grant of Share Options with, the release or other public announcement of material information regarding the Company or its subsidiaries or their results of operations.

(m) Due Authorization. The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken.

(n) Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

(o) Description of the Underwriting Agreement. This Agreement conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

(p) No Violation or Default. Neither the Company nor any of its significant subsidiaries is (i) in violation of its memorandum of association, charter or bye-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its significant subsidiaries is a party or by which the Company or any of its significant subsidiaries is bound or to which any property or asset of the Company or any of its significant subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction over the Company or any of its significant subsidiaries, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

-10-


(q) No Conflicts. The execution, delivery and performance by the Company of this Agreement and the consummation by the Company of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company or any of its significant subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its significant subsidiaries is a party or by which the Company or any of its significant subsidiaries is bound or to which any property, right or asset of the Company or any of its significant subsidiaries is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or any of its significant subsidiaries or (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i) and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

(r) No Consents Required. No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement and the consummation of the transactions contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority, Inc. (“FINRA”) and under applicable state securities laws in connection with the purchase and distribution of the Shares by the Underwriters, and except such consents, approvals, authorizations, orders, registrations or qualifications the failure to obtain or make would not reasonably be expected to have a Material Adverse Effect.

(s) Legal Proceedings. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (“Actions”) pending to which the Company or any of its subsidiaries is or may reasonably be expected to become a party or to which any property of the Company or any of its subsidiaries is or may reasonably be expected to become the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, could reasonably be expected to have a Material Adverse Effect; no such Actions are threatened or, to the knowledge of the Company, contemplated by any governmental or regulatory authority or threatened by others; and (i) there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii) there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

 

-11-


(t) Independent Accountants. KPMG Audit Limited (“KPMG”), who have certified certain financial statements of the Company and its subsidiaries, is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act.

(u) Title to Real and Personal Property. The Company and its subsidiaries have good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

(v) Intellectual Property. (i) The Company and its subsidiaries own or have the right to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, domain names and other source indicators, copyrights and copyrightable works, know-how, trade secrets, systems, procedures, proprietary or confidential information and all other worldwide intellectual property, industrial property and proprietary rights (collectively, “Intellectual Property”) used in the conduct of their respective businesses, except where the failure to own or have the right to use any of the foregoing would not reasonably be expected to result in a Material Adverse Effect; (ii) to the knowledge of the Company, the Company’s and its subsidiaries’ conduct of their respective businesses does not infringe, misappropriate or otherwise violate any Intellectual Property of any person; (iii) to the knowledge of the Company, no notice of any claim relating to Intellectual Property has been received, which claim, if determined unfavorably would reasonably be expected to have a Material Adverse Effect; and (iv) to the knowledge of the Company, the Intellectual Property of the Company and its subsidiaries is not being infringed, misappropriated or otherwise violated by any person, except where any such instance would not reasonably be expected to result in a Material Adverse Effect.

(w) No Undisclosed Relationships. No relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, shareholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package.

(x) Investment Company Act. The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an “investment company” or an entity “controlled” by an “investment company” within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Investment Company Act”).

 

-12-


(y) Taxes. The Company and its subsidiaries have paid all income and other U.S. federal, state and local and non-U.S. taxes (whether imposed directly or indirectly or through withholdings) (except for cases in which failure to pay would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, or, except as currently being contested in good faith by appropriate proceedings and for which adequate reserves in accordance with U.S. GAAP have been created therefor in the financial statements of the Company), and have filed all income and other tax returns required to be filed through the date hereof (except in any case in which the failure to file would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect), and all such returns are correct and complete in all material respects; and except as otherwise disclosed in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no material tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets.

(z) Licenses and Permits. The Company and its significant subsidiaries possess all licenses, sub-licenses, certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate U.S. federal, state or local or non- U.S. governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and except as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its significant subsidiaries has received notice of any revocation or modification of any such license, sub-license, certificate, permit or authorization or has any reason to believe that any such license, sub-license, certificate, permit or authorization will not be renewed in the ordinary course except where such revocation, modification or non-renewal would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 

-13-


(aa) Insurance Subsidiaries. Each subsidiary of the Company that is required to be organized and licensed as an insurance company (collectively, the “Insurance Subsidiaries”) is duly organized and licensed as required in its jurisdiction of organization and is duly licensed or authorized as required in each jurisdiction outside its jurisdiction of organization where it is required to be so licensed or authorized to conduct its business as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to be so licensed or authorized, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect. The Insurance Subsidiaries have made all required filings (including statutory annual and quarterly statements and statutory balance sheets and income statements included therein, as applicable) under applicable insurance statutes in each jurisdiction where such filings are required, except for such filings the failure of which to make would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. Each of the Insurance Subsidiaries has all other necessary authorizations, approvals, orders, consents, certificates, permits, registrations and qualifications (“Authorizations”), of and from all insurance regulatory authorities necessary to conduct their respective existing business as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to have such Authorizations, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect, and no Insurance Subsidiary has received any notification from any insurance regulatory authority to the effect that any additional Authorizations are needed to be obtained by any Insurance Subsidiary in any case where it would reasonably be expected that the failure to obtain such additional Authorizations or the limiting of the writing of such business would result in a Material Adverse Effect, and, except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no insurance regulatory authority having jurisdiction over any Insurance Subsidiary has issued any order or decree impairing, restricting or prohibiting (A) the payment of dividends by any Insurance Subsidiary to its parent, other than those restrictions applicable to insurance or reinsurance companies under such jurisdiction generally or (B) the continuation of the business of the Company or any of the Insurance Subsidiaries in all material respects as presently conducted, in each case except where such orders or decrees would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect.

(bb) Treaties, Contracts and Arrangements. To the Company’s knowledge, neither the Company nor any of its Insurance Subsidiaries has received any notice from any of the other parties to any reinsurance treaties, contracts, agreements or arrangements to which the Company or any Insurance Subsidiary is a party that such other party intends not to perform its obligations thereunder, except to the extent that such nonperformance would not reasonably be expected to have a Material Adverse Effect.

(cc) Insurance Reserving. Since December 31, 2023, neither the Company nor any of its Insurance Subsidiaries have made any material change in their respective insurance reserving practices.

(dd) No Labor Disputes. No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries’ principal suppliers, contractors or customers, except as would not have a Material Adverse Effect. Neither the Company nor any of its subsidiaries have entered into any collective bargaining agreement.

 

-14-


(ee) Certain Environmental Matters. (i) The Company and its subsidiaries (x) are in compliance with all, and have not violated any, applicable U.S. federal, state or local or non-U.S. laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other legally enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (y) have received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and (z) have not received notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i) and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii) except as described in each of the Pricing Disclosure Package and the Prospectus, (x) there is no proceeding that is pending, or, to the knowledge of the Company, that is known to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y) the Company and its subsidiaries are not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be expected to have a material effect on the capital expenditures, earnings or competitive position of the Company and its subsidiaries, and (z) none of the Company or its subsidiaries is required to account for any material capital expenditures relating to any Environmental Laws on its financial statements.

(ff) Compliance with ERISA. (i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group” (defined as any entity, whether or not incorporated, that is under common control with the Company within the meaning of Section 4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section 414(b),(c),(m) or (o) of the Code) would have any liability (each, a “Plan”) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section 302 of ERISA or Section 412 of the Code) applicable to such Plan; (iv) no Plan is, or is reasonably expected to be, in “at risk status” (within the meaning of Section 303(i) of ERISA) and no Plan that is a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA is in “endangered status” or “critical status” (within the meaning of Sections 304 and 305 of ERISA) (v) the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no “reportable event” (within the meaning of Section 4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii) each Plan that is intended to be qualified under Section 401(a) of the Code has received a favorable determination, advisory or opinion letter from the Internal Revenue Service indicating that it is qualified, and, nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification; (viii) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guaranty Corporation, in the ordinary course and without default) in respect of a Plan (including a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA); and (ix) none of the following events has occurred or is reasonably likely to occur: (A) a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company’s and its Controlled Group affiliates’ most recently completed fiscal year; or (B) a material increase in the Company and its subsidiaries’ “accumulated post-retirement benefit obligations” (within the meaning of Accounting Standards Codification Topic 715-60) compared to the amount of such obligations in the Company and its subsidiaries’ most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i) through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect.

 

-15-


(gg) Disclosure Controls. The Company and, on a consolidated basis, its subsidiaries maintain an effective system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company’s management as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act.

(hh) Accounting Controls. The Company and, on a consolidated basis, its subsidiaries maintain systems of “internal control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. GAAP. The Company and its subsidiaries maintain internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with U.S. GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences and (v) interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Based on the Company’s most recent evaluation of its internal controls over financial reporting pursuant to Rule 13a-15(c) of the Exchange Act, except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any material weaknesses in the Company’s internal controls (it being understood that this subsection shall not require the Company to comply with Section 404 of the Sarbanes-Oxley Act of 2002, as amended and the rules and regulations promulgated in connection therewith (the “Sarbanes-Oxley Act”), as of an earlier date that it would otherwise be required to so comply under applicable law). The Company’s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report financial information; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal controls over financial reporting.

 

-16-


(ii) eXtensible Business Reporting Language. The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission’s rules and guidelines applicable thereto.

(jj) Insurance. The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are generally maintained by similarly situated companies and which the Company reasonably believes are adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.

(kk) Cybersecurity; Data Protection. The Company and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are in the Company’s reasonable belief adequate for, and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (“Personal Data”)) used in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without, or would not reasonably be expected to result in, material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification. To the extent applicable to the operations of the Company and its subsidiaries, the Company and its subsidiaries are in material compliance with the European Union General Data Protection Regulation (and all other laws and regulations applicable to the operations of the Company and its subsidiaries with respect to Personal Data, and for which any non-compliance with the same would be reasonably likely to create a material liability).

 

-17-


(ll) No Unlawful Payments. Neither the Company nor any of its subsidiaries, nor any director or officer of the Company or any of its subsidiaries nor, to the knowledge of the Company, any employee, agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws.

(mm) Compliance with Anti-Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including, without limitation, those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules, orders and regulations thereunder and any related or similar rules, orders, regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

-18-


(nn) No Conflicts with Sanctions Laws. Neither the Company nor any of its subsidiaries, directors, officers or employees, nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S. government (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) or the U.S. Department of State and including, without limitation, the designation as a “specially designated national” or “blocked person”), the United Nations Security Council (“UNSC”), the European Union, His Majesty’s Treasury (“HMT”) or other relevant sanctions authority (collectively, “Sanctions”), nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or target of Sanctions, without limitation, Cuba, Iran, North Korea, Syria, the Crimea Region of Ukraine, the so-called Donetsk People’s Republic, the so-called Luhansk People’s Republic and the disputed territories of Kherson and Zaporizhzhia (each, a “Sanctioned Country”). For the past ten years, the Company and its subsidiaries have not engaged in and are not now engaged in any dealings or transactions in violation of applicable Sanctions.

(oo) No Restrictions on Subsidiaries. No subsidiary of the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary’s share capital or similar ownership interest, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary’s properties or assets to the Company or any other subsidiary of the Company.

(pp) No Broker’s Fees. Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against any of them or any Underwriter for a brokerage commission, finder’s fee or like payment in connection with the offering and sale of the Shares.

(qq) No Registration Rights. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or, to the knowledge of the Company, the sale of the Shares to be sold by the Selling Shareholders hereunder.

 

-19-


(rr) No Stabilization. Neither the Company nor any of its subsidiaries or affiliates has taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of any securities of the Company.

(ss) Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.

(tt) Statistical and Market Data. Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus is not based on or derived from sources that are reliable and accurate in all material respects.

(uu) Sarbanes-Oxley Act. To the extent applicable to the Company on the date hereon, there is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act, including Section 402 related to loans.

(vv) Status under the Securities Act. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Shares and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1) under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein) and in any event prior to the Closing Date.

(ww) No Immunity. Neither the Company nor any of its subsidiaries or their properties or assets has immunity under Bermuda, U.S. federal or New York state law from any legal action, suit or proceeding, from the giving of any relief in any such legal action, suit or proceeding, from set-off or counterclaim, from the jurisdiction of any Bermudan, U.S. federal or New York state court, from service of process, attachment upon or prior to judgment, or attachment in aid of execution of judgment, or from execution of a judgment, or other legal process or proceeding for the giving of any relief or for the enforcement of a judgment, in any such court with respect to their respective obligations, liabilities or any other matter under or arising out of or in connection herewith; and, to the extent that the Company or any of its subsidiaries or any of its properties, assets or revenues may have or may hereafter become entitled to any such right of immunity in any such court in which proceedings arising out of, or relating to the transactions contemplated by this Agreement, may at any time be commenced, the Company has, pursuant to Section 18(e) (Waiver of Immunity) of this Agreement, waived, and it will waive, or will cause its subsidiaries to waive, such right to the extent permitted by law.

 

-20-


(xx) Enforcement of Foreign Judgments. The courts of Bermuda would recognize as a valid judgment, a final and conclusive judgment in personam obtained in any U.S. federal or New York state court located in the State of New York against the Company based upon this Agreement under which a sum of money is payable (other than a sum of money payable in respect of multiple damages, taxes or other charges of a like nature or in respect of a fine or other penalty) and would give a judgment based thereon provided that (a) such courts had proper jurisdiction over the parties subject to such judgment; (b) such courts did not contravene the rules of natural justice of Bermuda; (c) such judgment was not obtained by fraud; (d) the enforcement of the judgment would not be contrary to the public policy of Bermuda; (e) no new admissible evidence relevant to the action is submitted prior to the rendering of the judgment by the courts of Bermuda; and (f) there is due compliance with the correct procedures under the laws of Bermuda.

(yy) Valid Choice of Law. The choice of laws of the State of New York as the governing law of this Agreement is a valid choice of law under the laws of Bermuda and will be honored by the courts of Bermuda, subject to the restrictions described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. The Company has the power to submit, and pursuant to Section 18(c) (Submission to Jurisdiction) of this Agreement, has legally, validly, effectively and irrevocably submitted, to the personal jurisdiction of each New York state and U.S. federal court sitting in the City of New York and has validly and irrevocably waived any objection to the laying of venue of any suit, action or proceeding brought in such court.

(zz) Passive Foreign Investment Company. Subject to and other than as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company should not be characterized as a “passive foreign investment company” (“PFIC”) as defined in Section 1297 of the Code for its most recently completed taxable year and the Company does not expect to be a PFIC for the foreseeable future.

(aaa) Stamp Taxes. No stamp, registration, documentary, issuance, transfer or other similar taxes or duties (“Stamp Taxes”) are payable by or on behalf of the Underwriters in Bermuda, the United Kingdom, the United States or any other jurisdiction in which the Company is organized or incorporated, engaged in business for tax purposes or is otherwise resident for tax purposes, or any political subdivision or taxing authority thereof, or any jurisdiction from or through which payment or delivery to or for the benefit of the Underwriters is made by or on behalf of the Company under this Agreement (each, a “Company Relevant Tax Jurisdiction”) in connection with (A) the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby, (B) the delivery of the Shares in the manner contemplated by this Agreement and the Prospectus or (C) the sale and delivery by the Underwriters of the Shares as contemplated by this Agreement and the Prospectus.

 

-21-


(bbb) No Withholding Tax. All payments to be made by or on behalf of the Company under this Agreement may, under the current laws and regulations of any Company Relevant Tax Jurisdiction, be paid in U.S. dollars that may be converted into another currency and freely transferred out of any Company Relevant Tax Jurisdiction, and all such payments will not be subject to withholding or deduction for taxes under the laws and regulations of any Company Relevant Tax Jurisdiction and shall be made without the necessity of obtaining any governmental authorization in any Company Relevant Tax Jurisdiction.

(ccc) Dividends. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, no approvals are currently required in Bermuda or the United Kingdom in order for the Company to pay dividends or other distributions declared by the Company to the holders of Shares. Under current laws and regulations of Bermuda or the United Kingdom and any political subdivision thereof, any amount payable with respect to the Shares upon liquidation of the Company or upon redemption thereof and dividends and other distributions declared and payable on the share capital of the Company may be paid by the Company in U.S. dollars or euros and freely transferred out of Bermuda or the United Kingdom, and all such payments made to the holders thereof or therein who are non-residents of Bermuda or the United Kingdom will not be subject to income, withholding or other taxes under laws and regulations of Bermuda, the United Kingdom or any political subdivision or taxing authority thereof or therein and shall be made without the necessity of obtaining any governmental authorization in Bermuda, the United Kingdom or any political subdivision or taxing authority thereof or therein.

(ddd) Legality. The legality, validity, enforceability or admissibility into evidence of any of the Registration Statement, the Pricing Disclosure Package, the Prospectus, this Agreement or the Shares in any jurisdiction in which the Company is organized or does business is not dependent upon such document being submitted into, filed or recorded with any court or other authority in any such jurisdiction on or before the date hereof or that any tax, imposition or charge be paid in any such jurisdiction on or in respect of any such document.

(eee) Legal Action. A holder of the Shares and each Underwriter are each entitled to sue as plaintiff in the court of the jurisdiction of formation and domicile of the Company for the enforcement of their respective rights under this Agreement and the Shares and such access to such courts will not be subject to any conditions which are not applicable to residents of such jurisdiction or a company incorporated in such jurisdiction except that plaintiffs not residing in Bermuda may be required to guarantee payment of a possible order for payment of costs or damages at the request of the defendant.

(fff) Fair and Accurate Summary. The statements in (x) the Registration Statement, the Pricing Disclosure Package and the Prospectus, under the headings (i) “Certain Tax Considerations—United States Taxation,” to the extent that they constitute summaries of U.S. federal law or regulation or legal conclusions with respect thereto and (ii) “Certain Tax Considerations—Bermuda Taxation,” to the extent that they constitute summaries of Bermuda law or regulation or legal conclusions with respect thereto, and (y) the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, under the headings (i) Item 4. Information on the Company – B. Business Overview – Regulatory Matters, to the extent that they constitute summaries of Bermuda, United Kingdom, Ireland and U.S. law or regulation or legal conclusions with respect thereto and (ii) Item 19. Exhibits – Exhibit 2.1 Description of Securities, to the extent they constitute summaries of the terms of the Shares, have been reviewed by us and fairly and accurately summarize the matters described under that heading in all material respects.

 

-22-


(ggg) Foreign Private Issuer. The Company is a “foreign private issuer” as defined in Rule 405 under the Securities Act.

(hhh) No Subsidiary Securities. There are (and prior to the Closing Date will be) no debt securities, convertibles securities or preferred stock issued or guaranteed by any significant subsidiary that are rated by a “nationally recognized statistical rating organization,” as such term is defined by Section 3(a)(62) of the Exchange Act.

4. Representations and Warranties of the Selling Shareholders. Each of the Selling Shareholders severally and not jointly represents and warrants to each Underwriter and the Company that:

(a) Required Consents; Authority. All consents, approvals, authorizations and orders necessary for the execution and delivery by such Selling Shareholder of this Agreement and, if such Selling Shareholder is not Platinum Ivy B 2018 RSC Limited (“Platinum Ivy” or the “Direct Selling Shareholder”) (each such Selling Shareholder other than the Direct Selling Shareholder, a “Non-Direct Selling Shareholder”), the Power of Attorney (the “Power of Attorney”) and the Custody Agreement (the “Custody Agreement”) hereinafter referred to, and for the sale and delivery of the Shares to be sold by such Selling Shareholder hereunder, have been obtained; and such Selling Shareholder has full right, power and authority to enter into this Agreement and, if a Non-Direct Selling Shareholder, the Power of Attorney and the Custody Agreement and to sell, assign, transfer and deliver the Shares to be sold by such Selling Shareholder hereunder; this Agreement and, if a Non-Direct Selling Shareholder, the Power of Attorney and the Custody Agreement have each been duly authorized, executed and delivered by such Selling Shareholder, except, in each case, for (i) the registration of the Shares under the Securities Act (including any related authorizations, consents, approvals and orders in connection therewith), (ii) such consents, approvals, authorizations, orders and registrations or qualifications as may be required by FINRA or the NYSE and under applicable state securities laws or non-U.S. laws in connection with the purchase and distribution of the Shares by the Underwriters, and (iii) such consents, approvals, authorizations, orders, registrations or qualifications the failure to obtain or make would not reasonably be expected to materially impair the ability of such Selling Shareholder to consummate the transactions contemplated by this Agreement.

 

-23-


(b) No Conflicts. The execution, delivery and performance by such Selling Shareholder of this Agreement and, if a Non-Direct Selling Shareholder, the Power of Attorney and the Custody Agreement, the sale of the Shares to be sold by such Selling Shareholder and the consummation by such Selling Shareholder of the transactions contemplated herein or therein will not (i) conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of such Selling Shareholder pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which such Selling Shareholder is a party or by which such Selling Shareholder is bound or to which any of the property, right or asset of such Selling Shareholder is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar organizational documents of such Selling Shareholder, (iii) result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory agency applicable to such Selling Shareholder, or (iv) violate any insider trading policies of (A) the Company (to the extent applicable to such Selling Shareholder) or (B) such Selling Shareholder, as applicable, except in the case of clauses (i) and (iii) above, for any such conflict, breach, violation or default, as the case may be, that would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Selling Shareholder to perform its obligations under this Agreement or the consummation of any of the transactions contemplated hereby.

(c) Title to Shares. Such Selling Shareholder has good and valid title to the Shares to be sold at the Closing Date or the Additional Closing Date, as the case may be, by such Selling Shareholder hereunder, free and clear of all liens, encumbrances, equities or adverse claims other than those, in the case of a Non-Direct Selling Shareholder, set forth in the Custody Agreement; such Selling Shareholder will have, immediately prior to the Closing Date or the Additional Closing Date, as the case may be, good and valid title to the Shares to be sold at the Closing Date or the Additional Closing Date, as the case may be, by such Selling Shareholder, free and clear of all liens, encumbrances, equities or adverse claims; and, upon delivery of such Shares and payment therefor pursuant hereto, good and valid title to such Shares, free and clear of all liens, encumbrances, equities or adverse claims, will pass to the several Underwriters.

(d) No Stabilization. Such Selling Shareholder has not taken and will not take, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of any securities of the Company in connection with the offering of the Shares.

(e) Pricing Disclosure Package. The Pricing Disclosure Package, at the Applicable Time did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that such Selling Shareholder’s representation under this Section 4(e) shall only apply to any untrue statement of a material fact or omission to state a material fact made in reliance upon and in conformity with any information relating to such Selling Shareholder furnished to the Company in writing by such Selling Shareholder expressly for use in the Pricing Disclosure Package, it being understood and agreed that the only information furnished by each Selling Shareholder to the Company consists of (A) the legal name and address of such Selling Shareholder and the other information about such Selling Shareholder set forth in the footnote relating to such Selling Shareholder under the caption “Principal and Selling Shareholders” and (B) the number of shares of common stock beneficially owned by such Selling Shareholder before the offering (excluding percentages) that appears in the table (and corresponding footnotes) under the caption “Principal and Selling Shareholders” (collectively, the “Selling Shareholder Information”).

 

-24-


(f) Issuer Free Writing Prospectus and Written Testing-the-Waters Communication. Other than the Registration Statement, the Preliminary Prospectus and the Prospectus, such Selling Shareholder (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any Issuer Free Writing Prospectus or Written Testing-the-Waters Communication, other than (i) any document not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii) the documents listed on Annex A or Annex B hereto, each electronic road show and any other written communications approved in writing in advance by the Company and the Representatives.

(g) Registration Statement and Prospectus. As of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of the Additional Closing Date, as the case may be, the Prospectus will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that such Selling Shareholder’s representation under this Section 4(g) shall only apply to any untrue statement of a material fact or omission to state a material fact made in reliance upon and in conformity with the Selling Shareholder Information.

(h) Material Non-Public Information. As of the date hereof and as of the Closing Date and as of the Additional Closing Date, as the case may be, the sale of the Shares by such Selling Shareholder is not and will not be prompted by any material non-public information concerning the Company that is required by applicable law, rules and regulations to be disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus and is not so disclosed.

(i) No Unlawful Payments.

 

-25-


(i) Each Non-Direct Selling Shareholder represents that neither such Non-Direct Selling Shareholder nor, if applicable, any of its subsidiaries, nor any director or officer of such Selling Shareholder or any of its subsidiaries, nor, to the knowledge of such Non-Direct Selling Shareholder, any employee of, or any agent, controlled affiliate or other person acting on behalf of, such Non-Direct Selling Shareholder or, if applicable, any of its subsidiaries has within the past five years (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. Neither such Non-Direct Selling Shareholder nor, if applicable, any of its subsidiaries, directors, officers or employees will use, directly or, to the knowledge of the Non-Direct Selling Shareholder, indirectly, the proceeds of the offering of the Shares hereunder in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-bribery and anti-corruption laws.

(ii) Platinum Ivy represents that, in connection with the Company or its subsidiaries, Platinum Ivy has not violated and is not in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, and has not committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption law. Platinum Ivy shall not use the proceeds of the offering of the Shares hereunder in violation of any applicable anti-bribery and anti-corruption laws.

(j) Compliance with Anti-Money Laundering Laws.

(i) Each Non-Direct Selling Shareholder represents that, if such Non-Direct Selling Shareholder is an entity, the operations of such Non-Direct Selling Shareholder and, if applicable, its subsidiaries are and have been conducted at all times in compliance with applicable Anti-Money Laundering Laws, and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving such Non-Direct Selling Shareholder or, if applicable, any of its subsidiaries with respect to the applicable Anti-Money Laundering Laws is pending or, to the knowledge of such Non-Direct Selling Shareholder, threatened. Neither such Non-Direct Selling Shareholder nor, if applicable, any of its subsidiaries, directors, officers or employees (in each case, if applicable) will use, directly or, to the knowledge of the Non-Direct Selling Shareholder, indirectly, the proceeds of the offering of the Shares hereunder in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of applicable Anti-Money Laundering Laws.

 

-26-


(ii) Platinum Ivy represents that, in connection with the Company and its subsidiaries, the operations of Platinum Ivy and its subsidiaries are and have been conducted at all times in compliance with applicable Anti-Money Laundering Laws. Platinum Ivy shall not use the proceeds of the offering of the Shares hereunder in violation of any applicable Anti-Money Laundering Laws.

(k) No Conflicts with Sanctions Laws.

(i) Each Non-Direct Selling shareholder represents that neither such Non-Direct Selling Shareholder nor, if applicable, any of its subsidiaries, directors or officers (in each case, if applicable), nor, to the knowledge of such Non-Direct Selling Shareholder, any employee, agent, controlled affiliate or other person acting on behalf of such Non-Direct Selling Shareholder or, if applicable, any of its subsidiaries is currently the subject or the target of any Sanctions, nor is such Non-Direct Selling Shareholder or, if applicable, any of its subsidiaries located, organized or resident in a Sanctioned Country; and such Non-Direct Selling Shareholder will not directly or, to the knowledge of the Non-Direct Selling Shareholder, indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner in violation of Sanctions.

(ii) Platinum Ivy represents that neither Platinum Ivy nor any of its subsidiaries, directors, or officers, nor, to the knowledge of Platinum Ivy, any employee, agent, controlled affiliate or other person associated with or acting on behalf of Platinum Ivy or any of its subsidiaries is currently a person with whom or which transactions are restricted under any Sanctions, nor is Platinum Ivy or any of its subsidiaries located, organized or resident in a Sanctioned Country; and Platinum Ivy will not directly or, to the knowledge of Platinum Ivy, indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is a person with whom or which transactions are prohibited under any Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner, in each case of (i)-(iii), that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.

 

-27-


(l) Organization and Good Standing. Such Selling Shareholder, if a corporation or limited liability company, limited partnership or other business entity, has been duly organized and is validly existing and in good standing under the laws of its respective jurisdictions of organization.

(m) Stamp Taxes. No Stamp Taxes are payable by or on behalf of the Underwriters in any jurisdiction in which such Selling Shareholder is organized, incorporated, engaged in business for tax purposes or resident for tax purposes, or any political subdivision or taxing authority thereof, or any jurisdiction from or through which payment or delivery to or for the benefit of the Underwriters is made by or on behalf of such Selling Shareholder under this Agreement (each, a “Selling Shareholder Relevant Tax Jurisdiction”) in connection with (A) the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby, (B) the delivery of the Shares in the manner contemplated by this Agreement and the Prospectus or (C) the sale and delivery by the Underwriters of the Shares as contemplated by this Agreement and the Prospectus.

(n) No Withholding Tax. All payments to be made by or on behalf of such Selling Shareholder under this Agreement may, under the current laws and regulations of any Selling Shareholder Relevant Tax Jurisdiction in respect of such Selling Shareholder, be paid in U.S. dollars that may be converted into another currency and freely transferred out of any such Selling Shareholder Relevant Tax Jurisdiction, and all such payments will not be subject to withholding or deductions for taxes under the laws and regulations of any such Selling Shareholder Relevant Tax Jurisdiction and shall be made without the necessity of obtaining any governmental authorization in any such Selling Shareholder Relevant Tax Jurisdiction.

(o) Submission to Jurisdiction. Such Selling Shareholder has the power to submit to the personal jurisdiction of each New York state and U.S. federal court sitting in the City of New York.

(p) Each of the Non-Direct Selling Shareholders, represents and warrants that certificates in negotiable form or book entry securities entitlement representing all of the Shares to be sold by such Selling Shareholders hereunder have been placed in custody under a Custody Agreement relating to such Shares, in the form heretofore furnished to you, duly executed and delivered by or on behalf of such Selling Shareholder to Computershare, Inc., as custodian (the “Custodian”), and that such Selling Shareholder has duly executed and delivered Powers of Attorney, in the form heretofore furnished to you, appointing the person indicated in the Power of Attorney as such Selling Shareholder’s Attorney-in-fact (the “Attorney-in-Fact”) with authority to execute and deliver this Agreement on behalf of such Selling Shareholder, to determine the purchase price to be paid by the Underwriters to such Selling Shareholders as provided herein, to authorize the delivery of the Shares to be sold by such Selling Shareholder hereunder and otherwise to act on behalf of such Selling Shareholder in connection with the transactions contemplated by this Agreement and the Custody Agreement.

 

-28-


Each of the Non-Direct Selling Shareholders specifically agrees that the Shares held in custody for such Selling Shareholder under the Custody Agreement, are subject to the interests of the Underwriters hereunder, and that the arrangements made by such Selling Shareholder for such custody, and the appointment by such Selling Shareholder of the Attorney-in-Fact by the Power of Attorney, are to that extent irrevocable. Each of the Selling Shareholders specifically agrees that the obligations of such Selling Shareholder hereunder shall not be terminated by operation of law, whether by the death or incapacity of any individual Selling Shareholder, or, in the case of an estate or trust, by the death or incapacity of any executor or trustee or the termination of such estate or trust, or in the case of a partnership, corporation or similar organization, by the dissolution of such partnership, corporation or organization, or by the occurrence of any other event, in each case to the extent not prohibited under the laws of such Selling Shareholder’s jurisdiction of organization. If any individual Selling Shareholder or any such executor or trustee should die or become incapacitated, or if any such estate or trust should be terminated, or if any such partnership, corporation or similar organization should be dissolved, or if any other such event should occur, before the delivery of the Shares to be sold by such Selling Shareholder hereunder, to the extent not prohibited under the laws of such Selling Shareholder’s jurisdiction of organization or book entry securities entitlements representing such Shares to be sold by such Selling Shareholder shall be delivered by or on behalf of such Selling Shareholder in accordance with the terms and conditions of this Agreement and the Custody Agreement, and actions taken by the Attorney-in-Fact pursuant to the Powers of Attorney shall be as valid as if such death, incapacity, termination, dissolution or other event had not occurred, regardless of whether or not the Custodian, the Attorney-in-Fact, or any of them, shall have received notice of such death, incapacity, termination, dissolution or other event.

5. Further Agreements of the Company. The Company covenants and agrees with each Underwriter that:

(a) Required Filings. The Company will file the final Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule 430A under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to the Closing Date in such quantities as the Representatives may reasonably request.

(b) Delivery of Copies. Upon the written request of the Representatives, the Company will deliver, without charge, (i) to the Representatives, three signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii) to each Underwriter (A) a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B) during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term “Prospectus Delivery Period” means such period of time after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by any Underwriter or dealer.

 

-29-


(c) Amendments or Supplements, Issuer Free Writing Prospectuses. Before making, preparing, using, authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not make, prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably objects (which objections shall not be unreasonably delayed).

(d) Notice to the Representatives. The Company will advise the Representatives promptly, and confirm such advice in writing (which may be by email), (i) when the Registration Statement has become effective; (ii) when any amendment to the Registration Statement has been filed or becomes effective; (iii) when any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication or any amendment to the Prospectus has been filed or distributed; (iv) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any additional information including, but not limited to, any request for information concerning any Testing-the-Waters Communication; (v) of the issuance by the Commission or any other governmental or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written Testing-the-Waters Communication or the initiation or, to the Company’s knowledge, threatening of any proceeding for that purpose or pursuant to Section 8A of the Securities Act; (vi) of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, any of the Pricing Disclosure Package, any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, any such Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication is delivered to a purchaser, not misleading; and (vii) of the receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or, to the Company’s knowledge, threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to prevent the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or any Written Testing-the-Waters Communication or suspending any such qualification of the Shares and, if any such order is issued, will use its reasonable best efforts to obtain as soon as possible the withdrawal thereof.

 

-30-


(e) Ongoing Compliance. (1) If during the Prospectus Delivery Period (i) any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Prospectus to comply with applicable law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be filed with the Commission and incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with applicable law and (2) if at any time prior to the Closing Date (i) any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Pricing Disclosure Package to comply with applicable law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission (to the extent required) and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with applicable law.

(f) Blue Sky Compliance. If required by applicable law, the Company will qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Shares; provided that the Company shall not be required to (i) qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject.

(g) Earning Statement. The Company will make generally available to its security holders and the Representatives as soon as practicable an earning statement that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the “effective date” (as defined in Rule 158) of the Registration Statement provided that the Company will be deemed to comply with such requirement by filing such earnings statements on the Commission’s Electronic Data Gathering and Retrieval System (“EDGAR”) (or any successor system).

 

-31-


(h) Clear Market. For a period of 90 days after the date of the Prospectus, the Company will not (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of , directly or indirectly (any such sale, loan, pledge or other disposition, or transfer of economic consequences, a “Transfer”), or submit to, or file with, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or publicly disclose the intention to undertake any of the foregoing, or (ii) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of the Representatives other than the Shares to be sold hereunder. Additionally, for a period of 90 days after the date of the Prospectus, without the prior written consent of the Representatives, the Company will not (i) agree to waive or amend any provision of Section 3 (Lock-Up of Common Shares) or Section 4 (Lock-Up of Retention RSU Shares) of the Amended and Restated IPO Assistance and Lock-Up Agreement, dated June 12, 2023, with respect to the shareholders listed in Schedule 3 hereto or (ii) consent to any requests by Shelf Holdco II Limited (“TFP HoldCo”) to Transfer any of its Stock; provided that the foregoing restriction shall not prohibit repurchases by the Company of Stock held by TFP HoldCo pursuant to Section 7.01(b) of the Company’s common shareholders agreement dated June 16, 2023.

The restrictions described above do not apply to (i) the offer, sale and disposition of the Shares hereunder, (ii) the issuance of shares of Stock or securities convertible into or exercisable for shares of Stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise) or the settlement of RSUs (including net settlement), in each case outstanding on the date of this Agreement and described in the Prospectus; (iii) grants of options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of Stock or securities convertible into or exercisable or exchangeable for shares of Stock (whether upon the exercise of options or otherwise) to the Company’s employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the Closing Date and described in the Prospectus, provided that such recipients enter into a lock-up agreement with the Underwriters; (iv) the issuance of up to 5% of the outstanding shares of Stock, or securities convertible into, exercisable for, or which are otherwise exchangeable for, Stock, immediately following the Closing Date, in acquisitions or other similar strategic transactions, provided that such recipients enter into a lock-up agreement with the Underwriters; or (v) the filing of any registration statement on Form S-8 relating to securities granted or to be granted pursuant to any plan in effect on the date of this Agreement and described in the Prospectus or any assumed benefit plan pursuant to an acquisition or similar strategic transaction.

 

-32-


(i) No Stabilization. Neither the Company nor its subsidiaries or affiliates will take, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock.

(j) Reports. For a period of three years following the date hereof, so long as the Company is subject to the reporting requirements of either Section 13 or 15(d) of the Exchange Act, the Company will furnish to the Representatives, as soon as they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system; provided the Company will be deemed to have furnished such reports and financial statements to the Representatives to the extent they are filed on the Commission’s Electronic Data Gathering, Analysis, and Retrieval system.

(k) Record Retention. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act.

(l) Filings. The Company will file with the Commission such reports as may be required by Rule 463 under the Securities Act.

(m) Foreign Private Issuer. The Company will promptly notify the Representatives if the Company ceases to be a Foreign Private Issuer at any time prior to the later of (i) completion of the distribution of the Shares within the meaning of the Securities Act and (ii) completion of the 90-day restricted period referred to in Section 5(h) (Clear Market) hereof.

(n) Tax Indemnity. The Company will pay and will indemnify and hold harmless the Underwriters against any Stamp Taxes payable in connection with (A) the execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby, (B) the delivery of the Shares in the manner contemplated by this Agreement and the Prospectus or (C) the sale and delivery by the Underwriters of the Shares as contemplated by this Agreement and the Prospectus. All payments to be made by or on behalf of the Company to or for the benefit of the Underwriters under this Agreement shall be made without withholding or deduction for or on account of any present or future taxes, duties or governmental shares whatsoever unless the Company is compelled by law to deduct or withhold such taxes, duties or charges. In that event, the Company shall pay such additional amounts as may be necessary in order to ensure that the net amounts received by the Underwriters after such withholding or deductions shall equal the amounts that would have been received if no withholding or deduction has been made.

 

-33-


6. Further Agreements of the Selling Shareholders. Each of the Selling Shareholders severally and not jointly covenants and agrees with each Underwriter that:

(a) No Stabilization. Such Selling Shareholder will not take, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock.

(b) Tax Form. It will deliver to the Representatives prior to or at the Closing Date a properly completed and executed United States Internal Revenue Service Form W-9 or applicable Form W-8, establishing a complete exemption from U.S. backup withholding tax.

(c) Tax Indemnity. All payments to be made by or on behalf of such Selling Shareholder to or for the benefit of the Underwriters under this Agreement shall be made without withholding or deduction for or on account of any present or future taxes, duties or governmental shares whatsoever unless such Selling Shareholder is compelled by law to deduct or withhold such taxes, duties or charges. In that event, such Selling Shareholder shall pay such additional amounts as may be necessary in order to ensure that the net amounts received by the Underwriters after such withholding or deductions shall equal the amounts that would have been received if no withholding or deduction has been made.

(d) Use of Proceeds. It will not directly or, to its knowledge, indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other individual or entity (“Person”) (i) to fund or facilitate any activities of or business with any Person that, at the time of such funding or facilitation, is a person with whom or which transactions are prohibited under any Sanctions, (ii) to fund or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner, in each case if such use would result in a violation by any Person participating in the transaction, whether as underwriter, advisor, investor or otherwise of Sanctions, Anti-Money Laundering Laws and any applicable anti-bribery or anti-corruption law.

7. Certain Agreements of the Underwriters. Each Underwriter hereby represents and agrees that:

(a) It has not and will not use, authorize use of, refer to or participate in the planning for use of, any “free writing prospectus”, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i) a free writing prospectus that contains no “issuer information” (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii) any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section 3(c) or Section 4(c) above (including any electronic road show approved in advance by the Company), or (iii) any free writing prospectus prepared by such underwriter and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i) or (iii), an “Underwriter Free Writing Prospectus”).

 

-34-


(b) It has not used and will not use, in each case without the prior written consent of the Company, any free writing prospectus that contains the final terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; provided that Underwriters may use a term sheet substantially in the form of Annex C hereto without the consent of the Company; provided further that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or substantially concurrently with, the first use of such term sheet.

(c) It is not subject to any pending proceeding under Section 8A of the Securities Act with respect to the offering (and will promptly notify the Company and the Selling Shareholders if any such proceeding against it is initiated during the Prospectus Delivery Period).

8. Conditions of Underwriters’ Obligations. The obligation of each Underwriter to purchase the Underwritten Shares on the Closing Date or the Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company and each of the Selling Shareholders of their respective covenants and other obligations hereunder and to the following additional conditions:

(a) Registration Compliance; No Stop Order. No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to Section 8A under the Securities Act shall be pending before or, to the Company’s knowledge, threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section 5(a) (Required Filings) hereof; and all requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representatives.

(b) Representations and Warranties. The respective representations and warranties of the Company and the Selling Shareholders contained herein shall be true and correct on the date hereof and on and as of the Closing Date or the Additional Closing Date, as the case may be; and the statements of the Company and its officers and of each of the Selling Shareholders and their officers or authorized signatories made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing Date, as the case may be.

(c) No Downgrade. Subsequent to the earlier of (A) the Applicable Time and (B) the execution and delivery of this Agreement, (i) no downgrading shall have occurred in the rating accorded to (x) any debt securities, convertible securities or preferred stock issued or guaranteed by the Company (y) the Company’s and its Insurance Subsidiaries’ financial strength and claims paying ability by any “nationally recognized statistical rating organization”, as such term is defined under Section 3(a)(62) under the Exchange Act and (ii) no such organization shall have publicly announced that it has under surveillance or review, or has changed its outlook with respect to, its rating of (x) any such debt securities or preferred stock issued or guaranteed by the Company and (y) and of the Company’s and its Insurance Subsidiaries’ financial strength of claims paying ability (other than, in the case of (ii)(x) and (ii)(y), an announcement with positive implications of a possible upgrading).

 

-35-


(d) No Material Adverse Change. No event or condition of a type described in Section 3(g) (No Material Adverse Change) hereof shall have occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.

(e) Officers Certificate. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, (x) a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is satisfactory to the Representatives (i) confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations of the Company set forth in Sections 3(b) (Pricing Disclosure Package) and 3(d) (Testing-the-Waters Materials) hereof are true and correct, (ii) confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii) to the effect set forth in paragraphs (a), (c) and (d) above and (y) a certificate from (1) an attorney-in-fact on behalf of each of the Non-Direct Selling Shareholders and (2) Platinum Ivy, in form and substance reasonably satisfactory to the Representatives, (A) confirming that the representations of such Selling Shareholder set forth in Sections 4(e) (Pricing Disclosure Package), 4(f)(Issuer Free Writing Prospectus and Written Testing-the-Waters Communication) and 4(g) (Registration Statement and Prospectus) hereof is true and correct at or prior to the Closing Date and (B) confirming that the other representations and warranties of such Selling Shareholder in this Agreement are true and correct and that the such Selling Shareholder has complied with all agreements and satisfied all conditions on their part to be performed or satisfied hereunder at or prior to such Closing Date.

(f) Seaborne Russian Oil Certificate. The Representatives shall have received on and as of (i) the date hereof and (ii) the Closing Date or the Additional Closing Date, as the case may be, a certificate of the Company related to the price caps established by a coalition of the United States, United Kingdom, European Union, and other G7 countries in connection with purchases of seaborne Russian oil inform and substance reasonably satisfactory to the Representatives.

 

-36-


(g) Comfort Letters.

(i) On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be, KPMG shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as the case may be, shall use a “cut-off” date no more than two business days prior to such Closing Date or such Additional Closing Date, as the case may be.

(ii) On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be, the Company shall have furnished to the Representatives a certificate, dated the respective dates of delivery thereof and addressed to the Underwriters, of its chief financial officer with respect to certain financial data contained in the Pricing Disclosure Package and the Prospectus, providing “management comfort” with respect to such information, in form and substance reasonably satisfactory to the Representatives.

(h) Opinion and 10b-5 Statement of Counsel for the Company. Willkie Farr & Gallagher (UK) LLP, counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and 10b-5 statement, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in Annex D-1 hereto.

(i) Opinion of Bermuda Counsel for the Company. Conyers Dill & Pearman Limited, special Bermuda counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in Annex D-2 hereto.

(j) Opinions of Local Counsel for the Selling Shareholders. Each counsel set forth on Schedule 4 hereof, special counsel for the jurisdiction opposite the name of such counsel in Schedule 4 for certain of the Selling Shareholders, shall have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives.

(k) Opinions of Counsel for the Selling Shareholders. Whalen LLP, counsel for the Selling Shareholders, shall have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives.

 

-37-


(l) Opinion and 10b-5 Statement of Counsel for the Underwriters. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and 10b-5 statement, addressed to the Underwriters, of Latham & Watkins LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters.

(m) No Legal Impediment to Sale. No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted or issued by any U.S. federal or state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the sale of the Shares by the Selling Shareholders; and no injunction or order of any U.S. federal or state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the sale of the Shares by the Selling Shareholders.

(n) Good Standing. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing in such other jurisdictions as the Representatives may reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions to the extent the concept of good standing or an equivalent concept is applicable in such jurisdiction.

(o) Exchange Listing. The Shares to be delivered on the Closing Date or the Additional Closing Date, as the case may be, shall have been approved for listing on the NYSE.

(p) Lock-up Agreements. The “lock-up” agreements, each substantially in the form of Exhibit B hereto, between you and certain shareholders, officers and directors of the Company, including the Selling Shareholders, relating to sales and certain other dispositions of shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date or the Additional Closing Date, as the case may be.

(q) Additional Documents. On or prior to the Closing Date or the Additional Closing Date, as the case may be, the Company and the Selling Shareholders shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request.

 

-38-


All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters.

9. Indemnification and Contribution.

(a) Indemnification of the Underwriters and the Selling Shareholders by the Company. The Company agrees to indemnify and hold harmless each Underwriter, each Selling Shareholder and each of their respective affiliates, directors and officers and each person, if any, who controls such Underwriter or any Selling Shareholder within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, reasonable legal fees and other reasonable expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred and documented), joint or several, that arise out of, or are based upon, (i) any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii) any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Testing-the-Waters Communication, any road show as defined in Rule 433(h) under the Securities Act (a “road show”) or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any Selling Shareholder Information with respect to such Selling Shareholder or information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in paragraph (c) below.

(b) Indemnification of the Underwriters and the Company by the Selling Shareholders. Each Selling Shareholder severally and not jointly in proportion to the number of Shares to be sold by such Selling Shareholder hereunder, agrees to indemnify and hold harmless each Underwriter, the Company and each of their respective affiliates, directors and officers and each person, if any, who controls such Underwriter or the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above, but solely with respect to, any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any Selling Shareholder Information furnished to the Company in writing by such Selling Shareholder. Notwithstanding anything to the contrary herein, no Selling Shareholder shall be liable under the indemnity or contribution provisions of this Section 9 in excess of an amount equal to the Selling Shareholder Proceeds (as defined in paragraph (f) below).

 

-39-


(c) Indemnification of the Company and the Selling Shareholders by the Underwriters. Each Underwriter agrees, severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act and each of the Selling Shareholders to the same extent as the indemnity set forth in paragraph (a) above, but only with respect to, in each case, any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any Written Testing-the-Waters Communication, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the information contained in the twelfth paragraph under the caption “Underwriting.”

(d) Notice and Procedures. If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section 9, such person (the “Indemnified Person”) shall promptly notify the person against whom such indemnification may be sought (the “Indemnifying Person”) in writing; provided that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding paragraphs of this Section 9 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided, further, that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section 9. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the reasonable and documented fees and expenses in such proceeding and shall pay the reasonable and documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or (iv) the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the reasonable fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by the Representatives and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the Company shall be designated in writing by the Company and any such separate firm for the Selling Shareholders shall be designated in writing by the Attorney-in-Fact or any one of them. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for reasonable fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x) includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person.

 

-40-


(e) Contribution. If the indemnification provided for in paragraphs (a), (b) or (c) above is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits received by the Company and the Selling Shareholders, on the one hand, and the Underwriters on the other, from the offering of the Shares or (ii) if the allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the relative fault of the Company and the Selling Shareholders, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the Company and the Selling Shareholders, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company and the Selling Shareholders from the sale of the Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Shares. The relative fault of the Company and the Selling Shareholders, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company and the Selling Shareholders or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.

 

-41-


(f) Limitation on Liability. The Company, the Selling Shareholders and the Underwriters severally and not jointly agree that it would not be just and equitable if contribution pursuant to paragraph (e) above were determined by pro rata allocation (even if the Selling Shareholders or the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in paragraph (e) above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (e) above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (e) and (f), in no event shall (i) an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission and (ii) a Selling Shareholder be required to indemnify and/or contribute any amount in excess of the Selling Shareholder Proceeds (as defined below) received by such Selling Shareholder exceeds the amount of any damages that such Selling Shareholder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. For the purpose of this Agreement, “Selling Shareholder Proceeds” means the aggregate net proceeds (after deducting underwriting commissions and discounts, but before deducting expenses) applicable to the Shares sold by such Selling Shareholder pursuant to this Agreement. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ obligations to contribute pursuant to paragraphs (e) and (f) are several in proportion to their respective purchase obligations hereunder and not joint and each Selling Shareholder’s obligation to contribution pursuant to paragraphs (e) and (f) is several and not joint and limited in the manner and to the extent set forth in paragraph (b) above.

 

-42-


(g) Non-Exclusive Remedies. The remedies provided for in this Section 9 paragraphs (a) through (f) are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. For the avoidance of doubt, the provisions of this Section 9 shall not affect any agreement among the Company and the Selling Shareholders with respect to the indemnification or contribution, as it relates to any indemnification or contribution between the Company and the Selling Shareholders, and shall in no way impact any obligation by the Company or any of the Selling Shareholders to the Underwriters.

10. Effectiveness of Agreement. This Agreement shall become effective as of the date first written above.

11. Termination. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company and the Selling Shareholders, if after the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date (i) trading generally shall have been suspended or materially limited on or by any of the NYSE or The Nasdaq Stock Market; (ii) trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any over-the-counter market; (iii) a general moratorium on commercial banking activities shall have been declared by Bermuda, U.S. federal or New York State authorities; or (iv) there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.

12. Defaulting Underwriter.

(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to purchase the Shares that it has agreed to purchase hereunder on such date, the non-defaulting Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the Company and the Selling Shareholders on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the non-defaulting Underwriters do not arrange for the purchase of such Shares, then the Company and the Selling Shareholders shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the non-defaulting Underwriters to purchase such Shares on such terms. If other persons become obligated or agree to purchase the Shares of a defaulting Underwriter, either the non-defaulting Underwriters or the Company and the Selling Shareholders may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to five full business days in order to effect any changes that in the opinion of counsel for the Company, counsel for the Selling Shareholders or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term “Underwriter” includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section 12, purchases Shares that a defaulting Underwriter agreed but failed to purchase.

 

-43-


(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters, the Company and the Selling Shareholders as provided in paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, does not exceed one-eleventh of the aggregate number of Shares to be purchased on such date, then the Company and the Selling Shareholders shall have the right to require each non-defaulting Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter’s pro rata share (based on the number of Shares that such Underwriter agreed to purchase on such date) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made.

(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by the non-defaulting Underwriters, the Company and the Selling Shareholders as provided in paragraph (a) above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case may be, exceeds one-eleventh of the aggregate amount of Shares to be purchased on such date, or if the Company and the Selling Shareholders shall not exercise the right described in paragraph (b) above, then this Agreement or, with respect to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing Date, as the case may be, shall terminate without liability on the part of the non-defaulting Underwriters. Any termination of this Agreement pursuant to this Section 12 shall be without liability on the part of the Company or the Selling Shareholders, except that the Company will continue to be liable for the payment of expenses as set forth in Section 13 (Payment of Expenses) hereof and except that the provisions of Section 9 (Indemnification and Contribution) hereof shall not terminate and shall remain in effect.

(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company, the Selling Shareholders or any non-defaulting Underwriter for damages caused by its default.

 

-44-


13. Payment of Expenses.

(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, (A) the Company will pay or cause to be paid all documented costs and expenses incurred in connection with the performance of its obligations hereunder, including without limitation, (i) the costs incurred in connection with the sale, preparation and delivery of the Shares and any taxes payable in that connection; (ii) the costs incurred in connection with to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii) the costs of reproducing and distributing this Agreement; (iv) the fees and expenses of the Company’s counsel and Company’s independent accountants; (v) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Shares under the laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum (including the related reasonable and documented fees and expenses of counsel for the Underwriters) up to an aggregate of $10,000; (vi) the cost of preparing stock certificates if applicable; (vii) the costs and charges of any transfer agent and any registrar; (viii) all expenses and application fees incurred in connection with any filing with, and clearance of the offering by, FINRA (including the related reasonable and documented fees and expenses of counsel for the Underwriters) up to an aggregate of $35,000; (ix) all expenses incurred by the Company in connection with any “road show” presentation to potential investors; (x) all Stamp Taxes payable in connection with the delivery of the Shares to the Underwriters and sale and delivery of the Shares by the Underwriters in the manner contemplated by this Agreement and the Prospectus; and (xi) all expenses and application fees related to the listing of the Shares on the NYSE (if any) and (B) in accordance with the terms of the Company’s registration rights agreement, the Company will pay or caused to be paid all reasonable, documented fees and expenses of Whalen LLP, as designated counsel to the Selling Shareholders in connection with the offering of Shares contemplated hereby, and each Selling Shareholder will otherwise pay or cause to be paid any fees and expenses of any additional counsel for such Selling Shareholder.

(b) If (i) this Agreement is terminated pursuant to Section 11 (Termination), (ii) the Company or the Selling Shareholders for any reason fail to tender the Shares for delivery to the Underwriters or (iii) the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriters for all accountable out-of-pocket costs and expenses (including the reasonable fees and expenses of their counsel) reasonably and actually incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby. For avoidance of doubt, if this Agreement is terminated pursuant to Section 12 (Defaulting Underwriter), the Company and the Selling Shareholders shall have no obligation to reimburse a defaulting Underwriter for out of pocket costs and expenses (including the fees and expenses of their counsel) incurred by such defaulting Underwriter in connection with this Agreement and the offering contemplated hereby.

14. Persons Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein and the affiliates of each Underwriter referred to in Section 9 (Indemnification and Contribution) hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be deemed to be a successor merely by reason of such purchase.

 

-45-


15. Survival. The respective indemnities, rights of contribution, representations, warranties and agreements of the Company, the Selling Shareholders and the Underwriters contained in this Agreement or made by or on behalf of the Company, the Selling Shareholders or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company, the Selling Shareholders or the Underwriters or the directors, officers, controlling persons or affiliates referred to in Section 9 (Indemnification and Contribution) hereof.

16. Certain Defined Terms. For purposes of this Agreement, (a) except where otherwise expressly provided, the term “affiliate” has the meaning set forth in Rule 405 under the Securities Act; (b) the term “business day” means any day other than a day on which banks are permitted or required to be closed in New York City; and (c) the term “subsidiary” has the meaning set forth in Rule 405 under the Securities Act; and (d) the term “significant subsidiary” has the meaning set forth in Rule 1-02(w) of Regulation S-X under the Exchange Act.

17. Compliance with USA Patriot Act. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company and the Selling Shareholders, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients, and the Company shall provide to the Underwriters such information with respect to the Company as may be reasonably requested by the Underwriters from time to time.

18. Miscellaneous.

(a) Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o Barclays Capital Inc., 745 Seventh Avenue, New York, New York 10019 (Fax: (646) 834-8133); Attention: Syndicate Registration; c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179, Attention: Equity Syndicate Desk (Fax: (212) 622-8358); and c/o Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Registration Department. Notices to the Company shall be given to it at Fidelis Insurance Holdings Limited, Wellesley House South, 90 Pitts Bay Road, Pembroke, Bermuda, HM08 (email: Janice.Weidenborner@fidelisinsurance.com); Attention: Janice Weidenborner, Chief Legal Officer. Notices to the Selling Shareholders represented by Whalen LLP shall be given to the Company at the address set forth on the cover of the Registration Statement, Attention: General Counsel, with a copy, which shall not constitute notice, to Whalen LLP, 4701 Von Karman, Suite 325, Newport Beach, California 92660. Notices to Platinum Ivy shall be given to it at Level 26, Al Khatem Tower, Abu Dhabi Global Market Square, Al Maryah Island, Abu Dhabi, United Arab Emirates (email: private.equity@adia.ae; LegalDivision_PE_Europe@adia.ae) to the attention of The Directors of Platinum Ivy B 2018 RSC Limited, with a copy, which shall not constitute notice, to Cleary Gottlieb Steen & Hamilton LLP, Al Sila Tower, 27th floor, Abu Dhabi Global Market Square, Al Maryah Island, PO Box 29920, Abhu Dhabi United Arab Emirates, Attention: Gamal Abouali (email: gabouali@cgsh.com).

 

-46-


(b) Governing Law. This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York.

(c) Submission to Jurisdiction. Each of the Company and the Selling Shareholders hereby submit to the exclusive jurisdiction of the U.S. federal and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. Each of the Company and the Selling Shareholders waive any objection which it may now or hereafter have to the laying of venue of any such suit or proceeding in such courts. Each of the Company and the Selling Shareholders agree that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and each Selling Shareholder, as applicable, and may be enforced in any court to the jurisdiction of which Company and each Selling Shareholder, as applicable, is subject by a suit upon such judgment. The Company and each Selling Shareholder irrevocably appoint Puglisi & Associates, 810 Library Avenue, Suite 204, Newark, Delaware 19711, U.S, as its authorized agent upon which process may be served in any such suit or proceeding, and agrees that service of process upon such authorized agent, and written notice of such service to the Company or any such Selling Shareholder, as the case may be, by the person serving the same to the address provided in this Section 18(c) (Submission to Jurisdiction), shall be deemed in every respect effective service of process upon the Company and such Selling Shareholder in any such suit or proceeding. Each of the Company and the Selling Shareholders hereby, severally and not jointly, represent and warrant that such authorized agent has accepted such appointment and has agreed to act as such authorized agent for service of process. Each of the Company and the Selling Shareholders further, severally and not jointly, agree to take any and all action as may be necessary to maintain such designation and appointment of such authorized agent in full force and effect for a period of seven years from the date of this Agreement.

(d) Judgment Currency. The Company and each Selling Shareholder, severally and not jointly, agree to indemnify each Underwriter, its directors, officers, affiliates and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, against any loss incurred by such Underwriter as a result of any judgment or order being given or made for any amount due hereunder and such judgment or order being expressed and paid in a currency (the “judgment currency”) other than U.S. dollars and as a result of any variation as between (i) the rate of exchange at which the U.S. dollar amount is converted into the judgment currency for the purpose of such judgment or order, and (ii) the rate of exchange at which such indemnified person is able to purchase U.S. dollars with the amount of the judgment currency actually received by the indemnified person. The foregoing indemnity shall constitute a separate and independent obligation of the Company and each Selling Shareholder and shall continue in full force and effect notwithstanding any such judgment or order as aforesaid. The term “rate of exchange” shall include any premiums and costs of exchange payable in connection with the purchase of, or conversion into, the relevant currency.

 

-47-


(e) Waiver of Immunity. To the extent that the Company or any Selling Shareholder has or hereafter may acquire any immunity (sovereign or otherwise) from jurisdiction of any court of (i) Bermuda, or any political subdivision thereof, (ii) the United States or the State of New York, (iii) any jurisdiction in which it owns or leases property or assets or from any legal process (whether through service of notice, attachment prior to judgment, attachment in aid of execution, execution, set-off or otherwise) with respect to themselves or their respective property and assets or this Agreement, the Company and each Selling Shareholder hereby, severally and not jointly, irrevocably waive such immunity in respect of its obligations under this Agreement to the fullest extent permitted by applicable law.

(f) Waiver of Jury Trial. Each of the parties hereto hereby waives any right to trial by jury in any suit or proceeding arising out of or relating to this Agreement.

(g) Recognition of the U.S. Special Resolution Regimes.

(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.

(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

As used in this Section 18(g):

BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k).

Covered Entity” means any of the following:

(i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);

(ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or

 

-48-


(iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).

Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.

U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

(h) Counterparts. This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. This Agreement may be delivered via facsimile, electronic mail, electronic delivery of a portable document format (PDF) file (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com or www.echosign.com) or other transmission method of any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

(i) Amendments or Waivers. No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto.

(j) Headings. The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation of, this Agreement.

 

-49-


If the foregoing is in accordance with your understanding, please indicate your acceptance of this Agreement by signing in the space provided below.

 

Very truly yours,
FIDELIS INSURANCE HOLDINGS LIMITED
By:    
  Name:
  Title:
The Non-Direct Selling Shareholders, acting severally
By:    
 

Name:

Title:

As Attorney-in-Fact acting on behalf of each of the Selling Shareholders named in Schedule 2 to this Agreement other than Platinum Ivy B 2018 RSC Limited.
Platinum Ivy B 2018 RSC Limited
By:    
 

Name:

Title:

By:    
 

Name:

Title:

 

 

[Signature Page to Underwriting Agreement]


Accepted: As of the date first written above

BARCLAYS CAPITAL INC.

J.P. MORGAN SECURITIES LLC

GOLDMAN SACHS & CO. LLC

For themselves and on behalf of the several Underwriters listed in Schedule 1 hereto.
BARCLAYS CAPITAL INC.
By:    

Name:

Title:

 
J.P. MORGAN SECURITIES LLC
By:    

Name:

Title:

 
GOLDMAN SACHS & CO. LLC
By:    

Name:

Title:

 

 

[Signature Page to Underwriting Agreement]


Schedule 1

 

Underwriter

  

Number of
Underwritten Shares

  

Number of
Option Shares

Barclays Capital Inc.    [ • ]    [ • ]
J.P. Morgan Securities LLC    [ • ]    [ • ]
Goldman Sachs & Co. LLC    [ • ]    [ • ]
Evercore Group, L.L.C.    [ • ]    [ • ]
Citigroup Global Markets Inc.    [ • ]    [ • ]
BMO Capital Markets Inc.    [ • ]    [ • ]
Keefe, Bruyette & Woods, Inc.    [ • ]    [ • ]
UBS Securities LLC    [ • ]    [ • ]
Dowling & Partners Securities, LLC    [ • ]    [ • ]
JMP Securities LLC    [ • ]    [ • ]
Total    [ • ]    [ • ]

 

Sch. 1-1


Schedule 2

 

Selling Shareholders

  

Number of
Underwritten Shares

  

Number of
Option Shares

Capital Z Partners (Fidelis), L.P.    [ • ]    [ • ]
Crestview FIHL Holdings, L.P.    [ • ]    [ • ]
Crestview FIHL TE Holdings, Ltd.    [ • ]    [ • ]
Crestview IV FIHL Holdings, L.P.    [ • ]    [ • ]
Crestview IV FIHL TE Holdings, LLC    [ • ]    [ • ]
CVC Falcon Holdings Limited    [ • ]    [ • ]
Pine Brook Feal Intermediate, L.P.    [ • ]    [ • ]
Platinum Ivy B 2018 RSC Limited    [ • ]    [ • ]
SPFM Holdings, LLC    [ • ]    [ • ]

 

Sch. 2-1


Schedule 3

IPO Assistance and Lock-Up Shareholders

 

1.

Daniel Burrows

 

2.

Allan Decleir

 

3.

Denise Brown-Branch

 

4.

Ian Houston

 

5.

Hinal Patel

 

Sch. 3-1


Schedule 4

 

Selling Shareholders:

  

Local Counsel for Selling Shareholders

  

Local Counsel Jurisdiction

Capital Z Partners    Walkers (Cayman) LLP    Cayman Islands
Crestview IV FIHL TE Holdings, LLC    Maples and Calder (Cayman) LLP    Cayman Islands
Crestview IV FIHL Holdings, L.P.    Maples and Calder (Cayman) LLP    Cayman Islands
Crestview FIHL Holdings, L.P.    Maples and Calder (Cayman) LLP Maples and Calder (Cayman) LLP    Cayman Islands
Crestview FIHL TE Holdings, Ltd.    Walkers (Cayman) LLP    Cayman Islands
CVC Falcon Holdings Ltd    Maples and Calder (Cayman) LLP    Jersey
Pine Brook Feal Intermediate, L.P.    Maples and Calder (Cayman) LLP    Cayman Islands
Platinum Ivy B 2018 RSC Limited    Morgan, Lewis & Bockius LLP    Abud Dhabi Global Market (ADGM)

 

Sch. 4-1


Annex A

a. Pricing Disclosure Package

[ • ]

b. Pricing Information Provided Orally by Underwriters

 

  1.

Price per share: $[  ]

 

  2.

Number of Underwritten Shares to be sold by the Selling Shareholders: [ • ]

 

  3.

Number of Option Shares to be sold by the Selling Shareholders: [ • ]

 

Annex A-1


Annex B

Written Testing-the-Waters Communications

[None]

 

Annex B-1


Annex C

Fidelis Insurance Holdings Limited

Pricing Term Sheet

[None]

 

Annex C-1


Annex D-1

Form of Opinion of Counsel for the Company

 

Annex D-1-1


Annex D-2

Form of Opinion of Bermuda Counsel for the Company

 

Annex D-2-1


Exhibit A

[None]

 

Exhibit A-1


Exhibit B

FORM OF LOCK-UP AGREEMENT

BARCLAYS CAPITAL INC.

J.P. MORGAN SECURITIES LLC

GOLDMAN SACHS & CO. LLC

As Representatives of the

several Underwriters listed

in Schedule 1 to the

Underwriting Agreement

referred to below

c/o Barclays Capital Inc.

745 Seventh Avenue

New York, New York 10019

c/o J.P. Morgan Securities LLC

383 Madison Avenue

New York, New York 10179

c/o Goldman Sachs & Co. LLC

200 West Street

New York, New York 10282

 

  Re:

Fidelis Insurance Holdings Limited - Public Offering

Ladies and Gentlemen:

The undersigned understands that you, as Representatives of the several Underwriters, propose to enter into an underwriting agreement (the “Underwriting Agreement”) with Fidelis Insurance Holdings Limited, an exempted company organized under the laws of Bermuda (the “Company”), and the Selling Shareholders listed on Schedule 2 to the Underwriting Agreement, providing for the public offering (the “Public Offering”) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the “Underwriters”), of common shares of the Company (the “Securities”). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the Underwriting Agreement.

 

Exhibit B-1


In consideration of the Underwriters’ agreement to purchase and make the Public Offering of the Securities, and for other good and valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of Barclays Capital Inc. on behalf of the Underwriters, the undersigned will not, and will not cause any direct or indirect affiliate to, during the period beginning on the date of this letter agreement (this “Letter Agreement”) and ending at the close of business 90 days after the date of the final prospectus relating to the Public Offering (the “Prospectus”) (such period, the “Restricted Period”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any common shares, $0.01 per share par value, of the Company (the “Common Shares”) or any securities convertible into or exercisable or exchangeable for Common Shares (including without limitation, Common Shares or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant) (collectively with the Common Shares, the “Lock-Up Securities”), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the Lock-Up Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Lock-Up Securities, in cash or otherwise, (3) make any demand for, or exercise any right with respect to, the registration of any Lock-Up Securities, or (4) publicly disclose the intention to do any of the foregoing.

The undersigned acknowledges and agrees that the foregoing precludes the undersigned from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of Lock-Up Securities, in cash or otherwise. The undersigned further confirms that it has furnished the Representatives with the details of any transaction the undersigned, or any of its affiliates, is a party to as of the date hereof, which transaction would have been restricted by this Letter Agreement if it had been entered into by the undersigned during the Restricted Period.

Notwithstanding the foregoing, the undersigned may:

(a) transfer the undersigned’s Lock-Up Securities:

(i) as a bona fide gift or gifts, or for bona fide estate planning purposes,

(ii) by will or intestacy,

(iii) to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or if the undersigned is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust (for purposes of this Letter Agreement, “immediate family” shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin),

 

Exhibit B-2


(iv) to a partnership, limited liability company or other entity of which the undersigned and the immediate family of the undersigned are the legal and beneficial owner of all of the outstanding equity securities or similar interests,

(v) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (iv) above,

(vi) if the undersigned is a corporation, partnership, limited liability company, trust or other business entity, (A) to another corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned, or to any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as part of a distribution to members or shareholders of the undersigned,

(vii) by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement,

(viii) to the Company from an employee of the Company upon death, disability or termination of employment, in each case, of such employee,

(ix) as part of a sale of the undersigned’s Lock-Up Securities acquired in open market transactions after the closing date for the Public Offering,

(x) to the Company in connection with the vesting, settlement, or exercise of restricted stock units, options, warrants or other rights to purchase Common Shares (including, in each case, by way of “net” or “cashless” exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such restricted stock units, options, warrants or rights, provided that any such Common Shares received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement, and provided further that any such restricted stock units, options, warrants or rights are held by the undersigned pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the documents incorporated by reference, or

(xi) pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the Board of Directors of the Company and made to all holders of the Company’s share capital involving a Change of Control (as defined below) of the Company (for purposes hereof, “Change of Control” shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of share capital if, after such transfer, such person or group of affiliated persons would hold at least a majority of the outstanding voting securities of the Company (or the surviving entity)); provided that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the undersigned’s Lock-Up Securities shall remain subject to the provisions of this Letter Agreement;

 

Exhibit B-3


provided that (A) in the case of any transfer or distribution pursuant to clause (a)(i), (ii), (iii), (iv), (v), (vi) and (vii), such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the Representatives a lock-up letter in the form of this Letter Agreement, (B) in the case of any transfer or distribution pursuant to clause (a) (i), (ii), (iii), (iv), (v), (vi), (ix) and (x), no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration of the Restricted Period referred to above) and (C) in the case of any transfer or distribution pursuant to clause (a)(vii) and (viii) it shall be a condition to such transfer that no public filing, report or announcement shall be voluntarily made and if any filing under Section 16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of Common Shares in connection with such transfer or distribution shall be legally required during the Restricted Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer;

(b) exercise outstanding options, settle restricted stock units or other equity awards or exercise warrants pursuant to plans described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the documents incorporated by reference; provided that any Lock-Up Securities received upon such exercise, vesting or settlement shall be subject to the terms of this Letter Agreement;

(c) convert outstanding preferred stock, warrants to acquire preferred stock or convertible securities into Common Shares or warrants to acquire Common Shares; provided that any such Common Shares or warrants received upon such conversion shall be subject to the terms of this Letter Agreement;

(d) establish trading plans pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of Lock-Up Securities; provided that (1) such plans do not provide for the transfer of Lock-Up Securities during the Restricted Period and (2) any public announcement or filing under the Exchange Act made by any person regarding the establishment of such plan during the Restricted Period shall include a statement that the undersigned is not permitted to transfer, sell or otherwise dispose of securities under such plan during the Restricted Period in contravention of this Letter Agreement; and

(e) sell the Securities to be sold by the undersigned pursuant to the terms of the Underwriting Agreement.

If the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or “group” (within the meaning of Section 13(d)(3) of the Exchange Act) beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the undersigned.

 

Exhibit B-4


If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to any Company-directed Securities the undersigned may purchase in the Public Offering.

In furtherance of the foregoing, the Company, and any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement.

The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.

The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect to the Public Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Public Offering, the Representatives and the other Underwriters are not making a recommendation to you to participate in the Public Offering, enter into this Letter Agreement, or sell any Shares at the price determined in the Public Offering, and nothing set forth in such disclosures is intended to suggest that any Representative or any Underwriter is making such a recommendation.

The undersigned understands that, if the Underwriting Agreement does not become effective by June 30, 2024, or if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Shares to be sold thereunder, the undersigned shall be released from all obligations under this Letter Agreement. The undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement.

This Letter Agreement and any claim, controversy or dispute arising under or related to this Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York.

This Letter Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

 

Exhibit B-5


Very truly yours,
[NAME OF SHAREHOLDER]
By:    
  Name:
  Title:

 

[Signature Page to Lock-Up Agreement]

Exhibit 5.1

 

 

LOGO

  

CONYERS DILL & PEARMAN LIMITED

 

Clarendon House, 2 Church Street

Hamilton HM 11, Bermuda

Mail: PO Box HM 666, Hamilton HM CX, Bermuda

T +1 441 295 1422

 

conyers.com

 

20 May 2024

Matter No.: 402204

Tel: +1 441 278 8053

Email: alexandra.macdonald@conyers.com

Fidelis Insurance Holdings Limited

Wellesley House

90 Pitts Bay Road

Pembroke HM 08

Bermuda

Dear Sir/Madam

Re: Fidelis Insurance Holdings Limited (the “Company”)

We have acted as special Bermuda legal counsel to the Company in connection with a registration statement on form F-1 filed with the U.S. Securities and Exchange Commission (the “Commission”) on 20 May 2024 including as incorporated by reference the Company’s Annual Report on Form 20-F for the year ended December 31, 2023 as filed with the SEC on March 15, 2024, the Company’s Current Report on Form 6-K as filed with the SEC on May 9, 2024 (as specified in the Registration Statement, defined below) and the Company’s Current Reports on Form 6-K as filed with the SEC on May 8, 2024 and May 10, 2024 (collectively, the “Registration Statement”, which term does not include any other document or agreement whether or not specifically referred to therein or attached as an exhibit or schedule thereto) relating to the registration under the U.S. Securities Act of 1933, as amended, (the “Securities Act”), of 9,000,000 common shares, par value $0.01 per share (the “Issued Shares”) being offered by certain selling shareholders of the Company (the “Selling Shareholders”) together with an additional 1,350,000 common shares, par value $0.01 per share, subject to an option to purchase additional common shares the Selling Shareholders intend to grant to the underwriters (together, the “Common Shares”).

 

1.

DOCUMENTS REVIEWED

For the purposes of giving this opinion, we have examined a copy of the Registration Statement. We have also reviewed:

 

1.1.

copies of the memorandum of association and the bye-laws of the Company, each certified by the Assistant Secretary of the Company on 17 May, 2024;

 

1.2.

copies of minutes of a meeting of its directors held on 8 May, 2024 (together, the “Resolutions”) certified by the Secretary of the Company on 16 May, 2024; and


1.3.

such other documents and made such enquiries as to questions of law as we have deemed necessary in order to render the opinion set forth below.

 

2.

ASSUMPTIONS

We have assumed:

 

2.1.

the genuineness and authenticity of all signatures and the conformity to the originals of all copies (whether or not certified) examined by us and the authenticity and completeness of the originals from which such copies were taken;

 

2.2.

that where a document has been examined by us in draft form, it will be or has been executed and/or filed in the form of that draft, and where a number of drafts of a document have been examined by us all changes thereto have been marked or otherwise drawn to our attention;

 

2.3.

the accuracy and completeness of all factual representations made in the Registration Statement and other documents reviewed by us;

 

2.4.

that the Resolutions were passed at one or more duly convened, constituted and quorate meetings, or by unanimous written resolutions, remain in full force and effect and have not been rescinded or amended; and

 

2.5.

that there is no provision of the law of any jurisdiction, other than Bermuda, which would have any implication in relation to the opinions expressed herein.

 

3.

QUALIFICATIONS

 

3.1.

We have made no investigation of and express no opinion in relation to the laws of any jurisdiction other than Bermuda.

 

3.2.

This opinion is to be governed by and construed in accordance with the laws of Bermuda and is limited to and is given on the basis of the current law and practice in Bermuda.

 

3.3.

This opinion is issued solely for the purposes of the filing of the Registration Statement and the offering of the Common Shares and is not to be relied upon in respect of any other matter.

 

4.

OPINION

On the basis of and subject to the foregoing, we are of the opinion that:

 

4.1.

The Company is duly incorporated and existing under the laws of Bermuda in good standing (meaning solely that it has not failed to make any filing with any Bermuda governmental authority under the Companies Act 1981, or to pay any Bermuda government fee or tax, which would make it liable to be struck off the Register of Companies and thereby cease to exist under the laws of Bermuda).

 

LOGO


4.2.

Based solely upon a review of the register of members of the Company in respect of the common shares par value $0.01 each as at 17 May, 2024, certified by the Assistant Secretary of the Company on 17 May 2024, the Issued Shares are validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion as an exhibit to the Registration Statement and to the references to our firm under the caption “Legal Matters” in the prospectus forming a part of the Registration Statement. In giving this consent, we do not hereby admit that we are experts within the meaning of Section 11 of the Securities Act or that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission promulgated thereunder.

Yours faithfully,

/s/ Conyers Dill & Pearman Limited

Conyers Dill & Pearman Limited

 

LOGO

Exhibit 21.1

FIDELIS INSURANCE HOLDINGS LIMITED

SUBSIDIARIES OF THE REGISTRANT

 

Legal Name

  

Jurisdiction of Incorporation

Fidelis European Holdings Limited    United Kingdom
Fidelis Insurance Bermuda Limited    Bermuda
Fidelis Insurance Ireland DAC    Ireland
Fidelis Underwriting Limited    United Kingdom
FIHL (UK) Services Limited    United Kingdom

Names of certain of the Company’s subsidiaries and/or equity entities have been omitted because considered in the aggregate they would not constitute a single significant subsidiary.

Exhibit 23.1

 

LOGO

  

KPMG Audit Limited

Crown House

4 Par-la-Ville Road

Hamilton

HM 08

Bermuda

  

Telephone

Fax

Internet

  

+1 441 295 5063

+1 441 295 9132

www.kpmg.bm

Consent of Independent Registered Public Accounting Firm

We consent to the use of our report dated March 15, 2024, with respect to the consolidated financial statements of Fidelis Insurance Holdings Limited, incorporated herein by reference and to the reference to our firm under the heading “Experts” in the prospectus.

/s/ KPMG Audit Limited

Hamilton, Bermuda

May 20, 2024

 

© 2024 KPMG Audit Limited, a Bermuda limited liability company and a member firm of the KPMG global organisation of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

Exhibit 107

Calculation of Filing Fee Tables

Form F-1

(Form Type)

Fidelis Insurance Holdings Limited

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

 

                 
     Security
Type
 

Security

Class

Title

  Amount
Registered
 

Proposed
Maximum
Offering

Price Per

Unit

 

Fee

Calculation
or Carry
Forward

Rule

 

Maximum
Aggregate
Offering

Price (1) (2)

 

Fee

Rate

  Amount of
Registration
Fee
 
Newly Registered Securities
                 
Fees to Be Paid   Equity  

Common Shares, par

value $0.01 per share

      Rule 457(o)   $196,650,000   0.00014760   $29,025.54
           
   

Total Offering Amounts

         
           
   

Total Fees Previously Paid

         
           
   

Total Fee Offsets

         
           
   

Net Fee Due

              $29,025.54

 

(1)

Includes Common Shares subject to the underwriters’ option to purchase additional Common Shares.

(2)

Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(o) under the Securities Act of 1933, as amended.


Fidelis Insurance (NYSE:FIHL)
過去 株価チャート
から 5 2024 まで 6 2024 Fidelis Insuranceのチャートをもっと見るにはこちらをクリック
Fidelis Insurance (NYSE:FIHL)
過去 株価チャート
から 6 2023 まで 6 2024 Fidelis Insuranceのチャートをもっと見るにはこちらをクリック